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  Parkinson’s disease (PD) is the most common neurodegenerative movement 
disorder.  Pathologically, loss of nigrostriatal neurons and dopamine released by these 
neurons are responsible for PD motor symptoms.  During PD, activation of resident 
microglia and infiltrating lymphocytes leads to progressive neuroinflammation and 
reduction in the number and function of regulatory immune cells.  Neuroinflammation 
contributes to progressive neurodegeneration and declining motor function.  Reducing 
neuroinflammation is the target for novel PD therapeutics.  Our goal is to increase the 
number and function of regulatory T cells (Tregs) in PD patients to decrease 
neuroinflammation and reduce PD symptoms.  One potential therapy is granulocyte-
macrophage colony stimulating factor (GM-CSF) which induces Tregs, decreases 
neuroinflammation, and protects dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) model of PD. 
 In a Phase 1 trial, recombinant human GM-CSF (sargramostim) was well-
tolerated in PD patients, increased Treg frequency and function, and improved motor 
function.  Expression of helper T cell-related genes in CD4+CD25- cells in blood was 
determined by PCR array.  Sargramostim increased expression of both pro- and anti-
inflammatory cytokine genes supporting the notion that sargramostim alters the immune 
response by increasing the expression of immune mediators, including anti-inflammatory 
genes.   
 As T cells do not express GM-CSF receptors and to explore myeloid-mediated 
Treg induction, GM-CSF-induced bone marrow-derived dendritic cells were further 
cultured with GM-CSF and/or stimulated with nitrated α-synuclein. Continued culture with 
GM-CSF yielded little change in dendritic cells as determined by surface co-stimulatory 
molecule expression, and proinflammatory cytokine expression and release; however, 
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their ability to induce Tregs was diminished.  In contrast, stimulation with nitrated α-
synuclein, regardless of continued culture in GM-CSF, increases proinflammatory gene 
expression by dendritic cells, but showed variable effects on Treg induction.  In the 
MPTP model, adoptive transfer of GM-CSF-induced tolerogenic dendritic cells protect 
dopaminergic neurons in the substantia nigra, decrease neuroinflammation, and 
increase splenic Tregs in a fashion similar to direct administration of GM-CSF.   
 In conclusion, GM-CSF induces Tregs in part by acting on dendritic cells to 
change their response to stimulation.  The data suggest that GM-CSF may not suppress 
neuroinflammation directly, but rather alters the immune response with increased 
expression of anti-inflammatory mediators and induction of Tregs. Moreover, the 
introduction of nitrated α-synuclein and possibly other misfolded proteins diminishes 
homeostasis and Treg induction.     
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 Parkinson’s disease (PD) is the second most common neurodegenerative 
disease after Alzheimer’s disease (de Lau and Breteler, 2006; Olanow et al., 2009).  PD 
has several pathological hallmarks.  One, is degeneration of the nigrostriatal pathway, 
the dopaminergic neurons which project rostrally from the substantia nigra pars 
compacta to the dorsal striatum where they synapse on GABAergic neurons (Jenner, 
2008).  The loss of nigrostriatal dopaminergic neurons and released dopamine ultimately 
decrease glutamatergic signaling from the thalamus to the motor cortex resulting in 
decreased motor function.  Dopaminergic neurons in the substantia nigra pars compacta 
are particularly susceptible to PD degeneration, even compared to other dopaminergic 
neuron populations in adjacent brain regions.  The reasons for increased neuronal 
susceptibility to damage and loss are not clear.  Ideas include, decreased ability of these 
neurons to scavenge reactive oxygen species (Hornykiewicz and Kish, 1987), decreased 
expression of neuromelanin (Hirsch et al., 1988), decreased ability to degrade misfolded 
proteins (Dauer and Przedborski, 2003), increased generation of reactive oxygen 
species (ROS), decreased mitochondria mass, and decreased myelination which results 
in these dopaminergic neurons being more sensitive to energy stressors (Surmeier et 
al., 2011; Haddad and Nakamura, 2015).      
 Accumulation of Lewy bodies and Lewy neurites, proteinaceous aggregates 
predominately made up of misfolded, post-translationally modified α-synuclein (α-Syn) is 
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another PD hallmark (Spillantini et al., 1997; Duda et al., 2000; Giasson, 2000; Luk et 
al., 2009).  Lewy bodies were initially identified as eosinophilic inclusions found 
throughout the basal ganglia and thalamus (Spillantini et al., 1997; Fornai et al., 2003; 
Shults, 2006).  They are primarily composed of α-Syn, ubiquitin, parkin, microtubule 
associated protein 1B, phosphorylated IκBα, synphilin-1, amongst other proteins (Jensen 
et al., 2000; Fornai et al., 2003; Noda et al., 2005).  Due to α-Syn abundance at the 
synaptic terminal, it is putatively involved in vesicular transport and neurotransmitter 
release (Shults, 2006; Bendor et al., 2013).  In the cell, α-Syn is normally found as an 
unstructured monomer (Uversky et al., 2001) or tetramer (Bartels et al., 2011).  When 
bound to lipid membranes, α-Syn can adopt a more α-helical-rich structure (Davidson et 
al., 1998; Perrin et al., 2000).  In Lewy bodies, α-Syn takes on a fibril structure 
(Spillantini et al., 1998) with cross β-sheet conformation (Heise et al., 2005; Vilar et al., 
2008).  α-Syn in Lewy bodies also is post-translationally modified, including 
ubiquitination (Hasegawa et al., 2002; Nonaka et al., 2005), phosphorylation (Fujiwara et 
al., 2002; Wang et al., 2012), nitration (Duda et al., 2000; Giasson, 2000), and truncation 
(Li et al., 2005; Anderson et al., 2006).  While post-translational modifications such as 
nitration increase the propensity of α-Syn to fold into oligomers (Yamin et al., 2003; 
Hodara et al., 2004; Uversky et al., 2005), it is unclear in PD if α-Syn becomes modified 
prior to or after misfolding and forming Lewy bodies.  It is also unclear if Lewy body 
formation results in or causes PD pathology.  The Braak hypothesis posits that α-Syn 
aggregation starts in the enteric nervous system (Braak et al., 2003; Braak et al., 2004).  
According to the hypothesis, misfolded α-Syn accumulates and spreads neuron to 
neuron into and throughout the central nervous system.  The resuting Lewy bodies may 
cause neurodegeneration.  Evidence for the Braak hypothesis includes α-Syn 
expression being highest in regions with the highest accumulation of Lewy bodies, the 
detection of Lewy body pathology in neuronal transplants, the transfer of α-Syn between 
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neurons and between neurons and astrocytes ex vivo, and pathology induced by 
transfer of exogenous α-Syn into rodents (McCann et al., 2016; Karampetsou et al., 
2017; Loria et al., 2017; Rietdijk et al., 2017).  Despite the above evidence, there is 
evidence that the Braak hypothesis is not completely correct, such as α-Syn from PD 
patients being unable to cause pathology in rodents, the severity of PD symptoms not 
always correlating with the degree of Lewy body pathology, and detection of Lewy body 
pathology in non-PD patients (Prusiner et al., 2015; McCann et al., 2016).  Future 
studies will rectify the different lines of evidence.     
 A final hallmark of PD is neuroinflammation which will be discussed in detail in a 
later section. 
Symptoms 
 PD is generally diagnosed by the symptoms presented.  The four cardinal motor 
symptoms of PD are resting tremor, rigidity, bradykinesia, and postural instability with 
gait disturbance (Olanow et al., 2009).  All four cardinal symptoms may not be present in 
all PD patients, but the presence of these symptoms forms the basis of a PD diagnosis.  
At the time of PD cardinal symptom presentation, 50-60% of nigral dopaminergic 
neurons are already lost (Agid, 1991).  Many non-motor symptoms are associated with 
the enteric nervous system which present in PD patients prior to the presentation of the 
cardinal motor symptoms.  For example, PD patients may develop olfactory disruptions, 
drooling, urinary disturbances, sexual dysfunction, orthostatic hypotension, fatigue, rapid 
eye movement (REM) sleep dysfunction, and insomnia (Olanow et al., 2009; Ou et al., 
2016).  These symptoms are all non-descript and may be associated with other 
disorders, and as a result, these symptoms are not used as PD diagnostic criteria.  
These non-motor symptoms may be due to the loss of neurons caused by the 
accumulation of α-Syn aggregates and act as evidence for the Braak hypothesis.  
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Another major set of non-motor symptoms is neurocognitive symptoms such as 
depression, delirium, hallucinations, anxiety and dementia (Olanow et al., 2009; Ou et 
al., 2016).  Approximately 50% of PD patients suffer from these cognitive symptoms and 
about 30% of PD patients are diagnosed with dementia (Aarsland et al., 2005) making 
treatment of cognitive symptoms an important aspect PD patient care (Hely et al., 2005; 
Olanow et al., 2009).  The development of these non-motor symptoms may suggest a 
link between PD and Alzheimer’s disease.  In line with this idea, PD patients may display 
amyloid beta plaques, similar to Alzheimer’s disease patients (Mastaglia et al., 2003; 
Lashley et al., 2008), and Alzheimer’s disease patients plaques contain α-Syn (Uéda et 
al., 1993).             
Risk factors 
   Age is the number one risk factor for PD (de Lau and Breteler, 2006).  PD 
prevalence increases from less than 0.5% at age 60 to around 4% by age 80 (de Lau 
and Breteler, 2006).  There are several occupational and environmental risk factors 
which increase the risk of developing PD, including, exposure to pesticides and 
herbicides (de Lau and Breteler, 2006; Noyce et al., 2012; Bellou et al., 2016), heavy 
metal exposure and welding (de Lau and Breteler, 2006), residing in rural areas, drinking 
well water (de Lau and Breteler, 2006; Noyce et al., 2012; Bellou et al., 2016), ever 
having an influenza infection (Harris et al., 2012), or head trauma (de Lau and Breteler, 
2006; Noyce et al., 2012).  Factors which diminish the risk of developing PD include 
drinking coffee and caffeine (de Lau and Breteler, 2006; Noyce et al., 2012; Bellou et al., 
2016), smoking cigarettes (de Lau and Breteler, 2006; Noyce et al., 2012; Bellou et al., 
2016), using non-steroidal anti-inflammatory drugs (NSAIDS), especially ibuprofen (Gao 
et al., 2011; Noyce et al., 2012; Bellou et al., 2016), and red measles infection (Harris et 
al., 2012).   
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 While most cases of PD are classified as sporadic and the underlying cause is 
not known, a minority of patients have underlying genetic risk factors can increase the 
risk of PD.  For example, having a first degree relative with PD or tremor increases the 
risk of developing PD (Noyce et al., 2012).  The first identified gene associated with PD 
is SNCA, the gene for α-Syn (Hardy et al., 2003).  Duplication, triplication, or mutation of 
SNCA are all associated with development of PD (Hardy et al., 2003; Singleton et al., 
2003; Ahn et al., 2008).  Other genes involved in familial PD are PARK2 (the gene for 
parkin, an ubiquitin ligase), UCHL1 (the gene for UCHL-1, an ubiquitin hydrolase), 
PINK1 (the gene for Pink1, a PTEN-induced kinase which protects mitochondria), 
PARK7 (the gene for DJ-1, an oxidative stress sensor), PARK8 (the gene for LRRK2), 
as well as others (Hardy et al., 2003; de Lau and Breteler, 2006).  Mutations in these 
genes are causative for PD.  Genome-wide associated studies identified several other 
genes that are associated with PD patients such as CPLX1 (complexin 1 protein 
involved in synaptic vesicle exocytosis), KAT8 (the gene from lysine acetyltransferase 
8), CD38 (a cyclic ADP ribose hydrolase), PYGO2 (a signal transduction protein), HLA-
DR (MHC class II), TOX3 (a gene associated with neuron survival), SATB1 (a gene 
associated with T cell and Treg development), as well as others (Ahmed et al., 2012; 
Wissemann et al., 2013; Dumitriu et al., 2016; Chang et al., 2017).  Despite being 
identified as being associated with PD, it is unclear if these genes are playing a 
pathogenic role in PD or if these genes are changed because of PD.       
Models 
 Rodents do not develop PD naturally.  To mimic PD in rodents, several different 
intoxicants that mimic the neurodegeneration, neuroinflammation, Lewy body formation, 
and motor dysfunction to differing degrees.  The first of these models is 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD, which was first identified in 
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humans who self-administered improperly synthesized desmethylprodine (Gupta, 2011).  
These patients presented with rapid on-set PD symptoms.  MPTP is a pro-neurotoxin 
which rapidly diffuses across the blood-brain barrier (Heikkila et al., 1984; Markey et al., 
1984).  In the brain, MPTP is metabolized by monoamine oxidase B (MAO-B) to 1-
methyl-4-phenylpyridinium (MPP+), the active neurotoxin (Chiba et al., 1984; Heikkila et 
al., 1984; Markey et al., 1984; Scotcher et al., 1990).  MPP+ is structurally similar to 
dopamine (Klein et al., 1985), as a result, MPP+ is taken up through dopamine 
transporters into dopaminergic neurons.  Within neurons, MPP+ may be sequestered 
into vesicles (Staal and Sonsalla, 2000) which protects the neurons.  MPP+ may enter 
the mitochondria and block electron transport chain complex I (Singer et al., 1988).  
Blocking the electron transport chain results in energy depletion, neurodegeneration, 
and neuroinflammation (Mizuno et al., 1987; Scotcher et al., 1990; Przedborski et al., 
1996; Niranjan et al., 2010).  While MPP+ kills neurons itself, genetic knockout of 
proinflammatory cytokines such as interleukin (IL)-18 (Sugama et al., 2004) and tumor 
necrosis factor (TNF)-α (Ferger et al., 2004) leads to decreased dopaminergic neuron 
loss after MPTP intoxication compared to wild type.  This suggests a significant 
percentage of neuron loss is due to subsequent neuroinflammation and not MPP+ itself.  
CD4+ helper T cells are important for neuroinflammation because the absence of this 
cell type protects most dopaminergic neurons from degeneration (Benner et al., 2008; 
Brochard et al., 2009).  After neuroinflammation resolution, no additional dopaminergic 
neurons are lost (Jackson-Lewis et al., 1995).  While the MPTP model recapitulates the 
specific neurodegeneration and neuroinflammation found in PD, few if any Lewy bodies 
are detected, unless MPTP is administered through an osmotic pump (Fornai et al., 
2005; Shimoji et al., 2005).  Also, due to the rapid onset of neurodegeneration, there 
may (Sundström et al., 1990; Tillerson and Miller, 2003; Fornai et al., 2005) or may not 
(Hirst and Ferger, 2008; Hutter-Saunders et al., 2012) be motor impairment.  The lesion 
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in the MPTP model is more variable in female mice (Przedborski et al., 2001), meaning 
that commonly only male mice are used.  After MPTP intoxication, female mice express 
higher GFAP (suggesting greater astrocyte activation), decreased expression of the 
dopamine transporter in the striatum, and administration of 17β-estradiol in both male 
and female mice is neuroprotective, all of which may contribute to the increased 
variability of MPTP lesion in female mice (Ookubo et al., 2008; Ookubo et al., 2009).  
This is potentially a problem since female mice are not included in experiments testing 
efficacy of potential therapies.       
      Another toxin-based PD model is 6-hydroxydopamine (6-OHDA), an oxidized 
form of dopamine.  Unlike MPTP, which is peripherally administered, 6-OHDA cannot 
cross the blood brain barrier (Garver et al., 1975).  Therefore, 6-OHDA must be injected 
into the substantia nigra, median forebrain bundle, or striatum (Ungerstedt, 1968; Jeon 
et al., 1995; Rodrigues et al., 2003; Ma et al., 2014) to induce nigrostriatal degeneration.  
6-OHDA is usually injected unilaterally to minimize toxicity, leading to unilateral 
neuroinflammation and neurodegeneration (Cicchetti et al., 2002; Rodrigues et al., 2003; 
Walsh et al., 2011), unlike MPTP where neurodegeneration and neuroinflammation are 
bilateral.  After injection, 6-OHDA is taken up into catecholaminergic neurons through 
catecholamine transporters (Kostrzewa and Jacobowitz, 1974; Luthman et al., 1989).  
Once in neurons, 6-OHDA has two fates, oxidization which forms hydrogen peroxide, 
which subsequently forms ROS or impairment of complex I and IV of the electron 
transport chain (Heikkila and Cohen, 1971, 1972; Glinka and Youdim, 1995; Glinka et 
al., 1996).  Both the generation of ROS and inhibition of the electron chain leads to 
neurodegeneration of catecholaminergic neurons and neuroinflammation.  Unlike MPTP, 
which causes neurodegeneration and neuroinflammation specific for dopaminergic 
neurons, 6-OHDA affects both dopaminergic and noradrenergic neurons.  As with 
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MPTP, 6-OHDA does not induce Lewy body formation (Duty and Jenner, 2011; Bove 
and Perier, 2012).  While MPTP intoxication may or may not lead to motor symptoms, 6-
OHDA intoxication generates noticeable motor deficits.  After unilateral administration of 
6-OHDA lesion, administration of amphetamine is injected causing ipsilateral rotation in 
a dose-dependent fashion (Carey, 1992; Robinson et al., 1994).        
 Because pesticide and herbicide exposure has been linked to increased risk of 
PD, pesticides and herbicides were used to model PD symptoms and 
neurodegeneration in rodent models.  Both paraquat (a herbicide) and rotenone (a 
herbicide and insecticide) can be administered peripherally and taken up into the brain.  
Rotenone is lipophilic and rapidly crosses the blood brain barrier and paraquat is actively 
transported through neutral amino acid transporter (Shimizu et al., 2001).  Administration 
of either toxin causes nigrostriatal pathway degeneration (Betarbet et al., 2000; 
McCormack et al., 2002).  Rotenone is neurotoxic by inhibiting electro transport chain 
complex I (Betarbet et al., 2000).  Paraquat is neurotoxic by redox cycling and 
generating reactive oxygen and nitrogen species (Bus et al., 1976; Day et al., 1999).  
Unlike the 6-OHDA and MPTP models, injection of rotenone or paraquat increases 
expression of α-Syn and induces formation of inclusions that are similar to Lewy bodies 
found in PD patients (Brooks et al., 1999; Betarbet et al., 2000; Manning-Bog et al., 
2002).  In addition, administration of both rotenone and paraquat lead to motor 
symptoms of decreased rearing and spontaneous movement also mimicking PD (Alam 
and Schmidt, 2004; Cannon et al., 2009).  Rotenone and paraquat failed to achieve 
more acceptance because of variable degrees of degeneration following administration 
(Duty and Jenner, 2011; Bove and Perier, 2012).         
  Familial PD can also be modeled in rodents.  As indicated above, several genes 
have been implicated in the development of familial PD.  The gene most associated with 
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PD is SNCA.  Mice that overexpress mouse or human α-Syn, or express A30P or A53T 
mutants of α-Syn develop Lewy body-like inclusions in the nigrostriatal pathway (Kahle 
et al., 2000; van der Putten et al., 2000; Giasson et al., 2002; Lee et al., 2002; Rieker et 
al., 2011).  However, the degree of neurodegeneration in the nigrostriatal pathway is 
inconsistent (Masliah et al., 2000; Matsuoka et al., 2001).  This lack of dopaminergic 
neuron degeneration, even in older rodents, is a major reason these models have not 
gained more prominence.  The knockout of other genes associated with PD such as 
parkin (PARK2), PINK1 (PINK1), and DJ-1 (PARK7) are used as models of PD, 
however, these models also lack neurodegeneration (Goldberg et al., 2003; Goldberg et 
al., 2005; Kitada et al., 2007).   
Lastly, it should be noted that genetic and toxin models of PD exist in non-rodent 
organisms such as non-human primates, C. elegans and Drosophila.  Non-human 
primates do not develop PD spontaneously, but can develop PD symptoms after toxin 
administration (Emborg, 2007).  However, due to the cost and specialized facilities 
needed, the non-human primate models of PD have not been widely used.  PD models 
in C. elegans and Drosophila are beneficial because these organisms contain limited 
numbers of neurons and other cells in the CNS allowing for easy nerve tracing, quick 
generation time, and testing on large numbers needed for high throughput screening 
(Duty and Jenner, 2011).  However, these model organisms are more genetically 
divergent from PD patients than rodent models, meaning that results generated from 
these models may not translate into the human population.   
Treatments 
 Since PD symptoms are caused by the loss of dopamine in the striatum, the 
most clinically useful therapies for PD are replacing lost dopamine.  The most common 
therapy for PD is levodopa given alone or with carbidopa, an inhibitor of aromatic-L-
10 
 
amino acid decarboxylase, the enzyme which decarboxylates levodopa to dopamine 
(Calne, 1993; Samii et al., 2004; Dhall and Kreitzman, 2016; Oertel and Schulz, 2016).  
While this therapy is beneficial in the short-term, long-term treatment with levodopa often 
leads to dyskinesia (Calne, 1993; Rascol et al., 2000; Samii et al., 2004; Stocchi et al., 
2010).  Other approved PD therapies include inhibition of cathechol-O-
methyltransferase, the enzyme that metabolizes dopamine (Muller, 2015; Oertel and 
Schulz, 2016), and dopamine agonists (Calne, 1993; Oertel and Schulz, 2016).  
Combination therapy of rasagiline, an inhibitor of the dopamine-metabolizing enzyme 
MAO-B, and pramipexole, a dopamine receptor 2 agonist, is successful at reducing PD 
symptoms in a recent clinical trial (Olanow et al., 2017).  In addition, selegiline 
monotherapy, another MAO-B inhibitor, decreased the combined Unified Parkinson’s 
Disease Rating Scale (UPDRS) score, showing improvement compared to placebo 
(Mizuno et al., 2017). 
While these therapies are effective at replacing lost dopamine, these therapies 
do not address the underlying the cause of disease, the loss of dopaminergic neurons.  
One therapeutic strategy is the generation of the antibodies against α-Syn.  In practice, 
passive transfer of anti-α-Syn antibodies increases clearance of α-Syn fibrils (Games et 
al., 2014; Lindstrom et al., 2014).  Passive transfer of antibodies and increased 
autoantibodies against α-Syn, reduce α-Syn fibrils, and inclusions protect neurons from 
further degeneration (Masliah et al., 2005; Games et al., 2014; Lindstrom et al., 2014).  
While clinical trials using monoclonal antibodies to α-Syn (PRX002) were performed in 
humans, and these antibodies are safe to administer (Schenk et al., 2017), to date, 
these antibodies have yet to successfully reduce PD symptoms.  Other novel therapeutic 
approaches that slow or stop dopaminergic neurons loss by decreasing 
neuroinflammation could be used.  Such therapies such as minocycline and pioglitazone 
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were protective in rodent models of PD (Peng et al., 2006; Laloux et al., 2012), but these 
therapies were not been effective in PD patients (Investigators., 2006; Investigators., 
2015; Simon et al., 2015).  Despite advances in therapies for PD, a novel therapy which 
diminishes neuroinflammation is needed because the progression of neurodegeneration 
could be slowed.              
 
NEUROINFLAMATION AND PARKINSON’S DISEASE 
Inflammatory immune cells in PD  
 One byproduct of nigrostriatal degeneration and Lewy body formation is 
inflammation.  During PD, several types of immune cells are activated.  The first of these 
immune cell types is microglia, which reside in the brain.  Microglia arise from two 
sources (Chan et al., 2007; Kettenmann et al., 2011).  In the postnatal brain, a limited 
number of blood monocytes migrate into the brain and differentiate into microglia.  The 
second and major source of microglia are myeloid progenitors that arise from the bone 
marrow then migrate into the brain during embryonic development.  These two 
populations can be differentiated by the expression of CX3CR1 (found on resident 
microglia) and CCR2 (found on microglia infiltrating in postnatal mice) (Mizutani et al., 
2012).  Microglia have several described functions including pruning synapses (Paolicelli 
et al., 2011; Tremblay et al., 2011), repairing and promoting neuronal survival after 
damage (Cherry et al., 2014; Michell-Robinson et al., 2015), as well as clearing 
pathogens in the brain (Michell-Robinson et al., 2015; Orihuela et al., 2016).  Microglia 
primed for repair and neuronal survival are designated M2 microglia.  These microglia 
release anti-inflammatory cytokines IL-4, IL-13, IL-10 and transforming growth factor 
beta (TGF-β), and release neurotrophic factors such as prostanoids, and arginase 
(Minghetti and Levi, 1998; Orihuela et al., 2016).  Conversely, M1 microglia are primed 
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to release proinflammatory cytokines such as interferon gamma (IFNγ), TNF-α, IL-12, IL-
1β, and IL-6 as well as the release of reactive oxygen and reactive nitrogen species 
(Michell-Robinson et al., 2015; Orihuela et al., 2016).  The combination of these M1 and 
M2 microglia are responsible for resolution of inflammation and repair of damaged 
neurons in the central nervous system.   
During PD and other neurodegenerative disease, the debris from dead and dying 
neurons and the accumulation and release of amyloid aggregates, such as Lewy bodies, 
activate microglia (Meda et al., 1995; Beyer et al., 2000; Zhang et al., 2005; Kempuraj et 
al., 2016).  Aggregated α-Syn binds to pattern recognition molecules such as CD36 and 
Toll-like receptors 1, 2 and 4, to stimulate the release of proinflammatory mediators from 
microglia (Su et al., 2008; Stefanova et al., 2011; Fellner et al., 2013; Daniele et al., 
2015).  In PD, activated microglia accumulate in the striatum, globus pallidus, thalamus, 
and pons compared to age-matched controls as determined in vivo by positron emission 
tomography (PET) scanning for activated microglia marker PK11195 (Gerhard et al., 
2006).  In the postmortem brain, HLA-DR positive cells increase in the substantia nigra 
of PD patients compared to non-PD controls (McGeer et al., 1988).  Microglia in the post 
mortem PD patients show increased expression of the adhesion molecules ICAM-1 and 
LFA-1 which are important for the migration of microglia and lymphocytes to regions of 
neuronal loss (Miklossy et al., 2006).   PD patients also exhibit increased MHC II-positive 
cells in several different brain regions including the substantia nigra and putamen 
(Imamura et al., 2003).  Taken together, M1-activated microglia in PD patients and are in 
proximity of the degenerating neurons, suggesting that they play a role in degeneration.        
 Outside the central nervous system, dendritic cells (DCs), macrophages, and 
monocytes are the most important non-granulocyte myeloid cells.  These cells are 
derived from common myeloid progenitors in the bone marrow (Geissmann et al., 2010).  
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These cells are all part of the innate immune system which play an important role in the 
activation of the adaptive immune response (Medzhitov and Janeway, 1997; Liu, 2001).  
DCs are found in lymphoid tissue such as Peyer’s patches and non-lymphoid tissue 
such as the skin, lungs, and nasopharynx.  DCs arise from two origins, myeloid origin 
dendritic cells which originate from myeloid progenitor cells, or plasmacytoid dendritic 
cells which originate from the common dendritic cell progenitor or the lymphoid 
progenitor (Rutella et al., 2006).  After activation, DCs migrate from the peripheral tissue 
to the T cell zone of the draining lymph nodes to activate T cells (Martín-Fontecha et al., 
2009; Merad et al., 2013).  The primary role of DCs is uptake, processing, and 
presentation of antigens that activate T cells (Merad et al., 2013).  DCs can release 
cytokines and other proinflammatory mediators that influence the immune environment 
biasing the activation of T cells, leading to activation of the adoptive immune response.  
Macrophages are found within the tissues and monocytes are found in the blood 
(Gordon and Taylor, 2005).  Both cell types play a role in antigen processing and 
adaptive immune cell activation, but to a lesser extent than DCs (Steinman, 1991; 
Banchereau and Steinman, 1998).  Primarily, macrophages and monocytes are involved 
in clearance of pathogens and debris (Gordon and Taylor, 2005).  As with DCs, 
macrophages and monocytes release cytokines and proinflammatory mediators such as 
ROS that facilitate clearance of pathogens and wound healing.     
 In PD, the percentages of B and T cells are increased (see below), suggesting an 
important role for antigen-presenting cells (APCs) in the progression of disease.  Few 
studies tested the percentage of DCs in PD.  One study published a decrease in the 
percentage of both plasmacytoid and myeloid DCs (Ciaramella et al., 2013).  However, 
another study showed these populations are not changed (Goldeck et al., 2016).  In 
addition, PD patients show increased classical monocytes (CD14+ CD16-), the major 
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circulating monocyte population, and decreased non-classical monocytes (CD14+ 
CD16+), the major phagocytic macrophages (Grozdanov et al., 2014).  Monocytes from 
PD patients also exhibit a decreased phagocytic index compared to controls.  Classical 
monocytes in the PD patients display increased expression of CCR2, a chemokine 
receptor needed for monocyte recruitment to sites of inflammation (Funk et al., 2013).  
There is conflicting data concerning the release of IL-1β, TNF-α, and IL-6 from LPS-
stimulated monocytes derived from PD patients.  One publication indicated these 
cytokines were increased (Grozdanov et al., 2014), while another publication showed 
these cytokines were decreased (Hasegawa et al., 2000).    
 Lymphocytes are immune cells which are derived from a common lymphoid 
progenitor in the bone marrow (Galy et al., 1995; Kondo et al., 1997).  There are three 
lymphocyte subpopulations: natural killer (NK) cells, B cells and T cells.  NK cells can be 
differentiated by the expression of CD16, CD56, CD27, and CD11b on their surface and 
release perforin and granzyme-containing granules which kill cancer cells and virus-
infected cells (Goh and Huntington, 2017).  B cells display immunoglobulins on the 
surface (Pike and Ratcliffe, 2002). When activated, B cells undergo somatic 
hypermutation of the immunoglobulin V region, class-switching of the immunoglobulin 
constant region, and (for some B cells) differentiation into immunoglobulin-secreting 
plasma cells (Hwang et al., 2015).  There are 2 major T cell lineages: CD4+ helper T 
cells and CD8+ cytotoxic T cells.  CD4+ helper T cells are further subdivided into helper 
T subtypes (Th1, Th2, Th17), regulatory T cells (Tregs) and several other subsets 
depending on the cytokines released (Luckheeram et al., 2012; Tripathi and Lahesmaa, 
2014).  These helper T cells bias the immune response to clear antigens that are 
activating the immune system (Luckheeram et al., 2012).  Helper T cells can also be 
divided into naïve helper cells (CD4+ CD45RA+), which have yet to be activated in 
15 
 
response to antigens, and memory helper T cells (CD4+ CD45RO+) which have 
previously been activated and are maintained to more rapidly respond to that antigen in 
the future (Berard and Tough, 2002).  CD8+ T cells are cytotoxic, able to bind to and kill 
tumor or infected cells by release of perforin and granzyme-containing granules or 
through Fas ligand-Fas interactions (Harty et al., 2000).  Unlike B cells which can bind 
antigens without presentation, both CD8+ and CD4+ T cells need antigens to be 
presented in the cleft of major histocompatibility complex (MHC) I or MHC II, respectively 
(Teh et al., 1988; Bour et al., 1995).  T cells can also be divided into αβ or γδ T cells 
based on which T cell receptor gene segments are utilized by the T cell receptor.  In the 
periphery, most T cells are αβ T cells, but approximately 5% of the T cell population are 
γδ T cells (Carding and Egan, 2002).  In conclusion, the three lymphocyte subtypes 
control infection, with B and T cells being the primary components of the cellular 
adoptive immune response.     
 In PD patients, the percentage and function of lymphocytes is altered.  
Circulating NK cells are increased (Niwa et al., 2012) and circulating B cells are 
decreased in PD patients compared to healthy controls (Bas et al., 2001; Niwa et al., 
2012; Stevens et al., 2012; Horvath and Ritz, 2015).  Interestingly, PD patients have 
increased autoantibodies (Benkler et al., 2012), possibly including antibodies against α-
Syn (Papachroni et al., 2007).  This suggests that even with decreased B cell numbers, 
B cell-derived antibody production may be increased.  To date, no study has discerned 
significant changes in the percentages of plasma cells in PD patients.  Within the T cell 
population, PD patients exhibit increased circulating CD8+ (Bas et al., 2001; Baba et al., 
2005) and γδ T cells (Fiszer et al., 1994), but a decreased the percentage of circulating 
CD4+ T cells (Bas et al., 2001; Baba et al., 2005; Hutter-Saunders et al., 2012; Niwa et 
al., 2012; Stevens et al., 2012; Horvath and Ritz, 2015).  In PD, the percentage of 
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memory helper T cells (CD4+ CD45RO+) is increased and the percentage of naïve 
helper T cells (CD4+ CD45RA+) is decreased (Bas et al., 2001; Hutter-Saunders et al., 
2012; Stevens et al., 2012; Horvath and Ritz, 2015).  The percentage of proinflammatory 
helper T cell subsets Th1 and Th17 is increased and anti-inflammatory Th2 and Treg 
CD4+ cells are decreased (Chen et al., 2015).  The ratio of IFNγ- to IL-4-producing 
CD4+ cells is significantly increased in PD patients, also suggesting a shift toward Th1 
and away from Th2 (Baba et al., 2005).  The ability of Tregs from PD patients to 
suppress proliferation of CD4+ CD25- cells in culture is diminished compared to Tregs 
from age-matched controls (Hutter-Saunders et al., 2012).  Furthermore, PBMCs from 
PD patients show increased basal expression of IFNγ, IL-1β, TNF-α, IL-8, MCP-1 and 
MIP-1α, further highlighting that PD patients display increased expression of 
proinflammatory cytokines and chemokines (Reale et al., 2009).  Combined, these 
results indicate that lymphocyte percentages and functions are dysregulated leading to 
increased proinflammatory environments with diminished regulatory immune functions.    
A final population of immune cells are granulocytes, which are comprised of 
neutrophils, eosinophils, and basophiles, and differentiated from the common 
granulocyte progenitor (Akashi et al., 2000).  Unlike monocytes, macrophages, DCs, and 
lymphocytes which are all mononuclear cells, granulocytes possess multiple-lobed 
nuclei and are called polymorphonuclear cells.  As the name in implies, granulocytes 
also contain large numbers of granules, which contain proteases, cytotoxins, and 
antimicrobial peptides, and are released to eliminate extracellular pathogens as part of 
their function in the innate immune system (Geering et al., 2013).  Neutrophils are the 
most abundant immune cell population and are the first cells to respond after infection 
(Mestas and Hughes, 2004; Jones et al., 2016).  When neutrophils respond to infection, 
they phagocytize extracellular pathogens that are eliminated by the production of ROS 
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and antimicrobial peptides and enzymes (Mayer-Scholl et al., 2004; Kolaczkowska and 
Kubes, 2013).  For tumors, helminths, and pathogens too large to phagocytize, 
neutrophils release proinflammatory mediators such as IL-12, cationic defensins, 
extracellular enzymes such as elastase, collagenase, and matrix metalloproteinase 
(Olsson and Venge, 1974; Olofsson et al., 1976; Cadman and Lawrence, 2010; 
Kolaczkowska and Kubes, 2013).  Basophils and eosinophils represent less than 5% of 
the white blood cells in circulation and play roles in helminth infection, asthma, and 
allergies (Cadman and Lawrence, 2010; Stone et al., 2010; Siracusa et al., 2013).  
Basophils and eosinophils function by IgE bound to Fc receptors, which induce release 
of Th2 cytokines such as IL-4, IL-5, IL-9 and IL-13, leukotrienes, and histamines (Stone 
et al., 2010; Siracusa et al., 2013).   
 Even though granulocytes, especially neutrophils, play an important role in 
inflammation, little research has been performed to evaluate changes in number and 
function during PD.  One study indicated no increase in peripheral neutrophil number 
(Atac Ucar et al., 2016).  However, the total number of granulocytes are increased in the 
blood (Horvath and Ritz, 2015), but this study did not differentiate subsets of 
granulocytes.  Release of nitrogen oxygen species from PD patient neutrophils was 
increased compared to controls, suggesting increased proinflammatory function (Gatto 
et al., 1996).  Combined, these data suggest that the increase in granulocyte number 
and the increased release of reactive nitrogen species contribute to the inflammation in 
PD.   
Released mediators in PD  
 In addition to immune cells, the immune system requires the release of mediators 
to carry out its function.  These mediators may be cytokines, chemokines, reactive 
oxygen and nitrogen species, prostaglandins, histamines, leukotrienes, anti-microbial 
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peptides and extracellular enzymes which bias the immune system, regulate 
inflammation, control regulatory functions of the immune system, act as 
chemoattractants for immune cells, have intrinsic capacity to remove pathogens, and 
regulate the functions of non-immune cells (Bogdan et al., 2000; Vaday and Lider, 2000; 
Borish and Steinke, 2003; Peters-Golden et al., 2005; Zhang and An, 2007; Azad et al., 
2008; O'Mahony et al., 2011; Ricciotti and FitzGerald, 2011; Mangoni et al., 2016).   In 
PD, the concentration of proinflammatory mediators are increased compared to healthy 
controls.  This includes increased concentration of proinflammatory cytokines such as IL-
6, IL-1β and nitrate (a reactive nitrogen species) in the cerebrospinal fluid (CSF) (Mogi et 
al., 1994; Blum-Degen et al., 1995; Qureshi et al., 1995; Scalzo et al., 2010).  Counter to 
the expectation, an increase of IL-6 concentration in CSF correlated with diminished 
motor symptoms of PD (Müller et al., 1998).  The concentration of serum 
proinflammatory mediators appears to be more variable in some studies showing 
increased IL6, IL-1β, or RANTES (Rentzos et al., 2007; Lindqvist et al., 2012; Dursun et 
al., 2015) or decreased IL-6, IL-1α, IL-8, TNF-α and nitrite concentrations (Dursun et al., 
2015; Cubukcu et al., 2016; Gupta et al., 2016).  PD patients also exhibit increased 
serum IL-10, an anti-inflammatory cytokine (Rentzos et al., 2009), perhaps indicating a 
general increase in cytokine production or a compensatory response to the 
proinflammatory environment.  In the postmortem brain, PD patients also exhibit 
increased reactivity for proteins modified with 4-hydroxy-2-nonenal, an oxidized lipid 
(HNE) (Yoritaka et al., 1996), protein containing carbonyls (Alam et al., 1997a), and 8-
hydroxyguanine (an oxidized nucleotide DNA base) (Alam et al., 1997b), all are markers 
of an oxidatively stressed environment.  In the CSF, PD patients show increased 8-
hydroxyguanine compared to controls, suggesting increased oxidative damage (Abe et 
al., 2003).  PD lymphocytes also show increased micronuclei and more single strand 
breaks in the chromosomal DNA, suggesting that the oxidative damage detected in the 
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brain is also in peripheral immune cells (Migliore et al., 2001; Petrozzi et al., 2001; 
Migliore et al., 2002).   
In summary, there is a sustained proinflammatory environment in affected brain 
tissue.  This is demonstrated by increased activation of microglia (McGeer et al., 1988; 
Imamura et al., 2003), dysregulation of peripheral immune cells (Bas et al., 2001; Niwa 
et al., 2012), and increased concentrations of proinflammatory mediators in serum and 
CSF (Mogi et al., 1994; Blum-Degen et al., 1995; Qureshi et al., 1995; Rentzos et al., 
2007; Scalzo et al., 2010; Lindqvist et al., 2012; Dursun et al., 2015).  The presence of 
pro-inflammatory mediators in regions of neurodegeneration suggests a role for 
neuroinflammation in PD pathogenesis.  Mitigating neuroinflammation could diminish 
disease severity or slow degeneration in PD and may create an environment where 
repair can be initiated.                  
 
GRANUCLOCYTE-MACROPHAGE COLONY STIMULATING FACTOR (GM-
CSF) 
 Structure, function and signaling of GM-CSF to its receptor 
 One of the therapeutics that may be used to mitigate neuroinflammation and 
immune system dysfunction in PD is the cytokine GM-CSF (colony stimulating factor-2, 
CSF2).  In the body, GM-CSF is a monomer with four helical domains (Shearer, 2003).  
GM-CSF binds to its receptor (CSF2R), which is composed of two subunits.  The α 
subunit that contains the site of GM-CSF binding and the β subunit is a common chain 
shared by GM-CSF, IL-3 and IL-5 receptors, and is important for intracellular signaling 
(Hercus et al., 2009).  The crystal structure of the GM-CSF receptor bound to GM-CSF 
portrays a hexamer complex of 2 α subunits, 2 β subunits of the GM-CSF receptor 
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binding 2 GM-CSF monomers (Hansen et al., 2008).  After GM-CSF binding, the kinase 
JAK2 phosphorylates tyrosine amino acids in the cytoplasmic tail of both subunits of the 
GM-CSF receptor (Shearer, 2003; Hansen et al., 2008; Hercus et al., 2009).  
Phosphorylated tyrosines recruit the signal transducing STAT family members such as 
STAT1 and STAT5, MAPK pathway members such as ERK1/2, and PI3-K pathway 
members for downstream signaling (Shearer, 2003; Hercus et al., 2009).  As expected 
from activating of several pathways in several different cell types, GM-CSF displays 
several functions, the most important of which is that GM-CSF acts on CD34+ immune 
stem cells to suppress lymphocyte progenitor differentiation and promote differentiation 
into macrophages, IL-12-producing DCs, and granulocytes (Shearer, 2003).         
Therapeutic application of GM-CSF in rodent models and humans 
 GM-CSF has been used in two opposing ways to therapeutically modulate the 
immune system.  First, GM-CSF can be used as an adjuvant to improve the immune 
response to an antigen.  Recombinant GM-CSF, when combined with the hepatitis B 
vaccine, increased anti-hepatitis B antibody titer suggesting a more protective response 
(Cruciani et al., 2007).  GM-CSF has also been and is continuing to be used as an 
adjuvant for vaccines in melanoma, prostate cancer, pancreatic cancer, colon cancer, 
breast cancer, and renal cancer (Jones et al., 1996; Ryan et al., 2000; Parmiani et al., 
2007; Spitler et al., 2009; Garcia et al., 2014) (NCT00064129, NCT00669734, 
NCT01134614, NCT02466906, NCT01479244, NCT00458536).  GM-CSF is used to 
reduce myelosuppression in these cancers.  However, GM-CSF does not reliably 
increase T cell or antibody responses to antigens of these tumors, potentially due to 
differences in the dose of GM-CSF used.   
 In contrast to its role as an adjuvant, GM-CSF can also act to suppress immune 
responses in models of autoimmunity.  In the experimental myasthenia gravis mouse 
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model, there is progressive muscle weakness due to an immune response to muscle 
acetylcholine receptor (Sheng et al., 2011).  Administration of GM-CSF decreases 
severity of muscle weakness and production of antibodies reactive to acetylcholine 
receptor, decreases CD4+ T cell expression of proinflammatory cytokines, and increases 
Treg percentage.  The experimental model of thyroiditis is induced by immunization with 
thyroglobulin, leading to destruction of thyroid follicles (Vasu et al., 2003).  
Administration of GM-CSF diminishes thyroid damage, decreases expression of 
disease-exacerbating IL-12, and increases the percentage of Tregs (Vasu et al., 2003; 
Ganesh et al., 2009).  Additional research determined that GM-CSF acts on DCs that 
can induce Tregs and the suppression of autoimmunity (Ganesh et al., 2009; 
Bhattacharya et al., 2011).  NOD mice are a model of type 1 diabetes that develop 
insulitis and is mitigated by GM-CSF treatment (Cheatem et al., 2009).  GM-CSF 
administration increases the percentages of Tregs, Treg expression of IL-10 and TGF-β, 
and percentages of dendritic cells.  In addition to the aforementioned autoimmunity 
models, GM-CSF can also diminishes the colitis in the dextran sulfate sodium model 
(Sainathan et al., 2008).  In this model, GM-CSF treatment diminished expression of 
proinflammatory cytokines IL-1α, IL-1-β, and TNFα, and increased indolamine 2,3 
dioxygenase (IDO) expression in plasmacytoid DCs in the gut.  In a model of traumatic 
brain injury, GM-CSF administration diminished the number Iba-1+ microglia, decreased 
lesion size, and spared more damage to the cortex (Kelso et al., 2015).  Lastly, GM-CSF 
was protective in the MPTP PD model.  Administration of GM-CSF protects 
dopaminergic neurons and diminishes the number of activated microglia following MPTP 
(Kosloski et al., 2013).  This neuroprotective effect is mediated by an increase in Tregs, 
as the transfer of the induced Tregs was sufficient for neuroprotection and diminished 
neuroinflammation.  In conclusion, GM-CSF can act to diminish the inflammatory 
response in autoimmunity by acting on DCs to induce Tregs.     
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    One of the benefits of using GM-CSF as a therapy is that it is an FDA approved 
drug called sargramostim (Leukine), which is recombinant human GM-CSF produced in 
yeast with a leucine to proline substitution at position 23 (Dorr, 1993; Waller, 2007).  
Sargramostim decreased neutrophil recovery time and increased survival times in acute 
myelogenous leukemia (Rowe et al., 1995) and lymphoid neoplasia (Nemunaitis et al., 
1991).  Administration of sargramostim also diminishes the recovery time of immune 
cells following bone marrow replacement (Nemunaitis et al., 1991; Hussein et al., 1995).  
Sargramostim and filgrastim (recombinant GM-CSF produced in E. coli) display similar 
therapeutic effects (Beveridge et al., 2009), but sargramostim-treated patients reported 
fewer adverse events (Dorr, 1993).     
 Because of the benefit of GM-CSF in models of autoimmunity, ongoing research 
is determining whether sargramostim can act as an adjuvant or as an anti-inflammatory 
mediator in human patients.  As indicated above, ongoing research is testing the efficacy 
of sargramostim as an adjuvant for the hepatitis B vaccine and to increase immune 
responses to various tumors.  In addition, sargramostim is also being investigated for its 
ability to diminish clinical symptoms of Crohn’s disease, a chronic inflammatory disease 
of the gastrointestinal tract.  In several trials (Korzenik et al., 2005; Takazoe et al., 2009; 
Valentine et al., 2009), but not all (Roth et al., 2012), sargramostim diminishes clinical 
severity compared to placebo control.  Additional clinical trials have been completed to 
better investigate the clinical efficacy of sargramostim, but results have not been 
published (NCT00206674, NCT00206596).  To date, none of these trials addressed if 
the changes in clinical score were related to changes in immune cell, especially Treg, 
number or function.  The ability of sargramostim to mitigate the cognitive decline in 
Alzheimer’s disease is also being tested in ongoing clinical trials (NCT01409915 and 
NCT02667496).  In PD, sargramostim decreased the Unified Parkinson’s Disease 
23 
 
Rating Scale (UPDRS) part III clinical score in patients, mitigated the loss of beta ERD in 
the precentral gyrus, and increased Treg percentage and function (Gendelman et al., 
2017).  These data suggest that sargramostim mitigates PD symptoms which may be 
related to Treg number and/or function.  In total, GM-CSF and sargramostim have 
immune modulatory function related to increases in immune cell number.  Depending on 
which cells are increased, GM-CSF may display an immune-stimulating or immune-
diminishing function.  
 
MECHANISMS OF TREG INDUCTION  
 Tregs are derived from two sources.  The first is thymic-derived or natural Tregs, 
the second is induced or peripheral Tregs.  Natural Tregs are derived from the thymus 
and are part of the mechanism of central tolerance (Bluestone and Abbas, 2003; 
Povoleri et al., 2013).  These CD4+ T cells recognize self-antigens presented in the 
thymus with intermediate strength as part of CD4+ T cell differentiation.  Natural Tregs 
express high CD25, Foxp3, GITR, CTLA-4, and Helios.  Induced Tregs are derived from 
mature, naïve CD4+ T cells that interact with APCs in the periphery.  The absence of 
sufficient antigen stimulation, the presence of co-stimulatory molecules and cytokines 
such as IL-10 and TGF-β bias the activation of CD4+ T cells to induced Tregs.  Induced 
Tregs express variable amounts of CD25, Foxp3, GITR, and CTLA-4, but not Helios.  
Despite different origins, natural Tregs and induced Tregs possess similar suppressive 
functions such as release of immunosuppressive cytokines including IL-10 and TGF-β, 
cell to cell suppression with co-stimulatory molecules like CTLA-4, competition for 
growth factors such as IL-2 and tryptophan, and modulation of the functions of APCs. 
 Dendritic cells are the primary immune cells that induce Tregs in the periphery.  
As described above, two populations of dendritic cells, plasmacytoid and myeloid, arise 
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from different progenitors (Rutella et al., 2006).  Both dendritic cell populations display 
two maturation states, immature cells which actively take up antigens, but exhibit low 
antigen presentation capability, and mature dendritic cells which exhibit less antigen 
uptake and increased antigen presentation capabilities (Maldonado and von Andrian, 
2010; Raker et al., 2015).  Dendritic cells are functionally characterized as immunogenic 
or tolerogenic dendritic cells, which induce naive helper T cells to differentiate effector or 
regulatory helper T cells, respectively (Maldonado and von Andrian, 2010).  Tolerogenic 
dendritic cells induce Tregs by multiple mechanisms including release of anti-
inflammatory cytokines IL-10 and TGF-β, increased expression of IDO and its by-product 
kynurenine, and altered surface co-stimulatory molecule expression (Steinman et al., 
2003; Maldonado and von Andrian, 2010; Li and Shi, 2015; Raker et al., 2015).  The 
percentage of tolerogenic dendritic cells can be increased naturally by increased 
expression of anti-inflammatory cytokines, increased concentration of glucocorticoids, 
other anti-inflammatory modulators such as VIP and vitamin D3, and pharmacological 
inducers such as GM-CSF (Maldonado and von Andrian, 2010).  As indicated above, 
GM-CSF induces tolerogenic dendritic cells which can be productive in models of 
autoimmunity.  GM-CSF-induced tolerogenic dendritic cells induce Treg formation 
through the co-stimulatory molecules OX40L and Jagged-1 (Gopisetty et al., 2013; 
Haddad et al., 2016; Kumar et al., 2017).  Because of the neuroprotective effects of GM-
CSF in PD patients and in the MPTP model, research is warranted to determine whether 
the induction of tolerogenic dendritic cells is a mechanism of neuroprotection.       
 
SUMMARY AND CONCLUSIONS 
 PD is a neurodegenerative disease characterized by the loss of dopaminergic 
neurons in the pars compacta substantia nigra and accumulation of α-Syn-containing 
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Lewy bodies.  During PD disease, microglia become activated and the peripheral 
immune system becomes dysregulated.  Included in this peripheral dysfunction is a 
decrease in Treg percentage and function and increased expression of proinflammatory 
mediators, suggesting a bias toward inflammation.  Correcting this imbalance would be a 
novel therapeutic for PD.  GM-CSF is a cytokine which, among other functions, 
increases the number and function of Tregs.  Administration of GM-CSF increases the 
percentage of Tregs, diminishes neuroinflammation and protectes dopaminergic neurons 
in the MPTP model.  Sargramostim diminishes UPDRS part III scores and increases 
Treg percentage and function in PD patients.  In models of autoimmunity, GM-CSF 
diminishes autoimmunity by inducing tolerogenic dendritic cells which induce Tregs and 
suppress inflammation.  This project investigates whether tolerogenic dendritic cells are 













CHAPTER TWO  
GENE EXPRESSION IN T RESPONDER CELLS IN PD PATIENTS 
TREATED WITH SARGRAMOSTIM 
ABSTRACT 
 In Parkinson’s disease (PD) the percentage of peripheral immune cells and 
mediators is altered.  The increase in proinflammatory cytokines and helper T cell 
subsets and the decrease in anti-inflammatory cytokines and helper T cell subsets may 
contribute to the pathology and progression of PD.  A novel therapeutic agent that could 
restore balance between proinflammatory and anti-inflammatory cells and cytokines may 
decrease the symptoms of disease, slow the progression of disease, and create an 
environment to recover lost neurons.  Sargramostim is recombinant human GM-CSF 
which is an FDA approved drug.  From a phase I clinical trial, we isolated CD4+ CD25- T 
cells from healthy controls, PD placebo controls, or sargramostim-treated PD patients 
and isolated RNA for PCR arrays to test expression of genes for helper T cell 
differentiation.  We hypothesized that sargramostim-treated PD patients would show 
increased expression of anti-inflammatory genes and decreased expression of 
proinflammatory genes.  We found that sargramostim increased the expression of both 
pro- and anti-inflammatory genes as well as genes involved in helper T cell 
differentiation and proliferation.  These data demonstrate that sargramostim increases 
the expression of genes associated with all helper T cell subsets, and in general 
expands the immune response.  This suggests that GM-CSF alters the immune 
response in PD patients, including increasing Tregs and anti-inflammatory immune cells 





 Part of PD pathology of PD is inflammation in the substantia nigra and striatum.  
This neuroinflammation is mediated by activated resident microglia as well as infiltrating 
immune cells, including lymphocytes (Qian et al., 2010; Gonzalez and Pacheco, 2014).  
These activated cells release reactive oxygen and nitrogen species as well as 
proinflammatory cytokines and chemokines (Whitton, 2007).  This oxidizing environment 
leads to the post-translational modification of proteins such as nitration of α-synuclein 
(Duda et al., 2000; Giasson, 2000).  The resulting inflammatory and oxidizing 
environment promotes the loss of more dopaminergic neurons which, in turn, leads to 
more neuroinflammation and increased neurodegeneration (Mosley et al., 2012). 
Not only is there inflammation in the brains of PD patients, the peripheral immune 
system shows signs of dysregulation.  Peripheral blood of PD patients contain 
decreased numbers of plasmacytoid and myeloid dendritic cells in the blood (Ciaramella 
et al., 2013), and increased numbers of total granulocytes (Horvath and Ritz, 2015), but 
neutrophil number is not increased (Atac Ucar et al., 2016).  Total numbers of 
monocytes are not changed in PD patients’ blood; however, classical monocytes 
(CD14+ CD16-) are increased in PD patients while non-classical monocytes (CD14- 
CD16+) are decreased in PD patients (Grozdanov et al., 2014).  In addition to changes 
in the myeloid cells, changes within the lymphocyte population have also been 
described.  PD patients display increased γδ T cells (Fiszer et al., 1994) and CD8+ T 
cells (Baba et al., 2005), but decreased B cells (Niwa et al., 2012; Stevens et al., 2012; 
Horvath and Ritz, 2015) and CD4+ T cells (Baba et al., 2005; Hutter-Saunders et al., 
2012; Niwa et al., 2012; Stevens et al., 2012; Horvath and Ritz, 2015).  More specifically, 
PD patients exhibit decreased naïve CD4+ T cells (CD4+ CD45RA+) and increased 
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memory CD4+ T cells (CD4+ CD45RO+) (Hutter-Saunders et al., 2012; Stevens et al., 
2012; Horvath and Ritz, 2015).  In addition, the percentage of different helper T cell 
subsets is also changed within PD patients.  Percentages of proinflammatory Th1 and 
Th17 helper T cells are increased, but the percentage of the anti-inflammatory Th2 
helper T cells and Tregs are decreased (Chen et al., 2015).  Tregs also possess 
decreased ability to suppress the proliferation of CD4+ CD25-  responder T cells in 
culture (Hutter-Saunders et al., 2012), suggesting that Tregs from PD patients are less 
functional.  In addition to these alterations in immune cell number and function, serum 
proinflammatory cytokines including IL-6, MCP-1, MIP-1α, IL-1β, IFNγ, and TNF-α are 
increased in serum (Reale et al., 2009; Scalzo et al., 2010; Lindqvist et al., 2012).      
 Reestablishing immune homeostasis is a novel target for PD treatment.  By 
increasing the percentages and concentration of anti-inflammatory cells and 
concentrations of cytokines, thus decreasing the percentage of proinflammatory cells 
and concentration of cytokines, neuroinflammation and neuroprotection can be 
mitigated.  Several potential therapies target diminution of neuroinflammation and are 
neuroprotective in models of PD; some increase Treg percentage and function.  One 
potential therapeutic is vasoactive intestinal peptide (VIP).  This short peptide is 
neuroprotective in the MPTP model (Delgado and Ganea, 2003; Reynolds et al., 2010; 
Olson et al., 2015) and induces Tregs (Gonzalez-Rey and Delgado, 2007).  Adoptive 
transfer of splenocytes from VIP-treated mice is neuroprotective (Olson et al., 2015).  
VIP decreases reactive microglia numbers in the substantia nigra following MPTP 
intoxication (Delgado and Ganea, 2003; Reynolds et al., 2010; Olson et al., 2015).  This 
effect of VIP is mediated by binding to VIP receptor 2, since a specific agonist to this 
receptor, but not VIP receptor 1, has the same neuroprotective effect as VIP (Olson et 
al., 2015).  Bee venom, and its active component phospholipase A, protects 
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dopaminergic neurons and decreases neuroinflammation in the MPTP of PD (Doo et al., 
2010; Chung et al., 2012; Chung et al., 2015; Kim et al., 2016).  This neuroprotection 
was mitigated by Treg depletion, suggesting that bee venom acts through Tregs (Chung 
et al., 2012; Chung et al., 2015).  However, in a clinical trial, bee venom was unable to 
decrease Unified Parkinson’s Disease Rating Scale (UPDRS) scores of PD patients 
(Hartmann et al., 2016).  Minocycline is another anti-inflammatory drug that is protective 
in the MPTP model of PD (Du et al., 2001; Wu et al., 2002).  However, like bee venom, 
minocycline was unable to diminish PD symptoms in a clinical trial (Investigators, 2006).  
Lastly, pioglitazone, a ligand for peroxisome proliferator-activated receptor gamma 
(PPAR-γ), treatment results in protected neurons and reduced neuroinflammation in 
MPTP-intoxicated mice (Laloux et al., 2012).  However, pioglitazone was unable to 
improve outcomes in PD patents (Investigators., 2015; Simon et al., 2015).  Despite 
neuroprotection and decreased neuroinflammation from the use of these and other 
therapeutics in PD models, no therapy to date has proven effective in PD patients.       
 GM-CSF represents a new potential therapy for PD.  Pre-treatment with GM-CSF 
protects dopaminergic neurons and decreases neuroinflammation in the model of MPTP 
(Kosloski et al., 2013).  GM-CSF also increases the percentage of splenic Tregs in a 
dose-dependent manner.  Adoptive transfer of Tregs from GM-CSF-treated mice are into 
MPTP-intoxicated mice decrease neuroinflammation and neurodegeneration, suggesting 
that the neuroprotective benefits of GM-CSF are mediated, at least in part, by the 
induced Tregs.  GM-CSF is a readily translatable drug since it is already FDA approved 
for humans.  Sargramostim (Leukine) is a yeast-produced recombinant human protein 
which is FDA approved for reconstitution of the immune system post-chemotherapy 
(Waller, 2007).  Sargramostim decreased the symptoms of Crohn’s disease, an 
inflammatory gastrointestinal disorder (Korzenik et al., 2005; Takazoe et al., 2009; 
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Valentine et al., 2009), but no research has been done to determine if gut inflammation 
is decreased or Treg numbers are increased in these patients.  The Nebraska Medical 
Center initiated a phase I clinical trial to test the benefit of sargramostim in PD patients.  
This trial tested Treg percentage and function as well as neurological changes, motor 
functions and metabolomic changes.  If Tregs are having an in vivo effect, we 
hypothesized that anti-inflammatory cytokines would be increased with decreased 
proinflammatory cytokines expression by CD4+ CD25- T cells, which are suppressed by 
Tregs.  To test this, we isolated CD4+ CD25- T cells and used PCR arrays to test the 
expression of genes related to CD4+ T cells expression and differentiation.  Here, we 
present the expression of these genes in healthy controls, and PD patients treated with 




A single-center, randomized, double-blind phase 1 clinical trial was performed at 
the University of Nebraska Medical Center (UNMC) and was approved by the UNMC 
Institutional Review Board (Gendelman et al., 2017).  Briefly, PD patients were recruited 
according to the following inclusion criteria: age 35-85, onset and persistence of 
symptoms ≥3 years and a Hoehn and Yahr disease scale ≤ stage 4.  Exclusion criteria 
include diagnosis of multiple system atrophy, corticobasal degeneration, prior head 
injury, stroke, brain surgery, mental illness, cognitive impairment, autoimmune disease, 
systemic inflammatory disorder, hematologic disorders, PD symptoms lasting less than 3 
years, and more than one blood relative diagnosed with PD. This trial also excluded 
individuals who had taken lithium, neuroleptics, or immunomodulatory treatment within 
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90 days of starting the study.  Allergies to benzyl alcohol, colony-stimulating factors or 
yeast-derived products and ferrous metal implants were also grounds for exclusion.  
Age-matched, non-PD controls were also recruited.  After referral to the clinical research 
center (CRC), written informed consent was obtained in accordance with Good Clinical 
Practice guidelines.   
 Healthy, non-PD controls, and PD patients had 3 pretreatment appointments to 
establish neurological and immunological baselines (visits 1-3).  The 3rd appoint was the 
final appointment for the healthy controls and the PD patients were randomized in equal 
numbers to receive sargramostim or placebo.  PD patients self-administered a 
subcutaneous injection of saline (placebo) or 6 µg/kg/day sargramostim every day for 56 
days.  Every two weeks during this treatment phase, patients continued doctor visits for 
blood draws and to monitor health and motor function (visits 4-7).  Patients returned for a 
post-treatment visit one month after ceasing treatment (visit 8).  During each visit, blood 
was drawn, the patient was examined by a physician, and the UPDRS part III clinical 
assessment was performed.  Patients remained on anti-PD medications and UPDRS III 
evaluation was performed while patients were in the "ON" state. Table 2.1 is a summary 
of the study design and the number of patients from each treatment group included for 
the gene expression analysis.     
A subset of healthy controls, placebo-treated PD patients, and sargramostim-



















































Table 2.1 Study design 
The table describes of the study design for this clinical trial.  The treatment phase, visit, 
and weeks indicate when each visit occurs relative to starting treatment with placebo or 
sargramostim and which visit belongs to each treatment phase.  For the treatment 
groups, the number of patients from which RNA was isolated out of the total number of 





isolate CD4+ CD25- cells, which were isolated from blood and combined with CD4+ 
CD127low CD25- cells remaining after Treg isolation.  The combination was used for 
flow cytometric analysis and RNA isolation. 
Isolation of CD4+ cells 
CD4+ cells were isolated by isolating lymphocytes using lymphocyte separation 
media (LSM, MP Biomedicals LLC Santa Ana, CA) prior to positive CD4+ isolation.   
Briefly, the whole volume of a single tube of blood was diluted by the addition of an 
equal volume of 1x HBSS (Gibco, Carlsbad, CA).  The lymphocytes and monocytes 
were separated by layering diluted blood on top of LSM before centrifugation at 400 xg 
for 20 min without breaking.  The buffy coat was transferred to a new tube and was 
washed in 3 volumes of 1x HBSS.  Cells were concentrated by centrifugation at 200 xg 
for 10 min. To the cell pellet, 80 μl of Miltenyi CD4+ buffer (0.5% bovine serum albumin 
(BSA), 2 mM EDTA in 1x DPBS (Gibco)) and 20 μl anti-CD4 magnetic beads (Miltenyi 
Biotec Auburn, CA) were added for every 1x107 cells.  After incubation at 4°C for 15 min, 
cells were washed in 2 ml Miltenyi CD4+ buffer for every 1x107 cells and cells were 
concentrated by centrifugation at 300 xg for 10 min.  The cell pellet was resuspended in 
500 μl Miltenyi CD4+ buffer and the whole volume was pipetted into a Miltenyi LS 
column which was placed in a magnet.  The column was washed three times with 2 ml 
Miltenyi CD4+ buffer.  Five milliliters of Miltenyi CD4+ buffer was added to the column, 
the column was removed from the magnet, and the buffer was forced through the 
column into a 15 ml conical tube using a plunger.  This procedure was used to isolate 
cells for XIL visits 1 and 2, YEA visits 1 and 2, ZNB visits 1 and 2, BED visit 1, CAE visit 
1, DBF visit 1, and ECG visit 1.     
Isolation of Responder T cells 
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Responder T cells were isolated according to the protocol for the R&D CD4+ 
enrichment kit as follows.  Briefly, lymphocytes were isolated by LSM as described 
above.  The resulting lymphocytes were resuspended in 1 ml 1x R&D CD4+ enrichment 
kit column buffer (R&D systems, Minneapolis, MN).  In addition to antibodies for the 
selection of CD4+ CD25- cells, 2 μg/1x106 cells of anti-CD16 (clone 3G8 BD, Franklin 
Lakes, NJ), anti-CD8 (clone HIT8a BD), and anti-CD25 (clone M-A251 BD) and 1 
μg/1x106 cells anti-CD16 (clone 245536 R&D Systems) was added to enhance purity.  
Cells were incubated with antibodies at RT for 15 min mixing the tube every 2 min,  
washed 2 times in 1x column buffer, and resuspended in 2 ml R&D column buffer before 
adding to the column.  After incubating the cells on the column for 10 min, the cells were 
washed through the column with R&D column buffer and cells were concentrated by 
centrifugation at 400 xg for 5 min.  These cells were combined with the cells isolated 
following the cell rosetting protocol as described below.  This method was used for 
isolating cells from the following patient visits: XIL visits 3, 4 and 5, YEA visit 3, ACC visit 
3, ZNB visits 3, 4 and 5, BED visit 2, CAE visit 2, DBF visit 2, ECG visit 2, FDH visits 1 
and 2, HFJ visits 1 and 2, and IGK visits 1 and 2.   
Isolation of CD4+ CD25- cells 
As with the responder T cells, lymphocytes and monocytes were isolated by LSM 
and these buffy coat cells were washed in 1x HBSS.  To the cell pellet, 80 μl of Miltenyi 
CD4+ buffer (0.5% BSA, 2 mM EDTA in 1x DPBS) and 20 μl anti-CD25 magnetic beads 
(Miltenyi Biotec) were added for every 1x107 cells. After incubation at 4°C for 15 min, 
cells were washed in 2 ml Miltenyi CD4+ buffer for every 1x107 cells, concentrated by 
centrifugation at 300 xg for 10 min, resuspended in 500 μl Miltenyi CD4+ buffer, and the 
whole volume was added into a Miltenyi LD column.  The column was washed 3 times 
with 2 ml Miltenyi CD4+ buffer.  The CD25-depleted cells were concentrated by 
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centrifugation at 300 xg for 10 min, and 40 μl Miltenyi CD4+ buffer and 10 μl CD4+ 
antibody cocktail was added for every 1x107 cells.  After incubation at 4°C for 5 min, 30 
μl Miltenyi CD4+ buffer and 20 μl of Miltenyi microbeads were added for every 1x107 
cells.  After incubation at 4°C for 10 min, 500 μl Miltenyi CD4+ buffer was added and the 
whole volume was added into a Miltenyi LS column.  Cell effluents through the column 
were collected as CD4+ CD25- T cells.  Cells were counted and combined with T cells 
isolated from the rosetted procedure for flow cytometry and RNA isolation.  This method 
was used for T cell isolation for the following patient visits: XIL visits 7 and 8, ZNB visits 
6, 7 and 8, BED visits 3-8, CAE visits 3, DBF visits 3-8, ECG visits 3, HFJ visits 3-8, IGK 
visit 3, JHL visits 1-8, KIM visits 1-3, LJN visits 1-8, MKO visits 1-8, and NLP visits 1-8.   
Isolation of CD4+ CD127low CD25- cells 
Tregs (CD4+ CD127low CD25+) were isolated from 6 tubes of blood using the 
RosetteSep human CD4+ CD127low CD25+ isolation kit (Stemcell Technologies, 
Vancouver, BC) as follows.  Briefly, 50 μL/mL RosetteSep human CD4+ CD127low pre-
enrichment cocktail was added to whole blood and the mixture was incubated for 20 min 
at RT.  Whole blood (25 ml) was layered onto 15 ml density media in a Sep-Mate-50 
tube and cells were separated by centrifugation at 1,200 xg for 10 min.  The top layer, 
which contains mononuclear cells, was decanted and washed two times in Treg buffer 
(1x DPBS with 2% fetal bovine serum (FBS, Sigma, St. Louis, MO)).  To isolate CD25+ 
cells, EasySep positive selection cocktail was added at 50 µl/ml, incubated at RT for 15 
min, 50 µl nanoparticles/ml was added, and incubated at RT for 10 min. The tube was 
placed in a magnet field and incubated for 5 min.  While remaining in the magnetic field, 
cells were washed 9 times by decanting supernatant and 2.5 ml of Treg buffer was 
added.  The negatively selected CD25- T cells decanted in the washes were 
concentrated by centrifugation at 400 xg for 5 min.  Red blood cells in the pellet were 
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osmolysed by incubating in 9 ml autoclaved ultrapure water for 30 sec and 1 ml 10x PBS 
was added to restore osmolarity and cells were concentrated by centrifugation at 400 xg 
for 5 min.  The cells were counted and combined with the CD4+, responder T cells or 
CD4+ C25- cells isolated above for flow cytometry and RNA isolation.  This method was 
performed for all patient visits and these cells combined with cells isolated using the 
above methods.   
Flow cytometry 
Flow cytometric analysis was performed at the UNMC flow cytometry research 
facility.  A volume corresponding to 250,000 cells was brought to 100 μl by the addition 
of flow cytometry stain buffer (FSB, 0.5% BSA and 0.1% sodium azide in 1x DPBS) and 
the cells were stained by the addition of anti-CD4-FITC (clone RPA-T4 BD), anti-CD25-
PE (clone M-A251 BD), anti-CD127-PERCPCy5.5 (clone HIL-7R-M21BD), anti-
CD45RA-AF700 (clone HI100, BD), anti-CD45RO-APC (clone UCHL1, BD) and anti-
CCR7-PECy7 (clone 3D12 BD) at 4°C for 20 min.  Cells were washed twice by the 
addition of 2 ml FSB per wash, concentrated by centrifugation at 400 xg for 5 min,   
resuspended in 500 μl flow cytometry fix (1% formaldehyde in 1x DPBS), and cells were 
incubated at RT for 10 min.  Fixed cells were concentrated by centrifugation at 400 xg 
for 5 min.  The cell pellet was resuspended in 300 μl FSB prior to analysis with a BD 
LSR II flow cytometer interfaced with FACSDiva analytical software (version 8.0) (BD 
Biosciences, San Jose, CA).    
 RNA isolation, cDNA conversion and PCR arrays 
With fewer than 3x106 total cells, then all cells were pelleted at 400 xg for 10 min 
and frozen at -80°C for RNA isolation when remaining samples were collected.  With 
more than 3x106 cells, half of the cells were pelleted and frozen as above.  The other 
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half of the cells were brought to ~1x106 cells/ml with the addition of complete media 
(RPMI 1640 supplemented with L-glutamine (Gibco), 10% FBS (Sigma), 1 mM sodium 
pyruvate (Gibco), 1x MEM non-essential amino acids (Hyclone, Logan, Utah), 1x 
Penicillin-Streptomycin (Gibco), 10 mM HEPES (Sigma), 2 mM L-glutamine (Gibco) and 
55 nM 2-mercaptoethanol (Gibco)) and 100 μl was added to each well of a U-bottom 96-
well plate.  An additional 100 μl media containing ~5x105 anti-CD3/CD28 magnetic, co-
stimulatory dynabeads was added to each well (Gibco).  After 6 hours of stimulation, the 
cells were removed from the 96-well plate, combined and concentrated at 400 xg for 10 
min, and cell pellets were frozen at -80°C.   
RNA was isolated according to the directions in the RNeasy mini kit (Qiagen, 
Valencia, CA).   Briefly, cell pellets were resuspended in Buffer RLT (350 µl RLT 
buffer/~5x106 cells) supplemented with 10 μl β-mercaptoethaol/ml RLT and cells were 
lysed by passing through a 20 Ga needle 10 times.  The cell lysate was clarified by 
centrifugation at 20,800 xg for 3 min, supernatant added to an equal volume of 70% 
ethanol, added to a spin column, and passed through at 10,800 xg for 1 min.  The flow 
through was discarded and the filter was washed in RW1 buffer.  DNA was digested 
using the RNase-free DNase kit (Qiagen) by adding 10 μl DNase I and 70 μl RDD buffer 
per column, and the digestions were incubated at RT for 15 min.  The column was 
washed in RW1 a second time and then in RDD buffer two times.  RNA was eluted by 
the addition of water.  The eluted RNA was passed through the column a second time to 
maximize RNA yield and RNA concentration was determined by UV spectrometry at 
260, 280, and 230 nm (NanoDrop spectrophotometer, ThermoScientific, Waltham, MA).   
Single-stranded cDNA was made as directed using the RevertAID single strand 
cDNA synthesis kit (ThermoScientific).  Briefly, depending on the RNA concentration, 
100, 125 or 250 ng RNA was brought to 11 μl with water provided in the kit and 1 μl 
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poly(T) primers and the secondary structure of RNA was disrupted by heating at 65°C 
for 5 min.  A master mix of 4 μl reaction buffer, 2 μl dNTPs, 1 μl ribolock RNase inhibitor 
and 1 μl reverse transcriptase/sample was added and synthesis was performed at 42°C 
for 1 hr.  The reaction was terminated by heating at 70°C for 5 min.  The multiple 
reactions of each sample were combined and frozen at -20°C until the PCR arrays were 
performed.   
The expression of genes related to helper T cell differentiation was determined 
using a Helper T cell differentiation array which was performed according to the 
manufacturer’s protocol SABiosciences (Frederick, MD).  Briefly, water, 2x RT2 ROX 
master mix, and the cDNA was combined and 25 μl was added to each well of the array.  
PCR was performed using an Realplex S2 thermocycler (Eppendorf, Hamburg, 
Germany) with a 10 min hot start at 95°C, then 40 cycles of a two-steps of 95°C for 15 
sec and 60°C for 1 min followed by a melting curve.  GAPDH was used as the 
housekeeping gene.  Data analysis was performed using the Qiagen software and fold 
changes were determined using the ΔΔCt method.    
Statistical analysis 
For flow cytometry samples, the Mann-Whitney U test was used to determine 
significant differences between the healthy controls, placebo-treated PD patients and 
sargramostim-treated PD patients at each visit.  Statistics for flow cytometry data were 
performed by GraphPad (La Jolla, CA) Prism version 6.  For the PCR arrays, the RT2 
Profiler PCR array data analysis software version 3.5 was used to calculate the fold 
change between samples.  For downregulated genes, fold changes are the negative 





Flow cytometry characterization of CD4+ CD25- 
Flow cytometric analysis was performed on CD4+ CD25- T cells isolated from 
participants to identify various subpopulations of T cells over the trial in the treatment 
groups.  In Figure 2.1A, the percentage of CD4+ T cells in the total population for each 
visit was graphed.  Consistently, around 40% of the total population was CD4+ T cells 
for the healthy controls, the placebo-treated PD patients and the sargramostim-treated 
PD patients.  The identity of the non-CD4 cells was not determined, though they 
appeared to be the same size and granularity as the CD4+ cells suggesting they were 
lymphocytes and/or monocytes.  In Figure 2.1B, no significant differences in the 
percentage of naïve CD4+ T cells (CD4+ CD45RA+ CCR7+) were discerned between 
placebo-treated and sargramostim-treated PD patients, with the exception at visit 7 
where sargramostim-treated patients have a significant decrease in these T cells.  
Healthy controls were not different from either PD patient group at visits 1-3.  No 
differences were detected between the percentage of central memory (CD4+ CD45RO+ 
CCR7+) or effector memory (CD4+ CD45RO+ CCR7-) helper T cells between healthy 
controls, placebo-treated, and sargramostim-treated PD patients at any visit (Figure 
2.1C and 2.1D respectively). Interestingly, sargramostim-treated PD patients tend to 
possess increased effector memory helper T cells compared to the placebo-control 
patients at visits 6 and 7 (Figure 2.1D).  In Figure 2.1E, the percentages of Tregs (CD4+ 
CD127- CD25+) were not different between the healthy controls, placebo-treated PD 
patients, and sargramostim-treated PD patients at any visit.  At visit 6, activated effector 
T cells (CD4+ CD127+ CD25+) in sargramostim-treated PD patients were elevated 









Figure 2.1 Flow cytometric analysis of CD4+ CD25- cells 
CD4+ CD25- cells were isolated from the blood of healthy controls (black lines), placebo-
treated (blue lines) and sargramostim-treated (red lines) PD patients at each visit.  Flow 
cytometric analysis was used to determine the surface expression of CD4, CD127, 
CD25, CD45RO, CD45RA and CCR7.  Within the whole blood, we determined the 
percentage of total CD4+ T cells (A).  The percentage of naïve helper T cells (CD4+ 
CD45RA+ CCR7+) (B), central memory helper T cells (CD4+ CD45RO+ CCR7+) (C), 
effector memory helper T cells (CD4+ CD45RO+ CCR7-) (D), regulatory T cells (CD4+ 
CD127- CD25+) (E) activated effector helper T cells (CD4+ CD127+ CD25+) (F) within 
the total CD4+ T cell population was determined.  Significance was determined by the 




difference and there were no differences compared to the healthy controls (Figure 2.1F).  
These data demonstrate that the isolated T cells population showed roughly equal 
percentages of these T cell subpopulations over time.  As such, changes in gene 
expression were not due to differences in cell type being analyzed. 
Gene expression comparing to PD patients to controls    
After isolating RNA from each sample, we determined the A260/A80 and 
A260/A230 by UV spectrometry.  Each PCR array contains a genomic DNA 
contamination control.  The result is included in Table 2.2 to give an indication of 
RNA/cDNA quality.  The first gene expression analysis we performed was to compare all 
PD patients to healthy controls pre-treatment (visits 1-3).  In unstimulated CD4+ CD25- 
cells (Figure 2.2A), PD patients upregulated more than 2-fold several genes associated 
with proinflammatory cell types.  For instance, STAT4 is a transcription factor induced by 
IL-12 (Watford et al., 2004), EOMES, a transcription factor upregulated in activated Th1 
helper T cells (Lupar et al., 2015), RORC is the master transcription factor for Th17 
helper T cells (Martinez et al., 2008; Jetten, 2009), and IL18RAP is the beta chain for the 
IL-18 receptor (Fiszer et al., 2007).  PD patients also downregulated by more than 2-fold 
anti-inflammatory genes such as CCR4, a chemokine receptor selectively expressed on 
Th2 helper T cells (Yoshie and Matsushima, 2015), and ICOS, a co-stimulatory molecule 
the favors development of Th2 helper T cells and proliferation and survival of Tregs 
(Simpson et al., 2010).   
 We also analyzed the gene expression of CD4+ CD25- cells stimulated with 
CD3/CD28 beads for 6 hours from healthy control and all PD patients prior to treatment 
(Figure 2.2B).  PD patients increase the expression of IRF4, a gene involved in the 









Table 2.2 RNA quality analysis 
A table listing the ratio of the RNA absorbance at 260 and 280 nm (A260/A280) and the 
ratio of RNA absorbance at 260 and 230 nm (A260/A230).  Lastly, we tested each 
sample for genomic contamination of the cDNA.  There was no genomic contamination 
when the ct value for the included control well on each PCR array was >35.  When the ct 
value was in the cycle 30-35 range, genomic contamination is possible.  Genomic DNA 
was confirmed when the ct value was less than cycle 30.  The PCR array for patient 
DBF at visit 2 unstimulated could not be determined because an improper PCR cycle 
program was used and there was insufficient sample to repeat the analysis.  This 







Figure 2.2 Gene expression comparing PD patients to healthy controls pre-treatment 




Figure 2.2 Gene expression comparing PD patients to healthy controls pre-
treatment with and without CD3/CD28 stimulation 
RNA was extracted from the isolated CD4+ CD25-, and cDNA copies were made from it 
prior to PCR using an array for human CD4+ T cell differentiation.  The fold change in 
expression from each gene was compared for the PD patients compared to healthy 
controls using the ΔΔCt method.  Heat maps were generated for all genes more than 2-
fold up- or downregulated for (A) unstimulated and (B) CD3/CD28 bead-stimulated CD4+ 
CD25- cells.  The numbers are the fold change.  Red shaded cells are upregulated 
genes and green shaded cells are downregulated genes.  The shade of color denotes 




compared to healthy controls.  However, PD patients exhibited 2-fold decreased 
expression of anti-inflammatory genes such as IL5, TNFSF11, CCR4, CCL7, IL9, 
PTGDR2 and ICOS.  Expression of proinflammatory genes such as SOCS5, IL17RE 
and IL17A were decreased in PD patients.  Combined, these data suggest PD patients 
express more proinflammatory genes at rest compared to healthy controls.  However, 
after stimulating CD4+ CD25- cells with CD3/CD28 beads, PD patients display lower 
gene expression compared to healthy controls.   
Gene expression compared to baseline for placebo or sargramostim PD patients 
We next tested the expression of genes in the placebo-treated and 
sargramostim-treated PD patients at visits 4, 5, 6, 7 and 8 compared to the baseline 
(visits 1-3) in unstimulated CD4+ CD25-.  Figure 2.3A is a heatmap of all 2-fold gene 
expression changes in placebo-treated PD patients for each visit compared to the 
baseline.  The gene changes in the placebo-treated PD patients were smaller compared 
to sargramostim-treated patients and no discernible peak in the expression was evident 
over time.   
Figure 2.3B is a heat map of all 2-fold gene changes at each visit for the 
sargramostim-treated patients compared to baseline.  Some increased genes were non-
associated genes; those involved in T cell differentiation and proliferation and included 
GATA4, TNFRSF9, IL2, KIF2C, and HOXA3.  Expression of proinflammatory genes 
were increased including IL21, IL12B, IL17A, IL1R1, IL17RE, SOCS5, and HAVCR2.  
Increased anti-inflammatory gene expression included IL4, CCL7, IL1RL1, IL9, PPARG, 
LRRC32, TNFSF11, IL13, IL5, PTGDR2, CCR4, and ICOS.  Expression of non-
associated genes such as STAT1, MAF, and RUNX3 were also decreased. Several 




Figure 2.3 Gene expression comparing unstimulated CD4+ CD25- on-treatment and 
post-treatment visits to baseline for placebo- or sargramostim-treated PD patients 
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Figure 2.3 Gene expression comparing unstimulated CD4+ CD25- on-treatment 
and post-treatment visits to baseline for placebo- or sargramostim-treated PD 
patients 
RNA was extracted from the isolated CD4+ CD25-, and cDNA copies were made from it 
prior to PCR using an array for human CD4+ T cell differentiation.  The fold change of 
expression from each gene was compared for the placebo and sargramostim-treated PD 
patients on-treatment (visits 4-7) and post-treatment (visits 4-8) relative to baseline 
(visits 1-3) using the ΔΔCt method.  Heat maps were generated for all genes more than 
2-fold up- or downregulated for the unstimulated CD4+ CD25- from (A) placebo-treated 
PD patients and (B) sargramostim-treated PD patients.  The numbers are the fold 
change.  Red cells are upregulated genes and green cells are downregulated genes.  
The color shade denotes the degree of upregulation.  Pro-inflammatory genes are those 
related to Th1 and Th17 cells.  Anti-inflammatory genes are related to Th2 and Tregs.  





and IL18RAP.  Anti-inflammatory genes including CCL5, ID2, Jak1, STAT6, and GATA3 
were also decreased.  In general, the peak in gene expression was at visit 5.  At visits 6  
and 7, expression remained elevated in sargramostim-treated PD patients compared to 
baseline, but the expression was decreased compared to visit 5.  In general, there is no 
peak in decreased expression of genes.  Interestingly, there was a trend to decreasing 
expression of CCL5 (the gene for the chemokine RANTES) over treatment, with 
expression lowest at visit 7.  Post-treatment (visit 8), most genes returned to near 
baseline, though some genes remained increased or decreased.       
 Counter to our hypothesis, sargramostim increased the expression of both pro- 
and anti-inflammatory genes compared to baseline in CD4+ CD25- T cells.  It is not 
surprising that sargramostim increased the expression of genes associated with 
proliferation, since sargramostim increases the number and percentage of CD4+ T cells 
compared to placebo control (unpublished data).  The increase in anti-inflammatory 
genes is in line with increased Treg number and function from peripheral blood 
(Gendelman et al., 2017).  From the data presented here, proinflammatory genes were 
also increased. Interestingly, sargramostim does not change in the number of Teffs 
(CD4+ CD127+ CD25+) in whole blood and the T cells isolates for these analyses 
compared to placebo controls.  These data demonstrate that sargramostim can stimulate 
the expression of proinflammatory and anti-inflammatory genes in helper T cells.  
However, to what degree these changes in gene expression promote the differentiation 
of helper T cells to different subsets was not determined.   
 Because the identity of helper T cells is often revealed after activation, we 
stimulated cells with CD3/CD28 beads.  Figure 2.4A is a heat map of the 2-fold gene 




Figure 2.4 Gene expression comparing CD3/CD28-stimulated CD4+ CD25- at baseline 




Figure 2.4 Gene expression comparing CD3/CD28-stimulated CD4+ CD25- at 
baseline to on- and post-treatment visits for placebo- or sargramostim-treated PD 
patients 
RNA was isolated from the isolated CD4+ CD25-, and copied to generate cDNA prior to 
PCR using an array for human CD4+ T cell differentiation.  The fold change of 
expression from each gene by PD patients was compared to healthy controls using the 
ΔΔCt method.  Heat maps were generated for all genes that were more than 2-fold up- 
or downregulated for the stimulated CD4+ CD25- from (A) placebo-treated PD patients 
and (B) sargramostim-treated PD patients.  The numbers are fold change.  Red shaded 
cells are upregulated genes and green shaded cells are downregulated genes.  The 
shade of color denotes the degree of upregulation. Pro-inflammatory genes are those 
related to Th1 and Th17 cells.  Anti-inflammatory genes are related to Th2 and Tregs.  












treatment compared to baseline.  We were unable to isolate sufficient cells for 
stimulation at each visit for each patient.  Due to lack of samples, data were grouped by 
treatment phase as opposed to grouping by visit.  As in Figure 2.3, gene changes are 
smaller in the placebo-treated PD patients compared to sargramostim-treated PD 
patients.  In addition, there were no apparent changes were discerned in the pattern of 
gene expression on treatment or post treatment compared to baseline.     
Figure 2.4B is a heat map of all 2-fold gene changes in CD3/CD28 bead-
stimulated CD4+ CD25- T cells from sargramostim-treated PD patients on- or post-
treatment compared to baseline.  CD3/CD28 bead-stimulated CD4+ CD25- T cells from 
the sargramostim-treated patients on treatment showed upregulated several non-
associated genes such as GATA4, HOXA10, PERP, HOXA3, and KIF2C and a 
downregulated IL2, STAT1, MAF, and IL2RA.  Several proinflammatory genes were 
upregulated such as IL17A, IL17RE, IL18, IL12B, and RORC, while several were 
downregulated such as IFNG, TNF, STAT4, and IL18RAP.  Anti-inflammatory genes that 
were upregulated included PTGDR2, ASB2, UTS2, PPARG, IL4, ICOS, and LRRC32 
were increased.  But the expression CCL5, FOXP3, IRF4, STAT6, REL, and JAK1 were 
downregulated.  Many of the genes changed in the CD3/CD28-stimulated cells are 
similar to the genes changed in unstimulated cells (Figure 2.3).  For example, non-
associated genes like GATA4 and PERP, pro-inflammatory genes like IL17A and 
IL17RE, and anti-inflammatory genes like IL4 and PTGDR2 are upregulated in both 
unstimulated- and CD3/CD28-stimulated CD4+ CD25- cells.  Interestingly, the fold 
change is smaller after CD3/CD28-stimulation compared to unstimulated cells.  In 
general, the fold change on-treatment is higher and returns to near baseline at the post-




 Combined, Figures 2.3 and 2.4 demonstrate sargramostim increases the 
expression of many genes, both pro- and anti-inflammatory, in unstimulated CD4+ 
CD25- T cells compared to pre-treatment baseline.  However, stimulating this cell 
population with CD3/CD28 beads also increased the expression of these genes in all 
treatment phases, but decreases the effect of sargramostim treatment on gene 
expression.   
Gene expression comparing the placebo to sargramostim PD patients 
 Figures 2.3 and 2.4 demonstrated changes in gene expression relative to 
baseline for the placebo controls and sargramostim-treated group.  Another way of 
analyzing these data is to test sargramostim-treated gene expression relative to the 
placebo control at each visit.  In Figure 2.5, the gene expression in unstimulated CD4+ 
CD25- cells in the sargramostim-treated PD patients was compared to the placebo-
treated PD patients at each visit.  At baseline (visits 1-3), some genes that were more 
than 2-fold up- or downregulated.  These changes were relatively small, indicating little 
differences in gene expression between T cells isolated from PD patients at baseline.  
Starting by 2 weeks (visit 4) after treatment initiation and increasing to visit 5 noticeable 
increases were evident in expression of non-associated genes such as GATA4, 
TNFRSF9, PERP, and KIF2C.  Expression of several non-associated genes such as 
HOXA3, RUNX1, STAT4, and STAT1 also was decreased.  As in Figure 2.3, expression 
of proinflammatory genes such as IL21, IL12B, IL1R1, and IL17A was increased.  
Downregulated expression of proinflammatory genes included RORA and IL18RAP.  As 
hypothesized, sargramostim treatment increased the expression of anti-inflammatory 
genes such as CCL7, TNFRSF11, IL13, IL1RL1, IL4, LRRC32, PPARG, and PTGDR2, 




Figure 2.5 Gene expression comparing unstimulated CD4+ CD25- cells from placebo-




Figure 2.5 Gene expression comparing unstimulated CD4+ CD25- cells from 
placebo-treated compared to sargramostim-treated PD patients  
RNA was extracted from the isolated CD4+ CD25-, and copied to cDNA prior to PCR 
using an array for human CD4+ T cell differentiation.  Fold changes of expression from 
each gene was compared for the PD patients compared to healthy controls using the 
ΔΔCt method.  Heat maps were generated for all genes more than 2-fold up- or 
downregulated for the unstimulated CD4+ CD25 cells.  Red shaded cells are 
upregulated genes and green shaded cells are downregulated genes.  The color shade 
denotes the degree of upregulation.  Pro-inflammatory genes are those related to Th1 
and Th17 cells.  Anti-inflammatory genes are related to Th2 and Tregs.  The non-




These data are in line with Figure 2.3 demonstrating that sargramostim increases 
the expression of CD4+ T cell proliferation/differentiation, proinflammatory and anti-
inflammatory genes.  The peak expression appears to be at visit 5 (4 weeks after 
initiation of treatment), although the timing is different for different genes. Gene 
expression appears to remain elevated at visits 6 and 7, but by visit 8 (the post-
treatment visit), gene expression returned to near baseline.  This demonstrates that 
sargramostim treatment increased the expression of genes relative to placebo patients 
as well as relative to baseline.   
We also tested the expression of genes in the CD3/CD28 bead-stimulated CD4+ 
CD25- T cells from sargramostim-treated PD patients relative to placebo-treated PD 
patients (Figure 2.6).  As in Figure 2.4, there were insufficient samples to compare visit 
by visit, so we tested by treatment phase.  There was only one sample for the 
sargramostim treatment group post treatment.  As in Figure 2.5, at baseline, there were 
some genes that were more than 2-fold increased or decreased in expression after 
sargramostim treatment.  These were relatively small changes and indicative that PD 
patients display similar responses to CD3/CD28 stimulation at baseline.  During the on-
treatment phase, sargramostim treatment increased the expression of several non-
associated genes, such as GATA4, PERP, and KIF2C. Sargramostim also 
downregulated several non-associated genes such as IL2, STAT4, IL2RA, STAT4, and 
STAT1.  Even after ceasing sargramostim treatment, KIF2C and GATA4 expression 
remained elevated.   
 Sargramostim treatment also increased the expression of proinflammatory genes 
such as IL17RE, IL17A, TLR6, and IL1R1, and significantly downregulated the 




Figure 2.6 Gene expression comparing unstimulated CD4+ CD25- T cells from placebo-




Figure 2.6 Gene expression comparing unstimulated CD4+ CD25- T cells from 
placebo-treated compared to sargramostim-treated PD patients  
RNA was extracted from the isolated CD4+ CD25- T cells and copied to cDNA, prior to 
PCR using an array for human CD4+ T cell differentiation.  The fold change of 
expression from each gene was compared for the PD patients compared to healthy 
controls using the ΔΔCt method.  Heat maps were generated for all genes more than 2-
fold up- or downregulated for the stimulated CD4+ CD25 cells.  Red colored cells are 
upregulated genes and green colored cells are downregulated genes.  The color shade 
denotes the degree of upregulation.  Pro-inflammatory genes are those related to Th1 
and Th17 cells.  Anti-inflammatory genes are related to Th2 and Tregs.  The non-




and IRF1.  Post-treatment, gene expression appears to return to near baseline for both 
the upregulated and downregulated genes.  Sargramostim also increased the 
expression of several anti-inflammatory genes such as IL1R1, HOXA10, TNFSF11 and 
PTGDR2, and downregulated several anti-inflammatory genes such as IRF4, IL4R, 
CCL5, NR4A1, and ID2.  Post-treatment gene expression returned to near baseline for 
all genes, although CEBPB was upregulated on-treatment and is decreased post-
treatment.   
 These data demonstrate that sargramostim alters expression of many genes in 
CD3/CD28-stimulated CD4+ CD25- T cells.  As in Figure 2.4, the increases in gene 
expression are smaller in the CD3/CD28 bead-stimulated compared to the unstimulated 
cells.  This is probably due to the CD3/CD28 beads activating, and leading to 
upregulation of gene expression in the placebo control cells, thereby diminishing the 
relative increase in gene expression due to sargramostim.  Combined, Figures 2.3, 2.4, 
2.5, and 2.6 demonstrate that sargramostim does increased the expression of genes 
relative to both the pre-treatment baseline as well as placebo treatment.  This increase 
in expression is in genes associated with T cell proliferation and differentiation, and in 
proinflammatory and anti-inflammatory genes, demonstrating broad effects across T cell 
subsets.     
Gene expression of individual placebo and sargramostim PD patients 
 From the above data, values were combined for all patients as another way to 
analyze these data by changes in gene expression for each patient.  Seven patients (4 
placebo controls (BED, HFJ, JHL, and MKO) and 3 sargramostim-treated patients (DBF, 
LJN, and NLP)) who had data for all 8 trial visits were utilized.  Gene expression of 
unstimulated cells at visits 4, 5, 6, 7 and 8 was determined relative to the baseline (visits 
1-3) for each patient.  In addition to determining gene expression for each individual, we 
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also tested if the degree of gene change was related to changes in the percentages of 
peripheral Tregs, which were increased in the sargramostim-treated patients 
(Gendelman et al., 2017).  Figure 2.7 shows the extent of gene expression as a function 
of CD4+ CD25+ Foxp3+ Treg percentages in peripheral blood for the 2 genesthat were 
most increased by sargramostim treatment (Figure 2.5) for each category including non-
associated genes (Figure 2.7A and B), proinflammatory genes (Figure 2.7C and D), and 
anti-inflammatory genes (Figure 2.7E and F).  The degree of gene change in response 
to sargramostim treatment varies between patients, but consistently patients LJN and 
NLP showed the greatest gene change.  These patients also had the highest percentage 
of Tregs within the CD4+ population.  Increase in Tregs percentages was associated 
with increased expression of all genes reported.  The sargramostim-treated patient DBF 
displayed gene expression and Treg percentage closer to the placebo controls, 
suggesting that this patient’s response was less compared to patients LJN and NLP.  
This figure shows that while each patient responded to different degrees, the trend within 
the group is replicated with each patient.  Notably, patients with the highest increase in 
gene expression also showed the highest increase in the percentage of Tregs, which 
provides evidence that these patients responded to sargramostim treatment.  We 
hypothesized that the increase in Tregs would reduce the expression of proinflammatory 
genes; however, patients with the highest percentage of Tregs also display elevated 
expression of proinflammatory genes.  This suggests that Tregs are not suppressing the 
expression of inflammatory cytokines in this cell population.     
 





Figure 2.7 Gene expression related to Treg frequency in placebo- and sargramostim-




Figure 2.7 Gene expression related to Treg frequency in placebo- and 
sargramostim-treated PD patients 
For each patient, the gene expression was compared to the baseline.  The frequency of 
Tregs (CD4+ CD25+ Foxp3+) within the CD4+ population was determined from the 
whole blood.  GATA4 (A) and TNFSF9 (B) are the non-associated genes with the 
highest expression in sargramostim-treated patients relative to placebo control PD 
patients.  IL21 (C) and IL12B (D) are the pro-inflammatory genes with the highest 
expression in sargramostim-treated patients compared to placebo controls.  CCL7 (E) 
and TNFSF11 (F) are the two anti-inflammatory genes with the highest expression in 
sargramostim-treated patients relative to placebo controls.  Each patient is a separate 
color.  Placebo controls are filled circles and the sargramostim-treated patients are open 





Ingenuity Pathway Analysis of placebo compared to sargramostim PD patients 
To determine how the genes whose expression was altered by sargramostim 
related to helper T cell subsets, Ingenuity Pathway Analysis (IPA) was used.  In the 
unstimulated T cells, comparing sargramostim-treated patients relative to placebo 
control showed genes altered by sargramostim associated with all helper T cell subsets 
(Figure 2.8A).  In addition, increases in GM-CSF (which in the figure is indicated by the 
gene name CSF2) is associated directly or indirectly to the expression of several genes 
which were increased, including IL-2R, TNF-α, IL-4, IFNγ, IL-15, IL-13 and Foxp3.  
Mapping the same pathways using stimulated T cell expression data to compare 
sargramostim-treated patients to placebo-treated patients, showed downregulation of 
many genes, including genes were increased in the unstimulated cells (IL2R, TNFα, 
IFNγ, and IL13) (Figure 2.8B).  \We also identified that GM-CSF (CSF2) was directly or 
indirectly associated with the expression of several altered genes including STAT1, TNF-
α, IFNγ, IL-13, Foxp3 and IL-2R.      
 
DISCUSSION 
 In this chapter, gene changes in the CD4+ CD25- T cells in PD patients treated 
with sargramostim were described.  First, the percentages of different populations of T 
cells over time were determined to ensure that the distribution of analyzed T cells did not 
change over time.  While some significant differences were evident at individual visits in 
cells isolated between placebo-treated and sargramostim-treated T cells, overall the 
distribution of analyzed cells did not change over time or between treatment groups.  




Figure 2.8 Ingenuity pathway analysis of genes altered by sargramostim in unstimulated 




Figure 2.8 Ingenuity Pathway Analysis of genes altered by sargramostim in 
unstimulated and stimulated helper T cells 
Ingenuity Pathway Analysis was used to map the gene changes from sargramostim-
treated patients relative to placebo controls for the (A) unstimulated cells and (B) 
stimulated cells.  The T cell differentiation pathways are showed.  Genes that are 
upregulated are red, downregulated genes are green.  In this analysis, the genes which 






cells and fewer naïve helper T cells, possibly indicating an activation of helper T cells, 
though this may be an artifact of isolation.  Sargramostim increases many genes 
associated with proliferation and differentiation of CD4+ T cells, which is consistent with 
the increase in total CD4+ T cells in the whole blood of sargramostim-treated patients 
compared to placebo controls (unpublished data).  It should be noted that CD25+ T cells 
were positively selected against for these analyses.  Given that ~2% of the analyzed 
cells are Teffs (CD4+ CD127+ CD25+) and ~2% are Tregs (CD4+ CD127- CD25+), 
most cells are CD25-.  However, by excluding CD25+ T cells, this analysis may be 
missing relevant gene changes in the effector T cell population, which may be the cells 
expressing genes that effect PD.  However, since CD4+ CD25- cells are the responder T 
cells suppressed by Tregs in the in vitro proliferation suppression assay (Gendelman et 
al., 2017), these are one population cells that Tregs target to suppress in vivo.  
Additional studies would be needed to determine which helper T cell populations and 
functions are most important for PD pathogenesis and to what degree Tregs suppress 
these cells and functions.      
 As expected, there was an increase in the expression of anti-inflammatory 
genes.  Some of these are genes for cytokines released from Th2 cells, such as IL4, 
IL13, and IL5 (Zhu and Paul, 2008).  Treg-related genes were also increased such as 
LRRC32, the gene for GARP, a transcription factor which is important for Treg 
development (Tran et al., 2009).  IKZF2 is a gene within the IKAROS family of 
transcription factors, including Helios, which is expressed in Tregs (Bhairavabhotla et al., 
2016).  Thymic-induced (or natural) Tregs contain increased IKZF2 expression 
compared to induced Tregs (Thornton et al., 2010).  Since Helios is preferentially 
expressed in natural Tregs, this suggests that the increase in the percentage of Tregs 
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after sargramostim treatment may be due to the expansion of natural Tregs and not 
inducing Tregs in the periphery.     
In addition to genes associated with Th2 and Tregs, sargramostim also increases 
expression of anti-inflammatory genes such as PPARG, the gene for the nuclear 
receptor PPARγ.  Agonists to PPARγ such as pioglitazone were successful at protcting 
neurons in preclinical studies (Laloux et al., 2012), but unsuccessful at reducing PD 
symptoms (Investigators., 2015).  Sargramostim increases ICOS expression, a co-
stimulatory molecule on T cells which promotes the release of Th2-related cytokines 
(Simpson et al., 2010).  The expression of the chemokine CCL7 is responsible for the 
recruitment of a variety of immune cells, especially monocytes (Cheng et al., 2014).  
However, CCL7 expression appears to promote a Th2 immune response (Katzman and 
Fowell, 2008).  Expression of TNFSF11 (the gene for RANKL) promotes the survival of 
DCs and Tregs (Wong et al., 1997; Loser et al., 2006).  As such, the increase in 
TNFSF11 may be promoting the increase by sargramostim-treated PD patients.  
Interestingly, even though Tregs represent about 1% of the population of cells in this 
analysis, genes associated with Tregs and immunosuppression are noticeably 
increased.  This suggests that the expression of these genes is very high in the Treg 
population, or these genes are expressed in cells that are beginning to upregulate CD25 
which are not phenotypically Tregs.  FOXP3 expression was tested in this analysis and 
was generally not increased noticeably, further supporting the interpretation that few 
cells in this analysis are Tregs or expressed genes associated with terminal Treg 
differentiation.  Combined, these data show that sargramostim increases the expression 
of anti-inflammatory genes that may be playing a role in the increased Treg numbers 
and/or functions.     
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Several genes were upregulated in sargramostim-treated patients relative to 
baseline and relative to the placebo control involved in helper T cell proliferation.  
Notable genes associated with proliferation include IL2 and IL2RA, which are the major 
cytokine and receptor for T cell proliferation (Olejniczak and Kasprzak, 2008).  One of 
the genes with the highest gene expression is GATA4, which is not highly transcribed in 
T cells (Caramori et al., 2001).  GATA4 does regulate the transcription of IL-5 
(Yamagata et al., 1995; Yamagata et al., 1997), which was also upregulated by 
sargramostim, suggesting that the increase in GATA4 expression promotes increased 
IL5 expression.  TNFRSF9 (the gene for CD137 (4-1BB), a cell surface protein which is 
upregulated upon T cell activation) is also upregulated by sargramostim treatment (Vinay 
and Kwon, 1998; Myers and Vella, 2005).  Both HOXA3 and HOXA10 are genes for 
transcription factors involved in the proper development of lymphocytes and other 
immune cells (Thorsteinsdottir et al., 1997; Su and Manley, 2000; Su and Manley, 2002).  
Interestingly, PERP, a gene involved in p53-mediated apoptosis (Ihrie et al., 2003) is 
also increased by sargramostim treatment.  This suggests that T cell activation and 
possibly apoptosis are increased.   
 To our surprise, sargramostim treatment increased the expression of 
proinflammatory genes.  We found that there were genes involved in both Th1 and Th17 
phenotypes that were upregulated.  Th1-related genes which were increased include 
IL12B, IL18 and receptors all of which promote and are released from Th1 CD4+ T cells 
(Zhu and Paul, 2008).  However, sargramostim also decreased expression of several 
factors also involved in Th1 differentiation such as TBX21 (gene for t-bet, the master 
Th1 transcription factor) and EOMES (another Th1 transcription factor) (Zhu and Paul, 
2008).  Sargramostim also increased several genes associated with Th17 cells including 
IL21, IL17A, IL17RE, and RORC (Zhu and Paul, 2008). Genes for Toll-like receptors 
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(TLR) 4 and 6 were upregulated.  Notably, α-synuclein binds to TLR4 and activates 
astrocytes and microglia (Rannikko et al., 2015) and TLR4 may promote α-synuclein 
clearance (Stefanova et al., 2011).   Clearly this increase in proinflammatory gene 
expression is not indicative of Treg-mediated suppression or other anti-inflammatory 
mediators.  Alternatively, it suggests that sargramostim not only increases Tregs and 
anti-inflammatory genes; but rather induces the expression of many genes expressed by 
several different T cell subsets.   
 From the above data, the gene changes reported were obtained by combining all 
data from all patients within a treatment group.  Additionally, we tested if these combined 
gene changes are indicative of gene changes in each patient.  While there were 
differences among patients, trends from the combined data are present within each 
patient.  From this analysis, in the patients for which a complete data set exists, 
sargramostim treatment increased percentage of Tregs in whole blood, but Teffs were 
not changed (Gendelman et al., 2017).  This trial did not specifically assess gene 
expression by Th1, Th2, and Th17 cells, so it is unclear to what extent the percentages 
of these helper T cell subsets are affected by sargramostim is unclear.  To test the 
relationship between gene expression in the CD4+ CD25- T cells and increased 
percentages of Tregs in whole blood, we graphed the expression of genes with the 
highest upregulation compared to Treg percentage.  Patients LJN and NLP displayed 
the highest level of gene expression and the highest percentage of Tregs.  In both 
patients, lower Treg percentage and lower gene expression at visit 8 followed treatment 
cessation.  Placebo-treated patients BED and MKO tended to display the lowest Treg 
response and lower gene expression.  The differences in gene expression and 
percentage of Tregs suggest that the responses are different between patients.  These 
data suggest that the effects of Tregs are consistent with the increase in gene 
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expression, including the proinflammatory cytokines.  Because the binding of GM-CSF to 
its receptor can activate several signal cascades (Shearer, 2003; Hercus et al., 2009), it 
appears that this activation increases the expression of many genes of different 
functions.  Further work will be needed to determine which of these pathways are 
important for increasing the expression of these genes and increase Treg levels.   
 One of the surprising results is that the CD3/CD28-stimulated T cells from 
sargramostim-treated patients display decreased expression of many genes from all 3 
groups compared to baseline or placebo control patients.  It is unclear why this is the 
case, but several possibilities exist.  It could be that sargramostim treatment is activating 
gene expression in T cells, and CD3/CD28 stimulation cannot increase expression 
further.  As a result, the difference in gene expression is decreased compared to 
unstimulated cells.  It may also be the case that sargramostim treatment may be altering 
the kinetics of CD3/CD28 stimulation.  Since we tested gene expression at a single time 
point, it is possible that gene expression peaked earlier or later, so the relative change in 
expression here may not be indicative of altered kinetics.  A final possibility is that 
sargramostim or the existing Tregs population dampens the ability of the T cells to be 
activated.  The result was that after sargramostim treatment, T cells did not increase the 
expression of all genes compared to T cells from placebo-treated PD patients.  The 
isolated CD4+ T cells from both the placebo and sargramostim-treated PD patients 
display similar Treg numbers that are relatively small, so it would not be thought that 
these Tregs are influencing the ability of the other helper T cells to activate after 
stimulation with CD3/CD28 beads.  However, since sargramostim-treated PD patients 
display more functional Tregs compared to placebo control (Gendelman et al., 2017), 
there may be more Treg suppression when stimulated with CD3/CD28 beads.  It is also 
possible that sargramostim has some suppressive effect apart from activated Tregs, but 
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this has not been described.  The bottom line is that more work is needed to test how 
sargramostim is affecting T cells and T cell activation both in culture and in vivo.         
 In conclusion, sargramostim treatment increased the expression of 
proinflammatory, anti-inflammatory and non-associated genes in unstimulated CD4+ 
CD25- T cells.  Interestingly, sargramostim treatment decreases the expression of these 
genes after CD3/CD28 stimulation.  Increases in gene expression were associated with 
an increased percentage of Tregs, suggesting that the patient-to-patient differences are 
due to different responses to sargramostim treatment.  These results suggest that 
sargramostim treatment does not suppress proinflammatory gene expression in CD4+ 
CD25- T cells, which would be expected from the increase in anti-inflammatory genes 













CHAPTER THREE  
GM-CSF-GENERATED BONE MARROW DERIVED DCs INDUCE 
REGULATORY T CELLS AND ARE NEUROPROTECTIVE IN MPTP 
INTOXICATED NICE 
ABSTRACT  
As shown in Chapter 2, GM-CSF increases the percentage and the function of 
Tregs in Parkinson’s disease and the MPTP model.  However, the mechanism by which 
GM-CSF increases the percentage and function of Tregs is unclear.  Models of 
autoimmunity demonstrated that GM-CSF induces a tolerogenic state in DCs which 
promotes Tregs leading to suppression of autoimmunity and inflammation.  Herein, I 
tested if GM-CSF promotes and maintains a tolerogenic state in bone marrow-derived 
dendritic cells (BMDCs) stimulated with nitrated α-synuclein (N-α-Syn) as determined by 
flow cytometry, gene expression, cytokine release, and ability to induce Tregs.  In 
addition, the ability of tolerogenic DCs to protect dopaminergic neurons, decrease 
neuroinflammation, and increase the percentage of Tregs in the spleen, was tested.  I 
found that GM-CSF was unable to maintain a tolerogenic state in DCs after stimulation, 
but there was an alteration of how the BMDCs respond to stimulation.  The adoptive 
transfer of BMDCs did protect tyrosine hydroxylase-positive neurons, decreased 
neuroinflammation, and increased the percentage of Tregs in the 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) model.  These results suggest that tolerogenic DCs 
can be protective, in part by increasing the percentage of Tregs.  BMDC supernatants 
were unable to directly protect MES23.5 cells, but did decrease the expression of 
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proinflammatory mediators from cultured microglia, suggesting tolerogenic DCs may 
possess functions in vivo in addition to inducing Tregs.   
 
INTRODUCTION 
 As stated previously, Parkinson’s disease (PD) patients exhibit a decreased 
percentage of Tregs in peripheral blood (Chen et al., 2015) and function (Hutter-
Saunders et al., 2012).  Administering GM-CSF increased the percentage of Tregs in the 
MPTP model which is associated with neuroprotection and decreased 
neuroinflammation (Kosloski et al., 2013) and sargramostim (human recombinant GM-
CSF) increased the percentage of Tregs in PD patients and improved Treg function 
while improving motor symptoms (Gendelman et al., 2017).  Interestingly, T cells are not 
thought to express the receptor for GM-CSF, CSF2R, based on 2 lines of evidence.  
Treating T cells with GM-CSF induces proliferation to a decreased extent compared to 
IL-2 and could not support the survival of T cells (Santoli et al., 1988).  Also, by flow 
cytometry, CD3+ T cells lack surface expression of the alpha chain of the CSF2R 
(Rosas et al., 2007).  However, in a single report, the GM-CSF receptor is expressed on 
the surface of CD4+ CD25+ T cells and GM-CSF promotes the proliferation of Tregs 
(CD4+ CD25+ Foxp3+) (Kared et al., 2008).  These data suggest that GM-CSF is unable 
to induce the formation of Tregs from the non-Treg T cell population, but may promote 
the proliferation of existing Tregs.   
 The ability of GM-CSF to induce Tregs and suppress inflammation is curious 
given that the main role of GM-CSF is to mobilize myeloid cells, including 
macrophages/monocytes, neutrophils and other granulocytes from the bone marrow to 
the periphery (Ushach and Zlotnik, 2016).  As a result, GM-CSF has been thought of as 
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a proinflammatory cytokine.  GM-CSF and sargramostim have been used in clinical trials 
as an adjuvant for the hepatitis B vaccine (Overton et al., 2010) and several cancers 
including renal cancer, melanoma, prostate cancer, lung cancer, and pancreatic cancer 
(Parmiani et al., 2007; Waller, 2007).  In addition, in the experimental autoimmune 
encephalomyelitis (EAE) model of multiple sclerosis, GM-CSF may (King and Thomas, 
2007) or may not (Pierson and Goverman, 2017) be required for the development of 
paralysis in the model and the GM-CSF-secreting CD4+ T cells induce EAE (Codarri et 
al., 2011).  Because GM-CSF is not thought to exert its effects directly on CD4+ cells 
and because GM-CSF has proinflammatory effects by expanding granulocytes and 
monocytes, it is unclear how the percentage of Tregs is being increased.     
 Despite the known functions of GM-CSF in myeloid cells, a growing body of 
research has demonstrated GM-CSF can exert beneficial effects in models of 
autoimmunity and inflammation.  For example, administering GM-CSF suppresses the 
immune response to thyroglobulin in the model of autoimmune thyroiditis (Gangi et al., 
2005), skeletal muscle nicotinic acetylcholine receptor in the mouse model of 
myasthenia gravis (Sheng et al., 2008), and lymphocyte infiltration into the pancreas in 
the NOD model of type 1 diabetes (Cheatem et al., 2009).  In addition, in models of 
inflammatory disease such as colitis (Sainathan et al., 2008) or traumatic brain injury 
(Kelso et al., 2015), treatment with GM-CSF also decreases inflammation to reduce the 
symptoms of disease.  As with the MPTP model (Kosloski et al., 2013), in many of these 
models GM-CSF increases the percentage of Tregs (Sheng et al., 2008; Cheatem et al., 
2009; Ganesh et al., 2009).  From these data, the prevailing thought is that GM-CSF 
increases Tregs by acting on DCs inducing a tolerogenic state (Gaudreau et al., 2007; 
Bhattacharya et al., 2011).  The tolerogenic DCs express OX40L and Jagged-1 (Jag-1) 
which bind to OX40 and Notch-3 respectively on T cells and are important for the 
77 
 
increase in the percentage of Tregs in culture (Gopisetty et al., 2013; Haddad et al., 
2016).  Tolerogenic DCs promote the proliferation of Tregs and induce naïve CD4+ T 
cells to become Tregs (Bhattacharya et al., 2011).  The resulting Tregs induced by 
tolerogenic DCs may be antigen specific or antigen independent.  In either case, 
increases in Tregs reduces the inflammatory immune response and reduces the 
symptoms of disease.   
 Like immature DCs, tolerogenic DCs display low expression of co-stimulatory 
molecules like MHC II, CD40, CD80, CD86, among others, and low expression of 
cytokines (Lutz and Schuler, 2002; Steinman et al., 2003; Rutella et al., 2006; Liu and 
Cao, 2015).  What cytokines are expressed are commonly anti-inflammatory, such as IL-
10.  Tolerogenic DCs also display increased expression IDO, an enzyme which 
metabolizes with tryptophan to kynurenine, and the expression of IDO and increased 
release of kynurenine are associated with induction of Tregs (Rutella et al., 2006).  
Unlike immature DCs, tolerogenic dendritic cells should maintain this low expression 
even in the presence of a maturation stimulation (Mahnke et al., 2002).  Maintenance of 
a tolerogenic state will make DCs less able to activate naïve CD4+ cells to effector 
helper T cells by reducing all 3 T cell maturation signals, but maintains the ability to 
induce Tregs (Lutz and Schuler, 2002; Mahnke et al., 2002).    
 In the study described in this chapter, I hypothesized that GM-CSF promotes and 
maintains a tolerogenic state in DCs which is the mechanism by which GM-CSF is 
neuroprotective.  We tested this in 2 DC lines (DC2.4 and DC3.2) and in BMDCs.  We 
also sought to determine if adoptive transfer of tolerogenic DCs are able to protect 
dopaminergic neurons, reduce neuroinflammation, and increase the percentage of Tregs 
in the spleen after MPTP, similar to GM-CSF administration.  I also tested if BMDC 
supernatant protects the MES23.5 dopaminergic neuron cell line and decreases the 
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expression of proinflammatory mediators from activated BV2 microglia cell lines.  Lastly, 
I tested if GM-CSF increases the number or tolerogenic state of splenic DCs, the DCs 




Male 6-18-week-old C57BL6/J mice (Jackson labs, Bar Harbor, ME) were used 
in all experiments described below.  All procedures were performed in accordance with 
the National Institutes of Health guidelines and all procedures were approved by the 
Institutional Animal Care and Use Committee of the University of Nebraska Medical 
Center. 
DC2.4 and DC3.2 cell culture 
 DC2.4 and DC3.2 cells were generously provided by the laboratory of Dr. 
Kenneth Rock (University of Massachusetts Medical Center, Worcester, MA).  Both cell 
lines were cultured in HCM-10% media (RPMI 1640 + L-glutamine (Gibco), 10% FBS 
(Atlanta Biologicals, Flowery Branch, GA), 1x MEM nonessential amino acids (Hyclone), 
100 U penicillin, 100 g/ml Streptomycin (Gibco), 10 mM HEPES (Gibco), 2 mM L-
glutamine (Gibco), and 55 nM 2-mercaptoethanol (Gibco)).  Both cell lines were passed 
by drawing off the whole volume of old media into a 15 ml conical tube (BD Falcon, 
Corning, NY) and pipetting 3 ml of 0.25% trypsin containing EDTA (Hyclone) per T-75 
flask.  Flasks were incubated at 37°C for 2 min to remove adhered cells from the bottom.  
The flask was tapped to dislodge cells and the whole volume was pipetted into the 15 ml 
conical tube to dilute the trypsin and cells were concentrated by centrifugation at 400 xg 
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for 5 min.  The supernatant was discarded and the cell pellet was resuspended in 1 ml 
HCM-10% media, and an aliquot was diluted 1:10 in trypan blue (Sigma) for cell 
counting.  A volume of cell suspension corresponding to ~2x106 cells was pipetted into a 
T-75 flask (BD Falcon) in 10 ml HCM-10% media.  The flasks were placed in an 
incubator at 37°C, 5% CO2 incubator.  Cells were passed whenever they reached 
confluence, which was about every 3 days.   
BMDC differentiation 
 BMDCs were differentiated from bone marrow according to standard protocols 
(Lutz et al., 2000; Bhattacharya et al., 2011).   The methods for differentiating and 
stimulating BMDCs are outlined in Figure 3.1.  Briefly, male 6-18-week-old C57BL6/J 
mice (Jackson Labs) were sacrificed by CO2 asphyxiation and cervical dislocation and 
both femurs were removed and washed twice in ice cold 10 ml 1x Hanks Buffered Salt 
Solution (HBSS, Gibco).  Each femur was flushed with 5 ml 1x HBSS and the cells were 
collected into a petri dish.  The cell suspension was drawn up through a 20 Ga. needle 
into a 50 ml conical tube (BD Falcon) and cells were concentrated by centrifugation at 
200 xg for 10 min.  The supernatant was discarded and the pellet was resuspended in 1 
ml ACK lysis buffer (Gibco) per mouse.  The red blood cells were lysed by incubation at 
37°C for 2 min.  Lysis was stopped by adding 1x HBSS and the cells were passed 
through a 70 μM cell strainer and the flow through was collected in a 50 ml conical tube.  
Cells were concentrated by centrifugation at 200 xg for 10 min.  The supernatant was 
discarded and the cell pellet was resuspended in R10 media (RPMI 1640 + L-glutamine 
(Gibco), 10% heat-inactivated FBS (Atlanta Biologicals), 100 U penicillin, 100 g/ml 










mercaptoethanol (Gibco)).  A cell suspension was diluted 1:10 in trypan blue for 
counting.  Cells were brought to a concentration so that each well of a 6-well plate (BD 
Falcon) contained 4x106 cells and 20 ng/ml mouse recombinant GM-CSF (Peprotech, 
Rocky Hill, NJ) in 4 ml of R10 media.  For the experiment testing optimal conditions for 
BMDC maturation, wells contained 10 ng/ml GM-CSF and some wells contained 10 
ng/ml IL-4 (Peprotech, Rocky Hill, NJ).  BMDCs were incubated for 4 days in the 37°C, 
5% CO2 incubator.     
 Four and 6 days after isolating BMDCs the media was changed as follows.  The 
6-well plate was removed from the incubator and the volume of media was removed and 
pipetted into 50 ml conical tubes and cells were concentrated by centrifugation at 200 xg 
for 10 min.  Two ml R10 media was added to each well.  The supernatant was discarded 
and the cell pellet was resuspended in R10 media supplemented with 40 ng/ml mouse 
recombinant GM-CSF so the total volume was brought to 4 ml, and the plate was placed 
back in the 37°C, 5% CO2 incubator.   
 On the eighth day after isolating bone marrow, the BMDCs had differentiated and 
could be treated as follows.   The 6-well plates were removed from the incubator and the 
whole volume was pipetted from each well into a 50 ml conical tube and 1 ml of R10 
media was added to each well.  Cells were concentrated by centrifugation at 200 xg for 
10 min.  The supernatant was discarded and the cell pellet was resuspended in R10 
media supplemented with 40 ng/ml mouse recombinant GM-CSF or R10 media alone 
depending on experiment.  One ml of the cell suspension was added to each well and 
the 6-well plate was placed back in the 37°C, 5% CO2 incubator for 2 days.   
 On day 10 after starting BMDC culture, stimulation was done as follows.  BMDCs 
were stimulated with 10, 30 or 100 μg/ml of nitrated recombinant mouse α-Syn (N-α-
Syn), which was made as described previously (Benner et al., 2008).  BMDCs were also 
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stimulated with 0.1, 10, 30 and 100 μg/ml E. coli O55:B5 LPS (Sigma).  To test gene 
expression, BMDCs were stimulated for 6 hr, a time frame in which there should be 
maximal expression of proinflammatory cytokine genes (Crabtree and Durand, 1986; 
Crabtree, 1989).  For all other experiments, BMDCs for stimulated for 24 hr.  At that 
time, BMDCs were removed for flow cytometry or to produce lysate for Western blot or 
the conditioned media was removed for cytokine detection, nitrite release detection, and 
kynurenine detection.   
Griess assay 
 The Griess assay was performed 2 different ways according to the 
manufacturer’s protocol (Promega Fisher Waltham, MA).  The assays for DC2.4 and 
DC3.2 cells in Figure 3.2 were performed using the Promega kit as follows.  Standards 
were diluted in HCM-10% media and were serially diluted to create a standard curve.  
Wells of a flat-bottom 96-well plate (BD Falcon) contained 50 μl of supernatant added.  
All wells contained 50 μl sulfanilamide added and the plate was incubated wrapped in 
foil at RT for 5 min.  All wells contain 50 μl NED solution added and the plate was 
incubated at RT for 5 min wrapped in foil.  The plate was read at 540 nm.   
 The Griess assays in Figure 3.5, 3.8, and 3.23 were performed using the 
ThermoFisher (Waltham, MA) kit as follows.  Nitrite standard was diluted in R10 or BV2 
media and serially diluted in R10 or BV2 media to generate a standard curve.  In 
addition, the 96-well plate contained 150 μl of BMDCs or BV2 cells supernatant added.   
To detect nitrite, 130μl MQ water, and 20 μl of the mixed Griess assay reagents added 
to all wells.  The 96-well plate was incubated at RT for 30 min wrapped in foil before the 
absorbance was read at 540 nm.     
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For both assays, the absorbance was background corrected by subtracting the 
average reading from wells containing fresh media, not that from cells, from all other 
wells. Based on the standard curve the concentration of nitrite was calculated from the 
absorbance.    
AlamarBlue cell viability assay 
 For DC2.4 and DC3.2 cells, the alamarBlue cell viability was performed by 
plating cells at 1x105 cells per well into a U-bottom 96-well plate with 20 ng/ml mouse 
recombinant GM-CSF added to the appropriate wells for 2 days.  To the appropriate 
wells, 10 μg/ml E. coli O55:B5 LPS (Sigma) was added 24 hr before reading to stimulate 
cells.  After 24 hr of treatment, 15 μl alamarBlue solution (ThermoFisher) was added to 
all wells and after 4 hours of incubation the absorbance was read at 570 and 600 nm.   
 For BMDCs, cells were treated in 6-well plates with R10 media alone or with R10 
media supplemented with 20 ng/ml mouse recombinant GM-CSF for 2 days prior to 
stimulation with 10 μg/ml E. coli O55:B5 LPS (Sigma) or 30 μg/ml recombinant N-α-Syn 
for 24 hr as described above.  At this time, BMDCs were removed from the 6-well plate 
using a cell scraper and 1x105 BMDCs was plated into each well of a U-bottom 96-well 
plate and 15 μl alamarBlue was added to each well.  After 4 hrs, the absorbance was 
read at 570 and 600 nm.   
 For both methods, the percentage of alamarBlue dye which was reduced (which 
can only happen in viable cells with functioning mitochondria) was calculated according 
to the manufacturer’s directions.    
Flow cytometry 
 DC2.4, DC3.2 and BMDCs were stained for flow cytometric analysis as follows.  
After removing cells from the dish by either trypsin-EDTA or cell scraper for DC2.4 and 
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DC3.2 cells or BMDCs respectively, cells were counted and ~5x105 cells were added to 
each 5 ml flow stain tube (BD Falcon) for staining.  The Fc receptors were blocked in a 
solution of 10 μg/ml rat gamma globulin FSB (1x DPBS, (Gibco) supplemented with 
0.5% BSA and 0.1% sodium azide).  After blocking for 30-60 min on ice, anti-CD11c-
alexaFluor 488, anti-CD11b-PECy7, anti-Jagged-1-PE, anti-OX40L-APC, anti-MHC II-
alexaFluor 700, anti-CD86-eFluor450, anti-CD39-PerCP-eFluor 710 (eBioscience, Santa 
Clara, CA) and anti-CD73-APC-vio 770 (Miltenyi Biotec) antibodies stained cells for 30 
min at 4°C.  Cells were washed 2 times in 2 ml FSB and cells were concentrated by 
centrifugation at 400 xg for 5 min.  Cells were fixed in a solution of 1% formaldehyde in 
1x DPBS for 15 min at RT.  Cells were concentrated by centrifugation at 400 xg for 5 min 
and the pellet was resuspended in FSB for analysis using a BD LSR II flow cytometer 
(Franklin Lakes, NJ) at the University of Nebraska Medical Center Flow Cytometry 
Research Facility.  Single cells were gated from the total event population and the 
percentage of total cells or CD11c+ cells expressing each marker was determined.  The 
mean fluorescent intensity (MFI) of each marker in the CD11c+ cells was also 
determined.   
 For testing the percentage of Tregs in total splenocytes, non-adhered cells from 
CD4+/BMDC co-culture, or cells enriched after Miltenyi CD4+ CD25+ kit, ~5x105 cells 
were blocked in a solution of 10 μg/ml rat gamma globulin in FSB for 30-60 min.  Cells 
were stained with anti-CD4-PECy7 and anti-CD25-PE for 30 min at 4°C.  Cells were 
washed twice in 2 ml FSB and concentrated by centrifugation at 400 xg for 5 min.  Cells 
were then fixed and permeablized for 1 hr at 4°C using the buffer from the 
Foxp3/transcription factor staining buffer set (eBioscience).  Cells were washed in 2 ml 
1x permeablization buffer and concentrated by centrifugation at 400 xg for 5 min.  Cells 
were stained with anti-Foxp3-APC for 30 min at 4°C.  Cells were washed twice by the 
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addition of 2 ml of 1x permeabization buffer followed by concentration by centrifugation 
at 400 xg for 5 min.  Cells were resuspended in FSB prior to analysis using the BD LSR 
II at the University of Nebraska Medical Center Flow Cytometry Research Facility.  
Within the single cell population, the percentages of CD4+ T cells was determined.  The 
percentage of CD4+ T cells double positive for CD25+ Foxp3+ was reported as the 
percentage of Tregs within the CD4+ T cell population.   
Luminex array 
 The release of cytokines and chemokines was determined from BMDCs cultured 
for 2 days in R10 media alone or R10 media supplemented with 20 ng/ml GM-CSF prior 
to no stimulation or 1 day stimulation with 30 μg/ml N-α-Syn.  The cell culture 
supernatant was clarified at 10,000 xg for 5 min and the resulting supernatant was 
transferred to a 1.5 ml snap-cap tube and stored at -80°C until analysis could be 
performed.  Concentration of cytokines and chemokines was determined with Luminex 
xMAP mouse cytokine and chemokines magnetic bead panel (Milipore, Billerica, MA) 
according to the manufacturer’s protocol.  Briefly, 25 μl of supernatant was added to the 
provided 96-well plate.  Standards and controls were prepared and diluted according to 
the protocol and 25 μl was added to the appropriate well.  Assay buffer was added to 
supernatant samples and R10 media was added to all controls and standards.  A master 
mix containing antibody-coated magnetic beads against IFNγ, IL-1α, IL-1β, IL-2, IL-4, IL-
5, IL-6, IL-7, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, Lix, IL-15, IL-17, IP-10, MIP-2, MIG, 
RANTES, and TNF-α was added to all wells and the 96-well plate was incubated at 4°C 
overnight.  Magnetic beads were concentrated and washed on a magnet.  Detection 
antibodies were added to each well and the samples were incubated at RT for 60 min.  
Strepavidin-PE was added to all wells and the 96-well plate was incubated at RT for 30 
min.  The beads were concentrated and washed in a magnet as above and resupended 
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in sheath solution.  All wells were analyzed using the Milipore Magpix system and 
Luminex Xponent 4.2 software.  A standard curve was generated for each of the 
cytokines and chemokines and based on this standard curve the concentration of each 
cytokine and chemokine was calculated.  For this experiment, for each of the 4 treatment 
groups, supernatants from 7 different wells containing BMDCs were used.  Supernatant 
from each of the 7 wells of supernatant were run in duplicate or triplicate.      
RNA isolation, cDNA conversion and PCR array 
 To test the expression of proinflammatory genes, BMDCs were cultured in R10 
media alone or R10 media supplemented with 20 ng/ml GM-CSF for 2 days prior to 
stimulation of cells with 30 μg/ml N-α-Syn, or BMDCs were left unstimulated with for 6 
hr.   BMDCs were removed from the 6-well dish by a cell scraper and cells were washed 
two times in 1x DPBS (Gibco).  There were 6 separate wells for BMDCs for each of four 
treatment groups.  Cells were transferred to a 1.5 ml snap-cap tube and cells were 
frozen at -80°C until RNA isolation.  The RNeasy mini kit (Qiagen) was used to isolate 
total RNA from all samples as follows.  The cell pellet was resuspended in RLT buffer 
supplemented with 2-mercaptoethanol and homogenized by trituration through a 27 Ga. 
needle 10 times.  The lysate was clarified by concentration at 20,800 xg for 3 min.   
 To test the expression of proinflammatory genes in the midbrain, BMDCs were 
transferred into mice via i.v. injection at 14 and 7 days prior to MPTP intoxication.  As 
controls, mice were injected with DPBS and intoxicated with MPTP.  Two days after 
MPTP intoxication, mice were sacrificed by CO2 asphyxiation and cervical dislocation.  
Brains were removed, hemisected and the midbrain was placed in a 1.5 ml tube 
containing 1 ml RNAlater (ThermoFisher).  Brains were incubated at 4°C overnight 
before being weighed and frozen at -80°C.  To isolate RNA, the midbrains were thawed, 
homogenized in 350 µl β-mercaptoethanol-supplemented RLT buffer (Qiagen, Valencia, 
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CA) for every 30 mg tissue.  Tissues were sequentially homogenized by trituration 
through 18, 20 and 27 Ga needles.  The tissue homogenate was clarified by 
concentration at 20,800 xg for 3 min.   
 The clarified supernatants from both cell pellets and from tissue were transferred 
to a new 1.5 ml tube containing 70% ethanol in water.  This mixture was pipetted into a 
filter and the nucleic acids were concentrated on the filter by centrifugation at 10,000 xg 
for 20 sec.  The flow through was discarded.  The filter was washed in RW1 at 10,000 xg 
for 20 sec.  DNase I from the RNase-free DNase kit (Qiagen) was diluted in RDD buffer, 
pipetted on the membrane, and incubated at RT for 15 min.  The filter was washed in 
RW1 then 2 times in RPE buffer by centrifugation at 10,000 xg for 20 sec.  The filter was 
eluted by the addition of 50 μl RNase-free water and centrifugation at 10,000 xg for 1 
min.  The flow through was added back to the filter and was eluted a second time at 
10,000 xg for 1min to increase RNA yield.  The concentration of RNA, as well as the 
260/280 and 260/230 ratios were determined by UV spectrophotometry using a Thermo 
ND-100 Nanodrop spectrophotometer.   
 Copying of mRNA to cDNA was achieved using the RevertAID first strand cDNA 
synthesis kit (ThermoFisher) according to the manufacturer’s protocol.  Briefly, 500 ng of 
RNA was brought to 11 μl by the addition of nuclease-free water and 1 μl oligo dT 
primers was added to each sample and heated at 65°C for 5 min.  After breaking the 
secondary structure of RNA, a master mix containing 5x reaction buffer, Ribolock Rnase 
inhibitor, 10 mM dNTPs, and RevertAID M-MuLV reverse transcriptase was added to all 
samples and incubated at 42°C for 1 hr.  After the production of cDNA from the mRNA 
template, the reaction was terminated by 5 min incubation at 70°C.  All samples were 
brought to 100 μl by the addition of nuclease-free water and samples were frozen at -
20°C until PCR could be performed.   
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 Each cDNA sample was added to RNase-free and DNase-free water (Invitrogen), 
2x RT2 SYBR green master mix (Qiagen), and 25 μl of this solution was added to each 
well of a mouse inflammatory response and autoimmunity array (Qiagen), and PCR was 
performed using an Eppendorf Realplex 2S Master Cycler (Eppendorf, Hamburg, 
Germany).  The PCR program used for this array which was as follows: hot start at 95°C 
for 10 min, followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min.  After 40 cycles, 
a melting curve was performed, Ct values were determined, and fold changes 
determinedusinng the ΔΔCt method using RT2 Profiler PCR array data analysis version 
3.5.  Changes were normalized relative to media-cultured, unstimulated BMDCs or from 
the PBS control midbrains. 
IDO expression by Western blot  
 To determine the relative expression of IDO relative to β-actin, Western blots 
were run as follows.  BMDCs were pretreated for 2 days in R10 media alone or R10 
media supplemented with 20 ng/ml GM-CSF and either unstimulated or 30 μg/ml N-α-
Syn for 1 day.  These BMDCs were removed from the dish by cell scraper, washed in 1x 
DPBS and concentrated into a 1.5ml snap-cap tube which was frozen at -80°C until 
analysis could be performed.  The cell pellets were thawed and lysed in 250 μl RIPA 
buffer (ThermoFisher) for 5 min on ice.  After mixing by vortexing, the lysate was clarified 
by centrifugation at 14,000 xg for 15 min at 4°C.  The supernatant was transferred to a 
new 1.5ml tube.   
 Protein concentration of the clarified lysate was determined by BCA assay 
(Pierce) as described by the manufacturer.  Briefly, BSA standards (ThermoFisher) were 
pipetted to a flat-bottom 96-well plate to make a standard curve and 25 μl of each 
sample was added to the same 96-well plate.  The BCA working solution was prepared 
and 200 μl added to each well and the 96-well plate was incubated at 37°C for 30 min.  
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The plate was allowed to equilibrate to RT for 10 min and read at 562 nm.  The 
absorbance reading was background corrected by subtracting the absorbance of the 
control not containing protein from all other wells.  Based on the standard curve, the 
protein concentration for each sample was calculated.    
 To perform Western blots, a volume of lysate corresponding to 10 μg of total 
protein was brought to 30 μl MQ water and 30 μl 2x sample buffer (Bio-Rad, Hercules, 
CA) supplemented with 2-mercaptoethanol.  Proteins were denatured by heating at 95°C 
for 5 min.  The whole volume was loaded into a pre-cast ExpressPlus PAGE 4-20% gel 
(Genscript, Piscataway, NJ) and gels electrophoresed for 85 min until the dye front was 
near, but not at the foot of the gel.  Proteins were transferred to PVDF membranes (Bio-
Rad) using the Bio-Rad wet-transfer apparatus in 1x Bio-Rad transfer buffer for 90 min.  
The membrane was blocked in 5% dried milk in PBS supplemented with 0.1% Tween 20 
(PBST) at RT for 60 min.  Membranes were incubated with a primary antibody solution 
containing mouse anti-mouse IDO antibody (Milipore) in blocking buffer overnight at 4°C.  
Membranes were washed for 30 min in PBS changing the PBS every 5 min prior to 
incubation in goat-anti-mouse HRP-conjugated secondary antibody solution for 30 min at 
RT.  Membranes were washed in PBST for 30 min as above.  The membrane was 
imaged with ECL femto solution (ThermoFisher) and images were taken with a 
chemiluminescent camera (ThermoFisher).  The ECL femto solution was washed off in 
PBST for 30 min.  The membrane was stripped using Restore Western blot stripping 
buffer (ThermoFisher), washed in PBST, and blocked in 5% dried milk blocking buffer for 
30 min.  The membrane was incubated in rabbit anti-mouse β-actin (Santa Cruz, Dallas, 
TX) overnight at 4°C, washed in PBST as above, incubated in donkey anti-rabbit HRP-
conjugated secondary antibody (Santa Cruz) for 30 min at RT, washed again in PBST 
for 30 min prior to development with ECL Pico solution (ThermoFisher), and the imaged 
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with a chemiluminescent camera.  From the images, ImageJ was used to determine the 
intensity of the IDO and β-actin and the IDO/ β-actin ratio was determined.   
Kynurenine detection and quantification  
The release of kynurenine was determined from BMDCs cultured for 2 days in 
R10 media alone or R10 media supplemented with 20 ng/ml GM-CSF prior to no 
stimulation or stimulation with 30 μg/ml N-α-Syn for 1 hr.  Cell culture supernatant was 
clarified at 10,000 xg for 5 min, the resulting supernatant was transferred to a 1.5 ml 
snap-cap tube, and stored at -80°C until analysis.  For analysis, to each of the 100 μl of 
supernatants, 10 μl of 10 μg/ml tryptophan HCl (Sigma Aldrich) was added to each 
sample as an internal standard.  A kynurenine standard curve was made by 2-fold 
serially dilutions 50 μg/ml kynurenine (Sigma Aldrich) in acetonitrile (Fisher) down to 
acetonitrile alone.  Each standard also had 10 μl of 10 μg/ml tryptophan HCl added as 
an internal standard.  Ice-cold acetonitrile was added to each sample and standard and 
mixed by vortexing for 3 min.  Samples and standards were clarified by centrifugation at 
14,000 RPM for 10 min, and 1 ml of supernatant was pipetted into a new 2 ml snap-cap 
tube, and samples and standards were concentrated by speed vacuum for 3 hr, and 
pellets were stored at -20°C overnight.  All samples and standards were resuspended in 
100 μl 0.1% formic acid in HPLC-grade water (Fisher), vortexed briefly, concentrated by 
centrifugation at 14,000 RPM for 15 min, and 30 μl of each supernatant from each 
standard/sample was pipetted into a 96-well plate for mass spectrometry analysis on a 
C8 Luna PFP column attached to a Waters TQS Micro mass spectrometer. 
CD4+ and CD11c+ cell isolation and BMDC co-culture 
 The CD4+ T cells used in co-culture were isolated from the spleens of male 
C57BL/6J mice (Jackson Laboratories) as follows.  Mice were sacrificed by CO2 
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asphyxiation and cervical dislocation and spleens removed, and pressed through a 70 
μM cell strainer into 10 ml 1x HBSS.  This cell suspension was drawn up through a 20 
Ga. needle into a 50 ml conical tube.  Cells were concentrated by centrifugation at 200 
xg for 10 min, the supernatant was discarded, and the pellet was resuspended in 1 ml 
ACK lysis buffer (Gibco) per spleen.  Red blood cells were lysed by incubation at 37°C 
for 2 min.  Cells and ACK were diluted by adding 1x HBSS and cells concentrated by 
centrifugation at 200 xg for 10 min.  The supernatant was discarded, the cell pellet was 
resuspended in Miltenyi CD4+ isolation buffer (0.5% BSA and 2 mM EDTA in 1x DPBS), 
and an aliquot was diluted for cell counting.  CD4+ T cells were negatively selected 
using the Miltenyi CD4+ isolation kit according to the manufacture’s protocol. Briefly, 
splenocytes were brought to 1x107 splenocytes per 90 μl CD4+ isolation buffer, 10 μl of 
CD4+ selection antibodies were added, and incubated at 4°C for 15 min.  After 
incubation, 30 μl CD4+ isolation buffer and 20 μl microbeads were added for every 
1x107 splenocytes and the mixture was incubated at 4°C for 10 min.  The labeled 
splenocytes were pipetted into a Miltenyi LS column, which was placed on a magnetic 
rack.  The antibody-bound, non-CD4+ cells adhered to the column and the CD4+ cells 
flowed through the column into a collection tube.  The column was washed 3 times in 
Miltenyi CD4+ isolation buffer and cells were also collected into the same tube.  The 
CD4+ cells that flowed through the column were concentrated by centrifugation at 200 
xg for 10 min.  The pellet was resuspended in complete media (RPMI 1640 media + L-
glutamine (Gibco), 10% FBS (Sigma), 1 mM sodium pyruvate (Cellgro, Pittsburgh, PA), 
1x MEM non-essential amino acids (Hyclone, Logan, UT), 100 U penicillin, 100 g/ml 
Streptomycin (Gibco), 10 mM HEPES (Gibco), 2 mM L-glutamine (Gibco), and 55 nM 2-
mercaptoethanol (Gibco)) and an aliquot was diluted 1:10 in trypan blue for cell counting.  
Cell concentration was adjusted to 2x106 cells per ml of complete media.  and an aliquot 
of CD4+-enriched cells was stained for Tregs to determine purity.   
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 BMDCs were pretreated in R10 media alone or R10 media supplemented with 20 
ng/ml GM-CSF for 2 days and either left unstimulated or stimulated with 30 μg/ml N-α-
Syn for 1 day.  BMDCs were scraped from the dish, washed 2 times in 1x DPBS, 
resuspended in complete media, and an aliquot was diluted in trypan blue for cell 
counting.  The concentration was adjusted to 1x106 BMDCs per ml of complete media.  
Co-cultures were initiated so that 1 ml of BMDCs and 1 ml of CD4+ T cell-enriched 
splenocytes were pipetted into each well of a 24-well plate, then incubated at 37°C, 5% 
CO2 for 5 days.   
 For transwell experiments, BMDCs and CD4+ cells were differentiated and 
isolated as above, however, CD4+ T cells were brought to 10x106 cells/ml.  To a 24-well 
pate, 1 ml BMDCs (~1x106 BMDCs) was added to each well.  The 3 μm transwell inset 
(Corning, Corning, NY) was placed in the well and 100 μl CD4+ cells and 100 μl 
complete media was added into the insert.  The 24-well plate was incubated at 37°C, 5% 
CO2 for 5 days.   
 CD11c+ cells were isolated from the spleen using the Miltenyi CD11c isolation kit 
according to the manufacturer’s protocol.  Single cell splenocytes were prepared and 
adjusted to 1x108 cells/400 μl Miltenyi CD4+ isolation buffer.  For every 400 µl of 
splenocytes, 100 μl CD11c microbeads was added and incubated for 15 min at 4°C.  
Cells were washed in Miltenyi CD4+ isolation buffer, concentrated by centrifugation at 
200 xg for 10 min and added onto a Miltenyi LS column placed within a magnetic field 
and the column washed in Miltenyi CD4+ isolation buffer.  The LS columns were 
removed from the magnet and CD11c+ cells were flushed from the column into a new 
collection tube and cells were concentrated by centrifugation at 200 xg for 10 min.  After 
cell counting in trypan blue, CD11c+ cells were adjusted to ~1x106 CD11c+ cells/ml in 
complete media and 1 ml of CD11c+ cells were co-cultured with 1 ml of enriched 2x106 
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CD4+ T cells/ml into wells of a 24-well plate which was incubated at 37°C in 5% CO2 
incubator for 5 days.  
 To determine the percentage of Tregs after co-culture, non-adherent cells were 
removed from the culture, washed twice in 1x DPBS (Gibco), and concentrated by 
centrifugation at 200 xg for 10 min.  The cell pellet was resuspended in FSB, an aliquot 
was counted in trypan blue, and 2.5-5x105 cells were stained for Treg purity.   
Treg functional assay 
 Treg function was tested for its ability to suppress the proliferation of the 
responder T cells (CD4+ CD25-) as described previously (Saunders et al., 2012; Olson 
et al., 2015).  Briefly, C57BL/6J mice were sacrificed by CO2 asphyxiation and cervical 
dislocation.  Splenocytes were isolated as described above and non-adhered cells were 
removed as described above from co-culture of CD4+ cells and BMDCs.  The Miltenyi 
CD4+ CD25+ isolation kit was used to enrich Tregs (CD4+ CD25+) and responder T 
cells (CD4+ CD25-) according to the manufacturer’s protocol.  Briefly, for every 1x107 
cells of splenocytes or non-adherent cells was added to 40 μl CD4+ isolation buffer and 
10 μl CD4+ biotinylated antibodies and the suspension was incubated at 4°C for 5 min.  
Then to every 1x107 cells was added 30 μl CD4+ isolation buffer, 20 μl Miltenyi anti-
biotin magnetic beads, and 10 μl anti-CD25-PE antibody and were incubated at 4°C for 
10 min.  The labelled cells were passed through Miltenyi LD columns attached to 
magnetic racks and the filtrate (CD4+ T cells) collected.  Cells were concentrated by 
centrifugation at 200 xg for 10 min, the pellet resuspended in 90 μl CD4+ isolation buffer, 
10 μl anti-PE microbeads per 1x107 cells added and cell suspensions incubated at 4°C 
for 15 min.  The cellular filtrates served as responder T cells.  The MS columns were 
flushed by adding 1 ml CD4+ isolation buffer and the volume forced through the column 
using the plunger.  These cells were enriched Tregs.  Aliquots of both cells were counted 
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by trypan blue.  Flow cytometry was performed on ~5x105 cells to confirm purity.  Treg 
concentrations were adjusted to ~1x106 cells/ml by the addition of complete media and 
responder T cells were adjusted to 2x106 cells/ml in CFSE buffer (0.1% BSA in 1x 
DPBS).   
 The responder T cells were labelled with carboxyfluorescein succinimidyl ester 
(CFSE, ThermoFisher) according to the manufacturer’s protocol.  Briefly, each vial of 
CFSE was reconstituted with 18 μl dimethyl sulfoxide (DMSO, Sigma).  For every 1 ml of 
responder T cells to be labelled, 3 μl of CFSE was added to 1 ml CFSE buffer, cells and  
buffer combined, and incubated for 15 min at 37 °C.  To quench the reaction, 30 ml ice-
cold complete media was added and the cell suspension was incubated on ice for 5 min.  
Cells were concentrated by centrifugation at 300 xg for 5 min, the supernatant 
discarded, the cell pellet resuspended in complete media, and cells concentrated by 
centrifugation at 300 xg for 5 min.  An aliquot was diluted in trypan blue for cell counting 
and responder T cells were adjusted to 5x105 responder T cells/ml in complete media. 
 To a U-bottom 96-well plate, 100 μl of Treg suspension and 100 μl complete 
media was added to a well and this volume was diluted by 2-fold serial dilutions into 5 
wells to yield ~50,000, 25,000, 12,500, 6,250 or 3,125 Tregs per well.  To the first 4 wells 
in the dilution was added to 50,000 CFSE-labelled responder T cells in 100 µl to yield 
Treg:responder T cell ratios of 1, 0.5, 0.25, and 0.125:1.  The fifth well is a Treg-only 
control.  CD3/CD28 Transactivator beads (ThermoFisher) were used to stimulate the 
proliferation of responder T cells by washing 1.25 μl transactivator beads per well 
(~50,000 beads) in CFSE buffer, adjusting the concentration of 10 µl per well in 
complete media, and pipetting 10 µl of beads to each well of the plate.  The plate was 
incubated at 37°C in 5% CO2 for 3 days.  The plate was concentrated by centrifugation 
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at 300 xg for 5 min, fixed in 100 µl 1% paraformaldehyde in 1x DPBS, and assessed by 
flow cytometric analysis. 
Adoptive transfer, MPTP intoxication, mouse perfusion, and immunochemistry for mac-1 
or tyrosine hydroxylase  
To determine if BMDCs, CD4+ CD25+, and non-adherent cells from the co-
culture of BMDCs and CD4+ T cells were neuroprotective after MPTP intoxication, the 
following protocol was used.  BMDCs, CD4+ CD25+, and non-adherent cells from co-
culture were isolated, and adoptively transferred via intravenous (i.v.) tail injection ~8-10 
hr post MPTP intoxication.  MPTP was handled and administered according to 
established protocols (Jackson-Lewis and Przedborski, 2007) and animal protocols 
approved by National institutes of Health and the University of Nebraska Medical Center 
Institutional Animal Care and Use Committee.  Briefly, mice were injected 4 times 
intraperitoneally at 2 hour intervals with 10 ml DPBS/kg as a control or 12 or 16 mg free 
base MPTP (Sigma)/kg.  Seven days after MPTP intoxication, mice were sacrificed to 
assess surviving tyrosine hydroxylase (TH) immunohistochemistry as described below.     
   To determine whether BMDCs are neuroprotective if administered prior to MPTP 
intoxication, BMDCs were differentiated in R10 media supplemented with 20 ng/ml GM-
CSF for 8 days and then in R10 media alone for 3 days.  At this time, BMDCs were 
removed from the dish by cell scraper and adjusted to ~1.5x106 BMDCs/250 μl 1x 
DPBS.  This volume was administered by tail vein to 8-9-week-old male C57BL/6J mice 
at 1 and 2 weeks prior to MPTP intoxication with 16 mg/kg of MPTP.  This adoptive 
transfer protocol for BMDCs was described for the experimental autoimmune 
encephalomyelitis (EAE) model of multiple sclerosis (Prado et al., 2012).   
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 Two (for Mac-1 immunohistochemistry) or 7 (for TH immunohistochemistry) days 
after MPTP intoxication, mice were sacrificed, perfused, and brains removed and 
processed for immunohistochemistry as previously described (Kosloski et al., 2013; 
Olson et al., 2015).  Briefly, mice were terminally anesthetized with Fatal-Plus 
(pentobarbital) (Vortech, Dearborn, MI) and mice were transcardially perfused with 1x 
DPBS (Cellgro, Corning, NY) until all blood was flushed.  At this time, the mouse was 
fixed with 4% paraformaldehyde in DPBS.  The brain was removed and post-fixed in 4% 
paraformaldehyde for 24 hr.  Brains were then incubated in 30% sucrose at 4°C to 
remove the formaldehyde and cryopreserve tissues prior to snap-freezing brains for 15 
sec in 2-methyl butane (ThemoFisher) which has been chilled on dry ice for 20 min.  
Brains were embedded in OCT (Tissue Tek, Radnor, PA) and 30 μm sections of the 
midbrain and striatum were cut and stored in 0.1% sodium azide (Sigma) in PBS at 4°C 
until immunohistochemistry was performed (Kosloski et al., 2013; Olson et al., 2015).   
For Mac-1 staining, 6 free floating sections of substantia nigra from each mouse 
were washed in 1x PBS (Cellgro), endogenous peroxidases blocked by incubation in 3% 
hydrogen peroxide (ThermoFisher) and 10% methanol (ThemoFisher, in PBS), and 
nonspecific staining blocked in 5% normal rabbit serum in PBS (Vector labs, Burlingame, 
CA).  Sections were incubated at 4°C with 1:500 dilution of rat anti-Mac-1 primary 
antibody (Bio-Rad) in 2% normal rabbit serum (in PBS) overnight, washed, and 
incubated in a 1:500 dilution of biotinylated rabbit anti-rat antibody in 2% normal rabbit 
serum in PBS (Vector labs) followed by ABC biotin-avidin peroxidase solution (Vector 
Labs) prior to color generation with 3,3'-diaminobenzidine (DAB).  The number of 
reactive Mac-1+ microglia per total area was determined by stereological analysis using 
Stereo Investigator software and the optical fractionator module (MBF Bioscience, 
Williston, VT) (Kosloski et al., 2013; Olson et al., 2015).   
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For TH staining, 6 free-floating sections of the striatum and 12 free-floating 
sections of the substantia nigra from each mouse were washed in 0.1 M Tris-buffered 
saline (TBS) and endogenous peroxidases were blocked with 3% hydrogen peroxide in 
methanol and 0.1 M TBS.  Sections were blocked in 5% normal goat serum (Vector 
Laboratories, in 0.1 M TBS) in 0.1 M TBS prior to staining with 1:2,000 or 1:1,000 
dilution of anti-tyrosine hydroxylase (TH) antibody (EMD/Milipore, Burlington, MA) in 2% 
normal goat serum in 0.1 M TBS for 48 hr at 4°C.  Sections were then washed in 0.1 M 
TBS, stained with a goat anti-rabbit secondary antibody (Vector Laboratories) in 2% 
normal goat serum in 0.1 M TBS, and washed again in 0.1 M TBS prior to incubation 
with avidin-biotin complex kit (Vector Laboratories) and development with DAB in PBS.  
Sections were washed in 0.1 M TBS and transferred to slides.  Midbrain sections 
containing the substantia nigra were Nissl counter-stained prior to counting TH+ Nissl+ 
and TH- Nissl+ neurons by stereological analysis using Stereo Investigator software with 
the optical fractionator module (MBF Bioscience, Williston, VT).  TH density of 
dopaminergic termini in the striatum was determined using ImageJ (Kosloski et al., 2013; 
Olson et al., 2015).      
Adoptive transfer of BMDCs into mice with and without MPTP for Treg percentage and 
function 
 To determine if BMDCs induce Tregs in vivo, BMDCs were differentiated in R10 
media supplemented with 20 ng/ml GM-CSF for 8 days and then in R10 media alone for 
3 days.  At this time, BMDCs were removed from the dish by cell scraper and brought to 
~1.5x106 BMDCs/250 μl 1x DPBS.  This volume was administered via tail vein injection 
to 8-9 week-old male C57BL/6J mice (Jackson Labs) 1 and 2 weeks prior to sacrifice to 
test Treg induction in the absence of MPTP or 2 days after MPTP intoxication which was 
done 1 week after the second BMDC adoptively transfer.  As a control for Treg induction 
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without MPTP, mice received 50 µg/kg mouse recombinant GM-CSF i.p. injected on 
each of 5 days prior to sacrifice.  For both experiments, mice were sacrificed by CO2 
asphyxiation and cervical dislocation.  Spleen and lymph nodes (cervical, brachial, 
axillary, and inguinal) were removed, kept separate for each mouse, and single cell 
suspensions prepared for each tissue.  Flow cytometry was performed to test the 
percentage of Tregs in ~500,000 splenocytes or lymph node cells.  The remaining 
splenocytes were pooled by treatment group, Tregs (CD4+ CD25+), and responder T 
cells (CD4+ CD25-) were isolated, and Treg suppression assays performed.  Blood 
samples were collected by submandibular bleed using 5 mm GoldenRod lancets 
(ThermoFisher) and blood was collected in BD microtainer EDTA-coated tubes 1 day 
prior to each adoptive transfer and sacrifice.  At least 50 μl blood was collected per 
mouse and Treg frequencies were determined by flow cytometry.      
MES23.5 cell culture 
 MES23.5 cells were cultured in MES23.5 media (DMEM/F12 with L-glutamine 
and 15mM HEPES supplemented (Gibco) and supplemented with 2% heat-inactivated 
FBS (Sigma), 100 U penicillin, 100 g/ml Streptomycin (Gibco), 1x N-2 supplement 
(Gibco)).  The cells were grown on poly-D-lysine-coated T-75 flasks (BD Falcon).  Flasks 
or 96-well plates (BD Falcon) were coated with 10 ml or 100 µl/well in 5 µg poly-d-
lysine/ml at 37°C overnight followed by removing the volume of coating solution, 
washing with sterile MQ water, and allowing the flask or plate to dry.  Cells were 
removed from the flask by incubation in 1 mM EDTA (Gibco) and ~1x106 MES23.5 cells 
were passed to a new flask with cells passed 2 times per week. 
BV2 cell culture 
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 BV2 cells were cultured in BV2 media (1x DMEM with glucose, glutamine, and 
phenol red (Gibco) supplemented with 5% FBS, 100 U penicillin, 100 g/ml streptomycin 
(Gibco), 10 mM HEPES (Gibco), 2 mM L-glutamine (Gibco), and 55 nM 2-
mercaptoethanol (Gibco)).  BV2 cells were passed 2 times per week by removing the 
BV2 cells from T-75 flasks (BD Falcon) using 1 mM EDTA (Gibco) and ~1x106 BV2 cells 
were passed to a new flask for passage into new T-75 flasks.  
 To stimulate BV2 cells, ~1x106 BV2 cells in 0.5 ml of volume was added to each 
well of a 24-well plate.  Each well was adjusted to 1 ml total volume by adding BV2 
media, BMDC supernatant (supernatants of BMDC culture from which cells were 
removed by centrifugation at 400 xg for 10 min), or R10 media.  LPS stimulation was 
achieved by adding 100 ng of LPS from E. coli O55:B5 (Sigma) to each well.  
Supernatants from each well were combined by treatment group and cells concentrated 
by centrifugation at 400 xg for 10 min.   
Celltiter-Glo Cell Viability Assay 
 Cell viability was determined using the CellTiter-Glo assay (Promega) as follows.  
Either ~20,000 or 10,000 MES23.5 cells (for MPP+ or BV2 supernatant respectively) 
was added to a black-walled 96-well assay plate which was coated with poly-D-lysine.  
An equal volume (50 µl) of MES23.5 media, R10 media, or BMDC supernatant was 
added to all wells.  As controls, equal volumes of media without cells were added to 
other wells.  After 24 hours of incubation, an equal volume (100 µl) of either MES23.5 
media containing 0 – 1,000 µM MPP+ (Sigma), or BV2 media or supernatant was added.  
MES23.5 cells were incubated for 24 hr.  Afterwards, the media was removed from each 
well and 100 µl CellTiter-Glo assay reagent (reconstituted as described in the kit) was 
added and the 96-well plate was incubated at RT for 2 min with shaking followed by 
equilibration at RT for 10 min prior to reading luminescence.  The raw luminescence 
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values from the no cell control wells were subtracted from all other wells.  The 
background corrected values were divided by the control values obtained from treatment 
with media or BV2 media to determine the percent viability.   
Cytokine bead array 
 Concentrations of IL-2, IL-4, IL-6, IL-10, IL-17a, TNF, and IFNγ were determined 
using the Th1/Th2/Th17 cytokine bead array (BD) as follows.  Standards from the kit 
were reconstituted according to the manufacturer’s protocol and 2-fold serially diluted 
into 5 ml flow cytometry tubes in duplicate.  In triplicate 50 µl samples of BV2 
supernatant were added to 5 ml flow cytometry tubes.  Capture beads from all analytes 
were combined and 50 µl assay detection reagent were added to 50 µl standards or 
samples which were incubated at RT for 2 hr.  All samples and standards were washed 
in the assay wash buffer and beads were concentrated by centrifugation at 200 xg for 5 
min.  The supernatant was discarded and pellet resuspended in 300 µl wash buffer and 
analyzed by flow cytometry.  The mean fluorescent intensity was determined for each 
cytokine in all samples and standards.  The log10-transformed mean fluorescent intensity 
was plotted against log10-transformed concentration of the standards.  The curve was 
fitted by five parameter logistical regression to determine the standard curve.  Based on 
standard curve, the concentration of each cytokine was determined from all samples.    
Testing splenic DC percentage after GM-CSF administration 
 Approximately 11-week-old C57BL/6J mice (Jackson Labs) were i.p. injected 
with 50 µg/kg mouse recombinant GM-CSF or a commensurate volume of 1x DPBS 
each of five days prior to sacrifice.  Mice were sacrificed by CO2 asphyxiation and 
cervical dislocation, spleens removed, and a single cell suspensions prepared.  Cells 
were immunostained for the surface expression of CD11c, CD11b, CD86, MHC II, Jag-1, 
101 
 
OX40L, CD39, and CD73 and percentages within the lymphocyte population determined 
by flow cytometric analysis using the previously-described antibodies.   
Statistics 
 For comparisons of multiple groups with only one parameter, one-way ANOVA 
was performed followed by Tukey’s post-hoc test was used.  For comparisons of multiple 
groups with 2 or more parameters a two-way ANOVA was performed followed by 
Tukey’s or Newmann-Keuls post-hoc test.  To determine if surface marker expression on 
BMDCs correlates with Treg induction, Pearson’s correlation was calculated using Prism 
GraphPad version 6.  For immunohistochemistry data of neuron counts and striatal 
density, all values outside the 99% confidence interval were censored and significance 
was determined by one-way ANOVA followed by Tukey’s post-hoc test.  Statistics were 
performed using Prism GraphPad version 6 (GraphPad Software Inc.).  A value was 
considered significant when the multiple comparison-adjusted P value was less than 
0.05.   
 
RESULTS 
Activation of DC2.4 and DC3.2 cells with LPS and N-α-Syn is mitigated by GM-CSF 
 One of the functional definitions of tolerogenic DCs is the lack of an inflammatory 
response to maturation stimulation (Mahnke et al., 2002).  To test if GM-CSF is inducing 
a tolerogenic state, we first needed to determine culture conditions where DCs are 
activated by LPS (a strong, general proinflammatory stimulus), N-α-Syn (a post-
translational form of α-Syn which is only found in synucleopathy patients (Duda et al., 
2000; Giasson, 2000)), or Poly I:C (a mimic of double stranded RNA).  One of DCs 
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responses to proinflammatory stimulus is increasing nitric oxide (NO) production.  The 
DC lines DC2.4 and DC3.2 were stimulated for 24 hr with increasing (0-100 µg/ml) LPS, 
N-α-Syn, or Poly I:C concentrations and the Griess assay was used to test the 
concentration of released nitrite (the product of the oxidation of nitric oxide after release 
from BMDCs).  LPS, and to a lesser extent N-α-Syn, significantly increase the release of 
nitrite in the media of both DC lines compared to media alone (0 µg/ml) (Figure 3.2A).  
Poly I:C did not increase the concentration of nitrite compared to media at any 
concentration.  For LPS, maximal nitrite concentration was found at 10 µg/ml and for N-
α-Syn the maximal nitrite concentration was found at 30 µg/ml.  These concentrations 
were used for all future experiments with these cell lines.   
 To determine if GM-CSF can diminish the concentration of released nitrite, 
DC2.4 and DC3.2 cells were cultured in cells with 10 µg/ml LPS and increasing 
concentrations (0-200 ng/ml) of GM-CSF, and the concentration of nitrite was tested with 
the Griess assay.  None of the tested concentrations of GM-CSF significantly decreased 
the LPS-induced increase in nitrite concentration in either cell line (Figure 3.2B).  This 
was done with GM-CSF administered at the same time as LPS.  If GM-CSF is inducing 
tolerogenic DCs, it may need to be administered before the stimulation with LPS to see 
an effect.  DC2.4 cells were treated for 2 days with increasing concentrations of GM-
CSF (0-200 ng/ml) prior to stimulation with LPS and N-α-Syn for 24 hr.  GM-CSF 
induces a dose-dependent decrease in nitrite after LPS and N-α-Syn stimulation (Figure 
3.2C).  It appears that even though 200 ng/ml GM-CSF leads to the most suppression of 
nitrite release, this is significant, but not dramatically different than 20 ng/ml.  To 
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Figure 3.2 GM-CSF pre-treatment, but not co-treatment, decrease the LPS- and N-
α-Syn-induced increase in nitrite release in DC2.4 and DC3.2 cells with no 
decrease in cell viability  
A) DC lines DC2.4 and DC3.2 were stimulated with increasing concentrations of LPS, N-
α-Syn, or Poly I:C for 24 hours and the Griess assay was used to test nitrite 
concentration in the supernatant.  B) DC2.4 and DC3.2 cells were treated for 24 hours 
with 10 µg/ml LPS, increasing concentrations of GM-CSF or the combination of GM-CSF 
and LPS and nitrite concentration in the supernatant was determined by the Griess 
assay.  C) DC2.4 cells were pre-treated with increasing concentrations of GM-CSF for 2 
days prior to 24 hours of stimulation with 10 µg/ml LPS or 30 10 µg/ml N-α-Syn and the 
NO concentration in the supernatant was determined by the Griess assay.  D) Cell 
viability was determined after 2 days of 20 ng/ml GM-CSF pre-treatment, then 24 hours 
of stimulation with 10 µg/ml LPS or the combination, and the AlamarBlue cell viability 
assay was used to determine the percentage of the dye reduced.  Significance was 
determined by One-way ANOVA followed by Tukey’s post-hoc test where a result is 
significant if p<0.05.  For A and B, a-significant from media alone, b-significant from LPS 
control and n=4 in A and n=5 in B.  For C, a-significantly different from media, b-
significantly different from 10 µg/ml LPS, 1-significantly different from 0 ng/ml GM-CSF, 
2-significantly different from 2 ng/ml GM-CSF, 3-significantly different from 20 ng/ml GM-
CSF and n=3.  For D, a-significant from media alone, b-significant from GM-CSF control, 





alamarBlue cell viability assay was used.  DC2.4 and DC3.2 cells were cultured in media 
or 20 ng/ml GM-CSF for two days, prior to simulation with LPS for 24 hr.  For both DC 
lines, the neither treatment with GM-CSF or LPS stimulation separately or in 
combination decreased cell viability compared to media alone, unstimulated control 
(Figure 3.2D). 
 To test the activation of DC2.4 cells by another method, we tested the surface 
expression of activation markers and co-stimulatory molecules.  DC2.4 cells were pre-
treated for 2 days with GM-CSF prior to 24 hr stimulation with LPS and N-α-Syn and flow 
cytometry was performed.  Few DC2.4 cells (5% or less) expressed CD11c (Figure 
3.3A), an integrin receptor which is a marker for myeloid lineage DCs (Ziegler-Heitbrock 
et al., 2010).  CD86 is an activation marker for DCs which binds to CD28 on T cells, 
leading to T cell proliferation and activation (Lu et al., 1997).  Even when cultured in 
media alone, about 90% of DC2.4 cells express CD86 (Figure 3.3B).  Pre-treatment with 
GM-CSF, LPS or N-α-Syn stimulation, or a combination can do decrease the high, basal 
surface expression of CD86.  Less than 5% of DC2.4 cells express OX40L, a co-
stimulatory molecule which preferentially promotes Th2 CD4+ cells proliferation 
(Ohshima et al., 1998) and Treg survival (Griseri et al., 2010) (Figure 3.3C).  Jagged-1 
(Jag-1) is a Notch-1 ligand which also promotes the differentiation of Tregs (Hoyne et al., 
2000).  GM-CSF, LPS and N-α- Syn, alone or in combination increases Jag-1 surface 
expression on DC2.4 cells (Figure 3.3D).  In all conditions, GM-CSF does not promote 
the surface expression of co-stimulatory molecules OX40L and Jag-1.  In addition, 
DC2.4 cells constitutively express high CD86 in all conditions, meaning there is no 
upregulation following stimulation with LPS and N-α-Syn.  As a result, the activation of 
DC2.4 could not be determined by flow cytometry.  Because CD86 surface expression is 




Figure 3.3 Flow cytometric analysis of DC2.4 cells after GM-CSF pre-treatment and LPS 




Figure 3.3 Flow cytometric analysis of DC2.4 cells after GM-CSF pre-treatment and 
LPS and N-α-Syn stimulation   
DC2.4 cells were pre-treated in 20 ng/ml GM-CSF for 2 days prior to 24 stimulation with 
10 µg/ml LPS or 30 µg/ml N-α-Syn prior to staining cells for CD11c  (A), CD86 (B), 
OX40L (C), and Jag-1 (D).  Data presented are from 1 replicate so no statistical 





and relatively unchanged, DC2.4 cells are not the best model for determining if GM-CSF 
is inducing a tolerogenic DCs.   
BMDC activation by LPS and N-α-Syn is mitigated by GM-CSF  
 Due to GM-CSF being unable to induce a tolerogenic state in DC lines, we next 
sought to determine if GM-CSF can induce a tolerogenic state in BMDCs.  First, we 
needed to determine optimal differentiation conditions for BMDCs by culturing BMDCs 
with 10 or 20 ng/ml GM-CSF with and without 10 ng/ml IL-4.  After 8 days, BMDCs were 
cultured in media alone for 3 days, 20 ng/ml GM-CSF for 3 days or 20 ng/ml GM-CSF for 
2 days prior to 1 day of stimulation with 10 μg/ml LPS and surface markers were 
determined by flow cytometry.  In all conditions, 50% or more of the BMDCs expressed 
CD11c with a generally higher percentage of CD11c+ cells found on BMDCs 
differentiated without IL-4 (Figure 3.4A).  Unlike the DC2.4 cells, LPS stimulation 
increase the surface expression of CD86 in all BMDC differentiation conditions (Figure 
3.4B).  BMDC differentiation with IL-4 increased the percentage of unstimulated BMDCs 
expressing CD86.  All conditions displayed fewer CD86-expressing BMDCs than DC2.4.  
OX40L expression was higher when BMDCs were differentiated with IL-4 (Figure 3.4C).  
When BMDCs were differentiated without IL-4, LPS-stimulation of BMDCs decreased 
the number of OX40L+ cells, however, BMDCs differentiated with IL-4 prior to LPS 
stimulation appeared to increase the number of BMDCs expressing OX40L.  
Differentiating BMDCs in the presence of IL-4 appears to diminish the number of BMDCs 
expressing Jag-1 (Figure 3.4D).  For BMDCs differentiated without IL-4, the number of 




Figure 3.4 Flow cytometric analysis of BMDCs after differentiation in GM-CSF or GM-




Figure 3.4 Flow cytometric analysis of BMDCs after differentiation in GM-CSF or 
GM-CSF and IL-4 prior to stimulation with LPS 
BMDCs were differentiated from the bone marrow for 8 days with 10 or 20 ng/ml GM-
CSF with 0 or 10 ng/ml IL-4.  After differentiation, BMDCs were cultured in media alone, 
media supplemented with 20 ng/ml GM-CSF or media supplemented with 20 ng/ml GM-
CSF for two days prior to 24 hours of stimulation with 10 µg/ml LPS.  Surface expression 
of CD11c (A), CD86 (B), OX40L (C), and Jag-1 (D) was determined by flow cytometry.  
There are 2 replicates of CD11c and 1 replicate of CD86, OX40L, and Jag-1.  No 





stimulation.  The conclusion from this experiment is that differentiating BMDCs in 20 
ng/ml GM-CSF without IL-4 appears to be the optimal condition for expressing all 4 of 
the markers tested.  BMDC differentiated with this condition showed a high percentage 
positive for CD11c, a noticeable increase in CD86+ cells after stimulation and a 
noticeable increase in the percentage of Jag-1+ BMDCs with GM-CSF treatment or LPS 
stimulation.  Because BMDCs exhibit lower basal activation state compared to the 
DC2.4 cells, BMDCs are a better model for testing the tolerogenic state of DCs.   
     Since there were surface expression differences on BMDCs with GM-CSF 
culture followed by LPS and N-α-Syn stimulation compared to DC2.4 cells, we next 
tested if BMDCs increase the release of nitrite after stimulation with LPS and N-α-Syn 
stimulation.  Stimulation with LPS and N-α-Syn increase the release of nitrite compared 
to BMDCs continued in culture with GM-CSF.  The continued culture of BMDCs with 
GM-CSF prior to LPS and N-α-Syn stimulation mitigates the increase in nitrite 
concentration (Figure 3.5A).  These data show that BMDCs can release nitrite after 
stimulation, just as DC2.4 cells.  However, it should be noted that the increase in nitrite 
after stimulating BMDCs with LPS and N-α-Syn stimulation is less than the increase after 
stimulating DC2.4 cells.   
 To ensure that the changes in nitrite production were not due to the loss of 
BMDCs by GM-CSF culture without or with LPS or N-α-Syn stimulation, the alamarBlue 
cell viability assay was performed.  The continued culture of BMDCs in GM-CSF prior to 
LPS stimulation significantly lowered cell viability compared to media and GM-CSF 
controls, however the cell viability was still over 90% (Figure 3.5B).  LPS stimulation 
alone, and N-α-Syn stimulation with or with continued GM-CSF culture, did not affect cell 
viability.  These data demonstrate that the decrease in nitrite production is not due to a 





Figure 3.5 BMDC culture with GM-CSF mitigates the LPS- or N-α-Syn-induced increase 




Figure 3.5 BMDC culture with GM-CSF mitigates the LPS- or N-α-Syn-induced 
increase in the nitrite concentration in the supernatant, without effecting cell 
viability     
BMDCs were matured for 8 days with 20 ng/ml GM-CSF.  BMDCs were either cultured 
in media alone or 20 ng/ml GM-CSF for 2 days prior to being stimulated for 24 hours 
with 100 ng/ml LPS or 30 µg/ml N-α-Syn.  A) The Griess assay was used to measure the 
nitrite concentration in the supernatant.  Significance was determined by One-way 
ANOVA followed by Tukey’s post-hoc test, n=9.  a-significantly different from media 
alone, b-significantly different from GM-CSF control, c-significantly different from LPS or 
N-α-Syn control.  B) Cell viability was also tested using the alamarBlue assay where cell 
viability was determined by measuring the percentage of the alamarBlue dye reduced.  
Significance was determined by One-way ANOVA followed by Tukey’s post-hoc test and 
p<0.05.  a-significantly different from media alone, b-significantly different from GM-CSF 





After determining the conditions to differentiate the BMDCs, the next experiments 
performed were designed to test if GM-CSF promotes a tolerogenic state in BMDCs.  
Tolerogenic DCs display low expression of co-stimulatory molecules, even with a 
maturation stimulus.  To test this hypothesis, flow cytometric analysis was used to 
determine if GM-CSF, N-α-Syn or the combination significantly increases the surface 
expression of different co-stimulatory molecules.  The percentage of CD11c+ cells in the 
single cell suspension was determined by flow cytometry.  More than 75% of cells in all 
treatment groups are positive for the DC marker CD11c, even though there was a 
significant reduction of CD11c+ cells in BMDCs continued in GM-CSF culture prior to N-
α-Syn (Figure 3.6A).  Flow cytometry was also used to determine the surface expression 
of the myeloid-origin cell marker CD11b.  As with CD11c, BMDCs continued in GM-CSF 
culture prior to N-α-Syn stimulation display significantly reduced surface CD11b, 
however more than 95% of single cells are CD11b+ (Figure 3.6B).  When DCs mature, 
they upregulate their surface expression of co-stimulatory molecules, such as MHC II 
and CD86.  The mean fluorescent intensity (MFI) of the activation state of MHC II and 
CD86 on CD11c+ BMDCs was significantly increased after N-α-Syn stimulation of 
media-cultured BMDCS, but this was significantly diminished by pretreatment with GM-
CSF (Figure 3.6C, D).  The MFI of OX40L was not altered by the pretreatment with GM-
CSF, N-α-Syn stimulation, or a combination (Figure 3.6E).  The surface expression of 
Jag-1 is significantly increased with GM-CSF pretreatment which is further increased by 
N-α-Syn stimulation (Figure 3.6F).  The surface expression of CD11c, OX40L, and Jag-1 
are similar to the results in Figure 3.4.  We also tested the expression of the surface 
ATPases CD39 and CD73.  CD39 is the enzyme that converts extracellular ATP to AMP 
and CD73 converts AMP to adenosine (Deaglio et al., 2007).  Neither the continuation of 








Figure 3.6 Surface expression of co-stimulatory molecules on CD11c+ BMDCs 
BMDCs were cultured in media alone or with 20 ng/ml GM-CSF for 2 days prior to 
stimulation with 30 µg/ml N-α-Syn for 1 day.  On the X-axis, treatment groups are 
designated as (1) media-cultured, unstimulated BMDCs; (2) GM-CSF-cultured, 
unstimulated BMDCs; (3) media-cultured, N-α-Syn-stimulated BMDCs; and (4) GM-CSF-
cultured, N-α-Syn-stimulated BMDCs.  BMDCs were stained for CD11c, CD11b, MHC II, 
CD86, OX40L. Jag-1, CD39 and CD73 for flow cytometric analysis.  Panels A and B are 
the percentage of single cells positive for CD11c and CD11b respectively.  The numbers 
are the mean percentage of single cells positive for each marker.  The mean fluorescent 
intensity (MFI) was determined on CD11c+ cells for MHC II (C), CD86 (D), OX40L (E), 
Jag-1 (F), CD39 (G) and CD73 (H).   There are 7 replicates for each treatment group.  
Significance was determined by one-way ANOVA and Tukey’s post-hoc test.  a- 
significantly different from media BMDCs, b-significantly different from GM-CSF-treated 





CD39 and CD73 (Figure 3.6G, H).  These data demonstrate that continued culture with 
GM-CSF diminishes the N-α-Syn-induced increase of CD86 and MHC II surface 
expression and increases Jag-1 surface expression.  In total, these data indicate that the 
BMDCs tested are in a tolerogenic state due to their decreased expression of the co-
stimulatory molecules (MHC II and CD86) and increased expression of anti-inflammatory 
Jag-1.   
 Next, we wanted to test the expression of proinflammatory cytokines and other 
proinflammatory mediators.  From all 4 BMDC treatment groups, RNA was isolated, 
cDNA was generated, and PCR arrays were run to test the expression of 
proinflammatory genes relative to the media-cultured, unstimulated BMDCs.  GM-CSF 
culture without stimulation did cause 2-fold upregulation of IL6, CXCL9, CXCL3, CCL17, 
SELE, CCL24, CCR1, CXCR2, and TNFSF14 and the downregulation of CXCL10, 
CD40, TNF, TLR1, and BCL6 (Figure 3.7).  N-α-Syn stimulation of media-cultured 
BMDCS increased expression of several genes including CXCL10, IL6, IL23A, PTGS2, 
CD40, among others.  Several genes are downregulated including CCR2, FOS, CXCR4, 
IL6RA among others.  The continued culture in GM-CSF prior to N-α-Syn stimulation 
diminished the expression of several genes such as IL6, PTGS2, CD40, and LTA among 
others.  Conversely, several genes were increased with the continued culture in GM-
CSF prior to N-α-Syn stimulation, for example, IL23A, NOS2, and IL1A.  Three genes 
that were downregulated by N-α-Syn stimulation in media-cultured BMDCs were further 
downregulated with GM-CSF pretreatment; these genes are CXCR2, CXCR4 and FOS.  
However, other genes downregulated by N-α-Syn stimulation of media-cultured BMDCs 






Figure 3.7 Gene expression of GM-CSF, N-α-Syn, or GM-CSF+N-α-Syn-treated BMDCs 




Figure 3.7 Gene expression of GM-CSF, N-α-Syn, or GM-CSF+N-α-Syn-treated 
BMDCs compared to media-cultured, unstimulated BMDCs 
BMDCs were differentiated for 8 days with 20 ng/ml GM-CSF and half of the BMDCs 
were cultured for 2 days with media alone 20 ng/ml GM-CSF.  Some BMDCs from each 
culture condition were stimulated with 30 µg/ml N-α-Syn for 6 hr.  RNA was isolated, 
converted to cDNA and PCR arrays of pro-inflammatory genes were performed.  Gene 
expression was determined relative to the media-cultured, unstimulated BMDCs.  n=6.  
The fold change is indicated, and red shading indicates upregulation of gene expression 




This gene expression data highlights several key points.  N-α-Syn stimulation 
increases the expression of proinflammatory cytokines like IL6, IL23A, TNF, IL1A, IL1B, 
IL18, and IFNG which may be increased or decreased by continued culture with GM-
CSF.  The expression of the anti-inflammatory gene IL10 was increased with N-α-Syn 
stimulation of media-cultured BMDCs, and further increased with continued culture in 
GM-CSF prior to N-α-Syn stimulation.  The increase in anti-inflammatory and decrease 
in proinflammatory cytokines are in line with GM-CSF-cultured BMDCS being 
tolerogenic.  However, some proinflammatory genes are increased, which is counter to 
our hypothesis.  Next, we tested the expression of other markers of maturation in our 
BMDCs.  Several genes associated with Toll-like receptor signaling, such as TLR1, 
TLR3, TLR2, CD14, MYD88, and NFKB1 are increased by N-α-Syn stimulation of 
media-cultured BMDCs, and continued culture in GM-CSF decreased the expression of 
TLR1 and TLR3 but increased the expression of TLR2.  This suggests that GM-CSF 
pretreatment may alter the expression of the TLRs, including TLR1, TLR2, and TLR4, 
which can be receptors for α-Syn (Su et al., 2008; Stefanova et al., 2011; Fellner et al., 
2013; Daniele et al., 2015).  However, the expression of MYD88 and NFKB1, the 
downstream signaling cascade of the Toll-like receptors, and CD14, the co-receptor for 
TLR4, was not affected by the continued culture of BMDCs in GM-CSF.  This suggests 
that it is not that GM-CSF is able to diminish the ability of the BMDCs to respond to N-α-
Syn, but rather GM-CSF alters the response of the BMDCs.  The continued culture of 
GM-CSF diminished the N-α-Syn-induced expression of CD40.  The gene expression of 
CD40, a T cell co-stimulatory molecule, is similar to the surface expression of CD86, a 
co-stimulatory molecule with similar function.  CCR7 is marker of DC maturation (Worbs 
and Forster, 2007), which was decreased -1.42-fold in the continued culture in GM-CSF 
without stimulation.  However, N-α-Syn stimulation increases CCR7 expression, which is 
further increased by continued culture of BMDCs with GM-CSF.  Lastly CEBPB, a 
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transcription factor involved in TNFα expression (Pope et al., 1994) was increased by 
stimulation with N-α-Syn and expression was further increased by culture with GM-CSF 
prior to N-α-Syn stimulation.  In total, these gene expression changes demonstrate that 
GM-CSF does not prevent the maturation of BMDCs or diminish the ability of BMDCs to 
respond to the N-α-Syn stimulation.  However, GM-CSF does alter how BMDCs respond 
to N-α-Syn stimulation, which increases the expression of some proinflammatory and 
anti-inflammatory genes.                     
 We also tested the release of nitrite from these BMDCs.  Overall, there was no 
significant change in nitrite concentration between the BMDC treatment groups (Figure 
3.8).  However, there was a trend to more nitrite release with N-α-Syn stimulation 
compared to all other groups, but the concentration of nitrite was decreased compared 
to previous experiments (Figure 3.5).  Interestingly, in the PCR array from Figure 3.7, 
NOS2, the gene for the major producer of NO in activated BMDCs, inducible nitric oxide 
(iNOS), was significantly increased with N-α-Syn stimulation and NOS2 was more highly 
expressed in BMDCs continued in culture with GM-CSF prior to N-α-Syn stimulation.  
The expression of NOS2 does not correlate with the nitrite concentration determined by 
the Griess assay.         
 In addition to testing the expression of proinflammatory genes, release of 
proinflammatory cytokines and chemokines from different treatment groups of BMDCs 
was tested by a Luminex magnetic bead assay.  N-α-Syn stimulation of media-cultured 
BMDCs significantly increased the release of IL-1β, IL-10, Lix, MIG, IL-6, IL-12p70, IL-
13, IL-15, IFNγ, RANTES and TNFα compared to the media-cultured, unstimulated 
controls (Figure 3.9).  Continued culture in GM-CSF prior to N-α-Syn stimulation 
increased the release of IL-1α, IL-1β, IL-2, IL-5, IL-7, IL-9, IL-10, IL-12p40, IL-17, and IP-








Figure 3.8 Nitrite concentration in supernatant from BMDCs 
BMDCs were matured for 8 days with 20 ng/ml GM-CSF.  BMDCs were then cultured in 
media alone or 20 ng/ml GM-CSF for 2 days prior to being stimulated for 24 hours with 
30 µg/ml N-α-Syn or being left unstimulated.  The Griess assay was used to measure 
nitrite concentration in the supernatant.  Significance was determined by One-way 
ANOVA followed by Tukey’s post-hoc test and p<0.05. n=28 (4 technical replicates from 




release of Lix and MIG.  The continued culture in GM-CSF decreased MIP2 release 
without N-α-Syn stimulation; however, N-α-Syn stimulation after the continued culture of 
BMDCs in GM-CSF prevented this decrease.  Continued culture of BMDCs in GM-CSF 
prior to N-α-Syn stimulation increased the release of IL-10, an anti-inflammatory 
cytokine.  The continued culture in GM-CSF did not significantly alter the N-α-Syn-
induced release of proinflammatory cytokines IL-6, IL-12p70, IL-13, IL-15, IFNγ, MIP2, 
RANTES, and TNFα.   In total, these data show that the continued culture in GM-CSF 
pretreatment does not mitigate the release of proinflammatory cytokines or chemokines, 
but does increase the release of IL-10.  While there are changes in the expression on 
the RNA level, but this does occur on the level of protein release. These data suggest 
that GM-CSF is more an immune modulator altering the response of BMDCs as 
opposed to broadly suppressing the immune response.     
 Lastly, we tested if the continued culture of BMDCs in GM-CSF with or without N-
α-Syn stimulation increases the expression of IDO in lysate as well as kynurenine 
release in the supernatant.  IDO is the enzyme that converts tryptophan to kynurenine 
(King and Thomas, 2007).  The increase in IDO expression, kynurenine concentration, 
and concentration of kynurenine’s metabolites are inducers of Tregs (Munn and Mellor, 
2013) and may be part of the mechanism of Treg induction.  BMDCs were cultured in 
media alone or with GM-CSF and left unstimulated or stimulated with N-α-Syn as above.  
BMDCs were lysed and Western blot was used to determine the expression of IDO 
relative to β-actin.  Media-cultured, unstimulated BMDCs displayed the highest 
expression of IDO, which was significantly decreased by continued culture in GM-CSF, 
with or without N-α-Syn stimulation (Figure 3.10A).  Mass spectrometry was used to 
quantify the kynurenine concentration in the media.  There was no significant difference 









Figure 3.9 Cytokines and chemokines released from BMDCs 
BMDCs were differentiated for 8 days in 20 ng/ml GM-CSF prior to culture with media 
alone or 20 ng/ml GM-CSF for 2 days, then stimulation with 30 µg/ml N-α-Syn for 1 day.  
On the X axis, treatment groups are designated as (1) media-cultured, unstimulated 
BMDCs; (2) GM-CSF-cultured, unstimulated BMDCs; (3) media-cultured, N-α-Syn-
stimulated BMDCs; (4) GM-CSF-cultured, N-α-Syn-stimulated BMDCs.  The supernatant 
was removed and the Luminex XMAP pro-inflammatory cytokine and chemokine array.  
There are three 2-3 technical replicates for each of 7 wells of BMDCs (n=19 for each 
group).  Significance was determined by One-Way ANOVA and Tukey’s post-hoc test.  
a-significantly different from media BMDCs, b-significantly different from GM-CSF-tested 




treatment groups, but the media-cultured, unstimulated BMDCs appear to exhibit the 
highest concentration of released kynurenine (Figure 3.10B).  This finding is contrary to 
our hypothesis that the continued culture in GM-CSF would increase expression of IDO 
or release of kynurenine, which are markers of tolerogenic DCs.   
In conclusion, from the flow cytometric data, it appears that GM-CSF decreases 
the surface expression of co-stimulatory molecules, and increases the surface 
expression of Jag-1, which is in line with our hypothesis of GM-CSF inducing a 
tolerogenic state.  However, GM-CSF does not mitigate the expression or release of 
proinflammatory cytokines, or increase the expression of IDO or kynurenine.  These data 
do not support the hypothesis.  Overall, it appears that GM-CSF is altering how BMDCs 
respond to stimulation with N-α-Syn, but does not maintain the tolerogenic state.           
BMDCs increase Treg frequencies 
 In the above section, we characterized the surface markers, genes expressed, 
and products released by BMDCs cultured in media alone or GM-CSF prior to N-α-Syn 
stimulation.  One of the properties of tolerogenic DCs is the ability to induce Tregs 
(Maldonado and von Andrian, 2010) and the next experiment was to determine if 
BMDCs cultured in media or GM-CSF with and without N-α-Syn stimulation were able to 
induce Tregs in culture.  BMDCs were differentiated and cultured as described above 
and were co-cultured with CD4+ cells isolated from spleens of C57BL/6J mice.  After 5 
days, the percentage of Tregs (CD4+ CD25+ Foxp3+) in the non-adhered cells was 
determine by flow cytometric analysis.  In CD4+ cells prior to co-culture, ~2% of the 
CD4+ cells are Tregs (Figure 3.11A).  All BMDC treatment groups significantly increased 
the percentage of Tregs (CD4+ CD25+ Foxp3+) compared to CD4+ cells alone.  Media-








Figure 3.10 Expression of IDO and kynurenine release in the supernatant    
BMDCs were differentiated for 8 days with 20 ng/ml GM-CSF.  At this time, the BMDCs 
were cultured in media alone or in 20 ng/ml GM-CSF for 2 days.  BMDCs were left 
unstimulated or stimulated with 30 µg/ml N-α-Syn for 24 hour.  A) Western blot was 
performed on lysate and the ratio of intensity for IDO and β-actin from each of the 
treatment groups (n=2 media, n=6 GM-CSF, n=7 N-α-Syn, and n=7 GM-CSF + N-α-Syn) 
was graphed.  Significance was determined by one-way ANOVA followed by Tukey’s 
post-hoc test and was significance was determined by p<0.05.  B) HPLC and Mass 
spectroscopy was used to determine the concentration of kynurenine in the supernatant 
of BMDCs treated as above.  n=7 for all groups.  Significance was determined by One-





than the GM-CSF-cultured BMDCs.  GM-CSF-cultured, N-α-Syn-stimulated BMDCs 
induced significantly fewer Tregs than all other BMDC treatment groups.  CD4+ T cells 
cultured with CD3/CD28 transactivator beads also increased the percentage of Tregs 
relative to CD4+ cells prior to culture, but to a significantly decreased degree than all 
BMDC treatment groups except for the GM-CSF-cultured, N-α-Syn-stimulated BMDCs 
(Figure 3.11A).  In a separate experiment, CD4+ cells were stained before culture (CD4+ 
alone), with media-cultured, unstimulated BMDCs directly or in transwell, or with CD11c+ 
cells positively enriched from the spleen of naïve C57BL/6J mice.  Non-adhered cells 
were removed and the percentage of Tregs was determined by flow cytometry.  While 
there were fewer Tregs in this experiment compared to the experiment in Figure 3.11A, 
media-cultured, unstimulated BMDCs still increased the percentage of Tregs ~20 fold 
compared to the starting CD4+ T population (Figure 3.11B).  When CD4+ T cells were 
cultured in a transwell assay with media-cultured BMDCs, the percentage of Tregs was 
reduced compared to direct culture, (Figure 3.11B).  Culture of CD4+ cells in a transwell 
assay increased Tregs ~3-fold, which was not significant compared to the starting CD4+ 
population, which is similar to the ~5-fold increase with CD3/CD28 transactivator beads.  
When splenic CD11c+ DCs were cultured with CD4+ cells, there was not a significant 
increase in the percentage of Tregs compared to the starting CD4+ population (Figure 
3.11B).  However, the splenic CD11c+ cells increased Tregs ~3-fold, compared to the 
starting CD4+ population, similar to the CD3/CD28 transactivator beads and transwell 
culture.  Combined, these data show that direct contact is needed for BMDCs to induce 
Tregs, and that Tregs induction is more than activation of T cells in general since neither 
CD3/CD28 activator beads nor CD11c+ DCs induce Tregs to the same percentage.  
However, contrary to our hypothesis, continuing GM-CSF culture significantly decreases 









Figure 3.11 BMDCs induce functional Tregs in vitro 
BMDCs were cultured with media or 20 ng/ml GM-CSF for 2 days prior to stimulation 
with 30 µg/ml N-α-Syn for 1 day.  These BMDCs or CD3/CD28 transactivator beads 
were then co-cultured with CD4+ T cells isolated from spleens for 5 days.  Non-adhered 
cells were removed from co-culture and the percentage of Tregs (CD25+ Foxp3+) was 
determined within the CD4+ T population.  (A) Representative, flow cytometric plots of 
non-adhered cells from the starting CD4+ T cells or the co-culture of CD4+ cells with 
BMDCs or CD3/CD28 beads are presented.  Quantification of 3 co-cultures of BMDCs of 
each treatment group with CD4+ T cells.  Significance was determined by one-way 
ANOVA followed by Newman-Keuls post-hoc test.  a-significantly different from CD4+ T 
cells alone, b-significantly different from media-cultured BMDCs, c-significantly different 
from GM-CSF-cultured, unstimulated BMDCs, d-significantly different from media-
cultured, N-α-Syn-stimulated BMDCs, e- significantly different from GM-CSF-cultured, N-
α-Syn-stimulated BMDCs.  (B) CD4+ T cells were cultured with media-cultured, 
unstimulated BMDCs directly or in transwell and CD4+ T cells were cultured with 
CD11c+ cells isolated from the spleen of naïve mice.  Quantification of 3 co-cultures of 
BMDCs of each treatment group with CD4+ T cells.  Significance was determined by 
one-way ANOVA followed by Tukey’s post-hoc test.  a-significantly different from CD4+ 
T cells alone, b-significantly different from media-cultured BMDCs.  (C) Non-adhered 
cells from media-treated BMDCs were removed after 5 days of co-culture and Tregs 
(CD4+ CD25+).  Tregs (CD4 CD25+) and responder T cells (CD4+ CD25-) were isolated 
from the spleens of naïve mice.  Dilutions of Tregs were cultured with CFSE-labelled 
CD4+ CD25- cells, which were stimulated with CD3/CD28 beads.  Linear regression was 
performed to compare the slopes of the lines.  a-significantly different slope (p=0.006) 
from spleen-derived Tregs.  
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To determine if CD4+ CD25+ Foxp3+ cells induced by BMDCs possess the 
proliferation suppression function, CD4+ CD25+ cells were isolated from co-culture with 
BMDCs and CD4+ T cells from naïve mouse spleen to test the ability of Tregs to 
suppress the proliferation of CFSE-labelled CD4+ CD25- responder T cells (Figure 
3.11C).  The BMDC-induced Tregs suppress CD4+ CD25- proliferation to a greater 
extent than splenic Tregs.  These results demonstrate that BMDCs can induce the 
formation of Tregs in the contact-dependent manner and these Tregs possess 
suppressive function.   
 Next, to determine if the surface expression of markers on BMDCs correlates 
with the induction of Tregs, 3 replicates of BMDCs were cultured with CD4+ cells 
isolated from mouse spleens.  The surface expression of each of the 8 surface markers 
was determined by mean fluorescent intensity (MFI).  Treg percentage was determined 
in the non-adhered cells.  Interestingly, there was a positive correlation between MFI of 
CD39, MHC II, and CD11c expression (Pearson’s correlation of 0.8357. 0.7573 and 
0.6266 respectively, Figure 3.12).  There were weaker positive correlations with Jag-1, 
CD73, and CD11b (Pearson’s correlation of 0.5535. 0.5396 and 0.5310 respectively, 
Figure 3.12).  There were moderate negative correlations between OX40L and CD86 
and Treg induction (Pearson’s correlation of -0.5504 and -0.4373 respectively, Figure 
3.12).  These data may suggest that the surface expression of proteins like CD39 may 
play a role in the development of Tregs.  Interestingly, Jag-1 expression did not seem to 
strongly correlate with Tregs and OX40L expression negatively correlates with Treg 
induction.  This is of note since both markers are reported to be important for Tregs 
induction (Gopisetty et al., 2013).       
 The increased percentage of the Tregs induced by BMDCs could be due to 
proliferation of the existing Treg population or inducing non-Tregs to become Tregs.  To 
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test this, splenocytes were enriched for CD4+ CD25- (non-Tregs, non-effector T cells) 
and CD4+ CD25+ (Tregs) and both were separately labelled with CFSE and cultured 
with media-cultured, unstimulated BMDCs or alone for 5 days.  Non-adhered cells were 
stained for CD4, CD25, and Foxp3 and flow cytometry was performed to determine the 
percentage of Tregs and the percentage of proliferating cells within the Treg population.  
For the CD4+ CD25- cells alone, less than 1% of the CD4+ cells were Tregs, but when 
cultured with media-cultured, unstimulated BMDCs, the percentage of Tregs in the 
population increased to ~11% of the population (Figure 3.13A). Based on the CFSE 
labelling, ~40% of the induced Tregs are proliferating.  Because the majority of Tregs did 
not proliferate and the Tregs that did proliferate, this demonstrates that BMDCs are 
inducing non-Tregs to become Tregs.  The 10-fold increase in Treg percentage cannot 
be accounted for by the proliferation of a minority of Tregs.  In the culture of CD4+ 
CD25+ cells alone, ~22% of the CD4+ T cells are Tregs, but when cultured with BMDCs 
the percentage of Tregs increased to ~50%.  Of these Tregs, ~41% are proliferating 
(Figure 3.13B); however, ~52% of the Tregs alone are proliferating.  Since the 
percentage of proliferating Tregs is similar with or without culture with BMDCS, the 
increase in the percentage of Tregs is likely due to the induction of non-Tregs in the 
culture to become Tregs.  Combined, these data suggest that BMDCs can induce the 
proliferation of Tregs, but it appears that more of the increase in the percentage of Tregs 
is induced from the non-Treg population.           
BMDCs are neuroprotective in the MPTP model 
 After characterizing the effects of GM-CSF on BMDCs, we next wanted to test 
the ability of these cells to be protective in the MPTP model.  Adoptive transfer of Tregs 
into MPTP-intoxicated mice leads to protection of dopaminergic neurons in the 








Figure 3.12 Correlation of BMDC surface markers with Treg induction 
The mean fluorescent intensities (MFI) of CD11c, CD11b, MHC II, CD86, Jag-1, OX40L, 
CD39, and CD73 on CD11c+ BMDCs were graphed with the frequency of Tregs (CD4+ 
CD25+ Foxp3+) after 5 days of co-culture.  The black dots are co-culture of media-
treated, unstimulated BMDCs with CD4+ cells, the red dots are co-culture of GM-CSF-
culture, unstimulated BMDCs with CD4+ cells, the blue dots are co-culture of media-
treated, 30 µg/ml N-α-Syn-stimulated BMDCs with CD4+ cells, the green dots are co-
culture of GM-CSF-cultured, 30 µg/ml N-α-Syn-stimulated BMDCs with CD4+ cells.  
Pearson correlation of the MFI of each marker with Treg frequency is indicated on each 
graph.  The dotted lines represent the 95% confidence interval for the linear regression 





Because Tregs are induced by DCs, we hypothesized that the adoptive transfer of 
tolerogenic DCs will increase the percentage of Tregs and protect dopaminergic neuron 
loss after MPTP.  The media-cultured, unstimulated BMDCs were the most tolerogenic 
given the low co-stimulatory molecule expression, low cytokine production, and highest 
induction of Tregs, so these BMDCs were used in all in vivo experiments.  Initially, the 
adoptive transfer of BMDCs 8 hr after intoxication with 12 or 16 mg/kg was tested for the 
protection of dopaminergic (tyrosine hydroxylase positive, TH+ Nissl+) neurons.  We 
found no significant protection of TH+ Nissl+ neurons in the substantia nigra in mice 
receiving BMDCs compared to MPTP control mice (Figure 3.14).  This result suggested 
that there was insufficient time for BMDCs to migrate from the site of injection into the 
tail vein to the secondary lymph organs to induce Tregs and protect dopaminergic 
neurons.  However, in the 16 mg/kg MPTP mice, there was a trend toward 
neuroprotection with the adoptive transfer of BMDCs.  This may suggest that BMDCs 
induce a greater effect when inflammation is greater.     
In order to give BMDCs more time to induce Tregs and be neuroprotective in 
vivo, BMDCs were adoptively transferred 1 and 2 weeks prior to MPTP.  This transfer 
scheme was used because it was protective in the EAE model (Prado et al., 2012).  
Seven days after MPTP intoxication, at the peak of dopaminergic neuron loss 
(Kohutnicka et al., 1998), mice were sacrificed and immunohistochemistry was 
performed for dopaminergic (TH+ Nissl+) neurons and the dopaminergic (TH+) termini in 
the striatum.  MPTP intoxication decreased the counts of TH+ neuron counts in the 
substantia nigra, but this loss was mitigated by the adoptive transfer of BMDCs (Figure 
3.15).  There was no significant change in the number of non-dopaminergic (TH- Nissl+) 
neurons, suggesting that the decrease in dopaminergic neurons was not due to the 










Figure 3.13 BMDCs cause both induction and proliferation of Tregs 
BMDCs were generated by culturing bone marrow with 20 ng/ml GM-CSF for 8 days.  
BMDCs were then cultured in media alone for 3 days.  At this time, BMDCs were 
cultured with A) CFSE-labelled CD4+ CD25- cells or B) CFSE-labelled CD4+ CD25+ 
cells enriched from the spleens of naïve mice.  As a control, the CD4+ CD25- and CD4+ 
CD25+ cells were cultured alone.  After 5 days, flow cytometric analysis was performed.  
The percentage of Treg (CD25+ Foxp3+ T cells) within the CD4+ T cell population is 
indicated in the top line.  The percentage of proliferating Tregs are indicated in the 











Figure 3.14 Adoptive transfer of BMDCs before MPTP does not protect 
dopaminergic neurons  
BMDCs were differentiated for 8 days in 20 ng/ml GM-CSF prior to 3 days of 
pretreatment in media alone.  Approximately, 1.5x106 BMDCs were transferred i.v. in 
250 µl 8 hours after intoxication with 4 doses of 12 or 16 mg/kg MPTP.  Seven days after 
MPTP intoxication, mice were sacrificed and immunohistochemistry for tyrosine 
hydroxylase (TH) was performed on 30 µM sections containing the substantia nigra.  
Substantia nigra sections were Nissl counter stained.  Stereology was used to count 
dopaminergic neurons (TH+ Nissl+) in the substantia nigra.  The scale bar is 200 µm.   
n=2 for PBS, n=4 for 12 mg/kg MPTP, n=2 12 mg/kg MPTP + BMDCs, n=5 for 16 mg/kg 
MPTP and n=5 for the MPTP + BMDCs.  Significance was determined by one-way 
ANOVA followed by Tukey’s post hoc test. No values were determined to be statistically 




the striatum.  The adoptive transfer of BMDCs did protect the TH termini in the striatum.  
Combined, these data show that the adoptive transfer of BMDCs prior to MPTP 
administration protects dopaminergic neuron cell bodies and termini from degeneration.      
To determine if BMDCs decrease neuroinflammation, reactive microglia in the substantia 
nigra were counted.  BMDCs were adoptively transferred as before, mice were 
intoxicated with 16 mg/kg MPTP, and 2 days after intoxication, at the peak of 
neuroinflammation (Jackson-Lewis et al., 1995; Kohutnicka et al., 1998), mice were 
sacrificed, brains perfused and fixed in 4% paraformaldehyde and 
immunohistochemistry was performed on sections of the substantia nigra for Mac-1.  
Based on the sterologic counting of the reactive microglia per area, MPTP significantly 
increased the number of reactive microglia relative to PBS (Figure 3.16).  However, the 
adoptive transfer of BMDCs significantly decreased the number of reactive microglia 
compared to the MPTP control, but this decrease was not to the level of the PBS control.   
To determine if the adoptive transfer of BMDCs decreases the expression of 
proinflammatory mediators induced by MPTP, mice were sacrificed 2 days after MPTP 
treatment, and RNA was isolated from hemisected midbrains to test expression using a 
PCR array for the inflammatory response and autoimmunity.  With gene expression 
normalized to the PBS control mice, MPTP intoxication increased the expression more 
than 2-fold of CCL3, CXCL10, CCL4, IL1R1, IL1RN, CEBPB, TLR2, and CSF1 (Figure 
3.17).  The expression of these genes, especially CXCL10 (the gene for IP-10), IL1R1 
(IL-1 receptor 1), and CEBPB, a transcription factor upregulated in activated microglia 
(Straccia et al., 2011), are indicative of the MPTP-induced neuroinflammation.   MPTP 
more than 2-fold downregulated C3AR1, MYD88, TLR1, CCL2, CCR3. CCR1, TLR9, 
CCL11, CXCR4, CCL25, CCL12, RIPK2, and TLR3.  The adoptive transfer of BMDCs 









Figure 3.15 BMDCs are neuroprotective in the MPTP mouse model 
BMDCs were differentiated for 8 days in 20 ng/ml GM-CSF prior to 3 days of culture in 
media alone.  Approximately 1.5x106 BMDCs were transferred i.v. in 250 µl 1 and 2 
weeks prior to intoxication with four doses of 16 mg/kg MPTP.  Seven days after MPTP 
intoxication, mice were sacrificed and immunohistochemistry for tyrosine hydroxylase 
(TH) was performed on 30 µM sections containing the substantia nigra and striatum.  
Substantia nigra sections were Nissl counter-stained.  Stereology was used to count 
neurons (both TH+ Nissl+ and TH- Nissl+) in the substantia nigra.  The scale bar is 200 
µm.   n=6 for PBS, n=8 for MPTP and n=7 for MPTP + BMDC group.  Numbers in the 
TH+ Nissl+ bars are the percentage of neurons remaining compared to PBS controls.  
Significance was determined by one-way ANOVA followed by Tukey’s post hoc test. a-
significantly different from PBS, b-significantly different from MPTP.  From the striatum, 
the scale bar is 1 mm.  TH density was determined for 1.4 mm2 area for each striatum 
which was normalized to density for the PBS striatum. n=7 for PBS, n=7 for MPTP and 
n=6 for the MPTP + BMDC group.  Significance was determined by one-way ANOVA 
followed by Tukey’s post hoc test. a-significantly different from PBS, b-significantly 

























Figure 3.16 BMDCs decrease the number of reactive microglia in the MPTP model 
BMDCs were differentiated for 8 days in 20 ng/ml GM-CSF prior to 3 days of 
pretreatment in media alone.  Approximately, 1.5x106 BMDCs were transferred i.v. in 
250 µl one and two weeks prior to intoxication with four doses of 16 mg/kg MPTP.  Two 
days after MPTP intoxication, mice were sacrificed and immunohistochemistry for Mac-
1+ microglia was performed on 30 µM sections containing the substantia nigra.  
Stereology was used to count the number of reactive microglia per area the substantia 
nigra.  The scale bar is 200 µm for the larger image and the inset scale bar is 20 µm.   
n=5 for PBS, MPTP, and MPTP + BMDC group.  Significance was determined by One-
Way ANOVA followed by Tukey’s post hoc test. a-significantly different from PBS, b-





there was an almost 2-fold increase in the expression of IL1RN, the antagonist for IL-1 
receptor (Gabay et al., 2010), which would diminish IL-1 signaling.  Of the genes 
downregulated by MPTP, there was an increase the expression of CCL2, CCL12, 
RIPK2, and TLR3, suggesting BMDCs are compensating for the downregulation of these 
genes by MPTP.  In addition, the adoptive transfer of BMDCs more than 2-fold increased 
proinflammatory genes IL6RA, IL17A, TNF, and IL6 and the anti-inflammatory IL10.  
BMDCs also increased the expression of chemokine-related genes: CXCL2, CXCR2, 
CCL1, CXCL1, CXCR1, CXCL3, CXCL9, CCR4, CCR2, CCL20, CCL24, CXCL5, and 
CCL8.  Combined, these data demonstrate that BMDCs do not suppress the expression 
of all pro-inflammatory genes, but does increase the expression of anti-inflammatory 
genes such as IL10 and IL1RN, which is contributing to the decreased microgliosis in 
Figure 3.16.  In addition to these anti-inflammatory genes, BMDCs are also increase the 
expression of chemokines which may be altering the balance of infiltrating immune cells 
may which also be contributing to the decreased neuroinflammation. 
 To better identify which genes are changed in the midbrain by the adoptive 
transfer of BMDCs prior to MPTP intoxication compared to MPTP control, Ingenuity 
Pathway Analysis was employed.  There were 24 genes which were 2-fold or more 
changed which are associated with the inflammatory response.  While the pattern of 
expression is indicative of inflammation as indicated by the increase in TNF, CCL11, 
CXCL10, CXCL6, CXCR4, CCR1, CCR3, and genes related to pathogen recognition 
such as TLR1, TLR2, TLR3, TLR9, MYD88, and RIPK2.  However, some gene changes 
are indicative of a decreased inflammation.  These include downregulation of IL-1 
receptor 1, which is the receptor of IL-1α and IL-1β that transduces signals intracellularly 










Figure 3.17 Gene expression of MPTP and BMDCs + MPTP midbrain compared to 
PBS control midbrain 
BMDCs were differentiated for 8 days in 20 ng/ml GM-CSF prior to 3 days of 
pretreatment in media alone.  These BMDCs were transferred i.v. 1 and 2 weeks prior to 
intoxication with 4 doses of 16 mg/kg MPTP.  Two days after intoxication, PBS, MPTP 
and BMDC + MPTP mice were sacrificed and the brain was removed and hemisected, 
and the midbrain was incubated in RNAlater for 24hr prior to freezing at -80°C.  RNA 
was isolated from the midbrain, copied to cDNA, and PCR arrays of pro-inflammatory 
genes were run.  (A) Gene expression was determined relative to the PBS control 
midbrains.  n=3 for PBS and n=4 for MPTP and MPTP+BMDC.  Fold change was 
determined using SA Bioscience software. (B) Ingenuity Pathway Analysis was used to 
determine the expression of genes associated with the inflammatory response in 
BMDCs + MPTP midbrain compared to MPTP control mice.  Red indicates an 
upregulation of genes and green represents a downregulation of gene expression with 
the darker color indicating the larger change in gene expression.  The orange lines 
indicate an effect in line with increased inflammation.  The yellow lines are gene 





(Pope et al., 1994), and chemokines CCL3L3 and CCL4, which promote inflammation 
(Yang and Wang, 2015) and leukocyte recruitment into the brain (Ubogu et al., 2006).  
CCL24 is a chemokine released from M2 macrophages which can recruit T cells, 
especially Tregs (Watanabe et al., 2002; Zamarron and Chen, 2011).  In glioblastoma 
multiforme, CCL2 is important for Treg recruitment into the brain and may perform a 
similar function after MPTP intoxication (Jordan et al., 2008; Chang et al., 2016).  IL1RN 
prevents the recruitment of IL-1 receptor associated protein to IL-1 receptor which is 
required for transduction of signals within the cell (Dinarello, 2009), therefore its 
increased expression, when combined with the downregulation of IL1R1 would diminish 
IL-1α and IL-1β signaling.  Combined, these data show that the adoptive transfer of 
BMDCs diminish, the MPTP-induced inflammation, in line with the data from Figure 6.     
BMDCs induce Tregs in vivo 
 To determine if the neuroprotective effects of BMDCs are due to their ability to 
increase Treg percentage and/or function in vivo, BMDCs were adoptively transferred 
into mice as described and sacrifice was performed 1 week after the second transfer of 
BMDCs.  As a control, 50 μg/kg GM-CSF was i.p. administered to a group of mice every 
day for 5 days prior sacrifice.  The percentages of CD4+ T cells and Tregs were 
determined by flow cytometry.  To test the percentages of CD4+ T cells and Tregs in the 
blood were determined in blood from cheek bleeds performed 1 day before each transfer 
or sacrifice.  There was no change in the percentage of CD4+ T cells in the blood over 
time nor was there a change in the percentage of CD4+ cells in the spleen or in the 
lymph nodes at time of sacrifice in unmanipulated controls, GM-CSF-treated controls or 
BMDC-transferred mice (Figure 3.18A).  There was also no increase in Tregs over time 
in the blood, nor in the lymph nodes at time of sacrifice (Figure 3.18B).  In the spleen, 
GM-CSF did trend to increase the percentage of Tregs, however, the increase was not 
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significant and was not an increase to the degree previously reported (Kosloski et al., 
2013).  The adoptive transfer of BMDCs decreased the percentage of Tregs in the 
spleen significantly compared to the GM-CSF-treated control, but the decrease was not 
significantly different from the unmanipulated control.  Since there was a significantly 
decreased percentage of Tregs in the spleen, next the suppressive function of Tregs 
was determined.  There was no significant change in the function of Tregs from control 
or GM-CSF-treated mice (Figure 3.18C).  However, the adoptive transfer of BMDCs 
significantly decreased the function of Tregs relative to both the control and GM-CSF- 
treated Tregs.  These data demonstrate that, without any inflammation, the adoptive 
transfer of BMDCs decreased the percentage and function of Tregs.    
In models where the adoptive transfer of BMDCs ameliorate disease and 
increase Tregs, there was an ongoing to autoimmune response (Li et al., 2008; Mari et 
al., 2016).  To test if BMDCs increase the percentage and/or function after MPTP 
intoxication, BMDCs were adoptively transferred 1 week apart and mice were MPTP 
intoxicated one week after the second transfer.  Two days after MPTP intoxication, at the 
peak of neuroinflammation, mice were sacrificed and CD4+ T cell and Treg percentages 
and Treg function from the spleen was determined.  There was no significant change in 
the percentage of CD4+ cells in any treatment group, but mice receiving BMDCs prior to 
MPTP displayed significantly more splenic Tregs than either PBS or MPTP controls 
(Figure 3.19A).  By multiplying the percentage of CD4+ T cells and Tregs by the count of 
total splenocytes, we determined the number of CD4+ T cells and Tregs.  MPTP 
intoxication decreased the number of CD4+ cells in the spleen compared to the PBS 
control.  This was increased by the adoptive transfer of BMDCs.  The number of Tregs in 
the spleen was decreased in the MPTP control mice, but was increased by the adoptive 











Figure 3.18 Treg frequency and function after the transfer of BMDCs 
BMDCs were differentiated for 8 days in 20 ng/ml GM-CSF followed by culture in media 
alone for 3 days.  These BMDCs were i.v. transferred into the tail vein of C57BL/6J mice 
two weeks and one week prior to sacrifice.  One day prior to each transfer and sacrifice, 
mice were cheek bleed.  As a positive control, mice were i.p. administered with 50 µg/kg 
GM-CSF once per day for 5 days.  (A) The frequency of CD4+ T cells in the single cell 
population and (B) Tregs (CD4+ CD25+ Foxp3+) in the CD4+ T cell populations were 
determined by flow cytometry.   Significance was determined by one-way ANOVA 
followed by Tukey’s post hoc test a-significantly different from control and b-significantly 
different from GM-CSF mice.  Control n=11, GM-CSF n=10, and i.v. BMDC n=12.  
Pooled spleens from all three groups had Tregs (CD4+ CD25+) enriched and dilutions 
were cultured with CFSE-labelled CD4+ CD25- cells that were stimulated with 
CD3/CD28 beads and proliferation suppression assay was used to test Treg function.  
Linear regression was used to compare the slope and elevation.  a-significantly different 
slope rom control Tregs, b -significantly different elevation compared to GM-CSF Tregs.  










Figure 3.19 Treg frequency and function after adoptive transfer of BMDCs prior to 
MPTP   
BMDCs were differentiated for 8 days in 20 ng/ml GM-CSF prior to 3 days of 
pretreatment in media alone.  These BMDCs were transferred i.v. 1 and 2 weeks prior to 
intoxication with 4 doses of 16 mg/kg MPTP.  Two days after MPTP intoxication, mice 
were sacrificed and spleens were removed.  (A) Flow cytometry was used to determine 
the frequency of CD4+ cells in the total splenocyte population and the frequency of 
Tregs (CD25+ Foxp3+) in the CD4+ population.  Based on this frequency and the 
splenocyte counts, the counts of CD4+ and Tregs were determined.  n=5 for all 3 
groups.  Significance was determined by One-way ANOVA followed by Tukey’s post hoc 
test.  a-significantly different from PBS and b-significantly different from MPTP.  (B) 
CD4+ CD25+ cells were enriched from the pooled splenocytes for each treatment group 
and dilutions of Tregs were cultured with CFSE-labelled CD4+ CD25- cells and 
CD3/CD28 transactivator beads for 3 days.  Linear regression was used to compare the 
slope and elevation.  a-significantly different elevation from PBS Tregs, b-significantly 
different elevation compared to MPTP Tregs.  N=3 for all 3 treatment groups except for 
0.125:1 dilution which only had 1 replicate for each treatment group and 1:1 MPTP 




Tregs.  These data highlight that BMDCs increase the percentage and the number of 
Tregs in the spleen following MPTP intoxication.  To test if BMDCs increase the function  
of Tregs, we isolated CD4+ CD25+ Tregs from spleens and assessed isolates for the 
capacity to suppress CD3/CD28 stimulated responder T cells.  Interestingly, it appears 
that MPTP treatment increases the suppressive function of Tregs relative to the Tregs 
from PBS control mice (Figure 3.19B).  Transfer of BMDCs diminishes the MPTP-
induced increase in Treg suppressive function.  More work will need to be done to verify 
the result of this experiment, but the data in Figure 3.19 show that BMDCs increase the 
percentage of Tregs in the spleen after MPTP, demonstrating the necessity of 
inflammation to increase the percentage of Tregs.  However, these BMDC-induced 
Tregs possess the same suppressive function compared to the PBS control.     
BMDC-induced Treg neuroprotection 
To determine if the Tregs that are generated from the co-culture of BMDCs and 
CD4+ cells are neuroprotective, BMDCs differentiated for 8 days in 20 ng/ml GM-CSF 
followed by 3 days in media alone were co-cultured with CD4+ cells for 5 days.  Either 
the total non-adhered population or the CD4+ CD25+ cells enriched from the non-
adhered population using the Miltenyi CD4+ CD25+ isolation kit as described above 
were transferred into MPTP-intoxicated mice.  The resulting ~400,000 CD4+ CD25+ 
cells or ~4,000,000 non-adherent cells were adoptively transferred into the tail vein of 
mice ~10 hours after intoxication with 16 mg/kg MPTP.  Based on the purity of the CD4+ 
CD25+ cells, the ~400,000 cells correspond to ~200,000 Tregs (CD4+ CD25+ Foxp3+) 
and the ~4,000,000 non-adhered cells correspond to ~400,000 Tregs.  The adoptive 
transfer of BMDCs increases the number of Tregs in the spleen by ~200,000.  The 









Figure 3.20 BMDC-induced Tregs are not neuroprotective 
BMDCs were differentiated for 8 days in 20 ng/ml GM-CSF prior to 3 days of 
pretreatment in media alone.  BMDCs were co-cultured with CD4+ cells from 
splenocytes.  After 5 days, the non-adhered cells were removed and either the whole 
population or enriched the CD4+ CD25+ cells were transferred i.v. in 250 µl 10 hours 
after intoxication with 16 mg/kg MPTP.  The flow cytometry was performed to determine 
purity of Tregs.  For the CD4+ CD25+ enriched cells, 60.6% of the CD4+ were CD25+ 
Foxp3+ cells which corresponds to ~200,000 Tregs transferred.  For the non-adhered 
population, 12% of the CD4+ population were CD25+ Foxp3+ cells which corresponds to 
~400,000 Tregs transferred.  Seven days after MPTP intoxication, mice were sacrificed 
and immunohistochemistry for tyrosine hydroxylase (TH) was performed on 30 µM 
sections containing the substantia nigra and striatum.  Substantia nigra sections were 
Nissl counter stained.  Stereology was used to count neurons (both TH+ Nissl+ and TH- 
Nissl+) in the substantia nigra.  The scale bar is 200 µm.   n=12 for PBS, n=9 for MPTP, 
n=7 for the MPTP + BMDC Treg groups, and n=5 for the MPTP+BMDC non-adhered 
cells.  Numbers in the TH+ Nissl+ bars are the percentage of neurons remaining 
compared to PBS controls.  Significance was determined by one-way ANOVA followed 
by Tukey’s post hoc test. a-significantly different from PBS, b-significantly different from 
MPTP.  From the striatum, the scale bar is 1 mm.  TH density was determined for 1.4 
mm2 area for each striatum which was normalized to density for the PBS striatum. n=7 
for PBS, n=7 for MPTP and n=6 for the MPTP + BMDC group.  Significance was 
determined by one-way ANOVA followed by Tukey’s post hoc test. a-significantly 




neurons in the substantia nigra or TH+ termini in the striatum (Figure 3.20).  These data 
suggest that this number of Tregs from BMDC co-culture is insufficient to protect 
dopaminergic neurons.  Previously, the lowest number of transferred Tregs which lead to 
neuroprotection was 500,000 (Reynolds et al., 2007), so more Tregs may need to be 
transferred to promote neuroprotection.  It is also possible that the Tregs from BMDC co-
culture may be less neuroprotective, even if they possess increased proliferation 
suppression function (Figure 3.11).          
BMDC supernatant does not protect MES23.5 cells, but does decrease BV2 release of 
nitrite, TNF and IL-6 
 We next wanted to determine if BMDCs are having direct effects on microglia 
and dopaminergic neurons apart from inducing Tregs.  In our experiments, we have not 
determined if the BMDCs can migrate to the brain, however, DCs can migrate to the 
brain after EAE (Clarkson et al., 2014; Clarkson et al., 2015) and stroke (Felger et al., 
2010; Manley et al., 2013) in order to promote the T cell response.  It is unclear to what 
degree the neuroprotective effects are due to the co-stimulatory surface expression or 
the released products of BMDCs.  To test the role of released products from BMDCs in 
decreased neuroinflammation and neurodegeneration, the BMDC supernatant was 
tested for the ability to protect the MES23.5 dopaminergic neuron line from toxic insult.  
MES23.5 cells were cultured for 24 hours with clarified conditioned media from the 
culture of media-cultured, unstimulated BMDCs after 11 days in culture.  As controls, 
MES23.5 cells were also cultured in MES23.5 media or R10 (BMDC) media.  After this 
pre-treatment, MES23.5 cells were treated with increasing concentrations of MPP+ (0-
1,000μM) for 24 hours.  At this time, the CellTiter-Glo cell assay was used to determine 
the production of ATP in MES23.5 cells, which is a surrogate marker for cell viability.  




Figure 3.21 BMDC supernatant does not protect MES23.5 cells viability after culture 




Figure 3.21 BMDC supernatant does not protect MES23.5 cells viability after 
culture MPP+ and BV2 supernatant  
MES23.5 neurons were cultured for 24 hours in and equal volume of MES23.5 media, 
supernatant from BMDCs cultured for 8 days in 20 ng/ml GM-CSF and 3 days in R10 
media, or R10 media.  (A) MES23.5 neurons were treated for 24 hr in an equal volume 
of MES23.5 media containing 0 - 1,000 µM MPP+.  Cell viability was determined by 
celltiter-glo assay.  Significance was determined by one-way ANOVA followed by 
Tukey’s post-hoc test.  The following markers correspond to significance from the 
following treatment groups a-0, b-0.1, c-1, d-10 e-100 µM or 1-MES23.5 media.  n=4.  
(B) MES23.5 neurons were treated with BV2 media or supernatants from BV2 cells 
cultured with and without 100 ng/ml LPS in BV2 media, BMDC supernatant, or R10 
media.  After 24 hr of treatment, cell viability was determined by the CellTiter-Glo assay. 
Significance was determined by one-way ANOVA followed by Tukey’s post-hoc test.  
The following markers correspond to significance from the following treatment groups a-
BV2 media, b-BV2 supernatant, c-BV2 + BMDC supernatant, d-BV2 + R10 media, e-
BV2 media + LPS, f-BV2 + BMDC supernatant + LPS.  n=10 for BV2 media and BV2 
supernatant unstimulated, n=7 BV2 + BMDC supernatant, BV2 + R10 media, BV2 




the BMDC-cultured MES23.5 cells, and 1,000 μM for MES23.5 media-cultured MES23.5 
cells (Figure 3.21A).  BMDC supernatant was unable to protect MES23.5 cells relative to 
the two media controls.  In fact, there was a trend toward decreased cell viability, though 
this was not significant.  It is interesting that the MES23.5 cells cultured with R10 media 
or BMDC supernatant decreased cell viability at lower concentration of MPP+ than 
MES23.5 cells.  This suggests that something in the R10 media, independent of 
products released from BMDCs, facilities MPP+ toxicity.  Possibly, this is due to the 
increased concentration of FBS or decreased concentration of N2 supplement that does 
not directly decrease cell viability, but fails to maintain MES23.5 cell viability with 
increased MPP+ toxicity.      
 Because only a small amount of the neurodegeneration is caused by MPP+ in 
the MPTP model (Benner et al., 2008; Brochard et al., 2009), BMDC supernatant was 
tested for the ability to protect MES23.5 cells from the supernatant from BV2 microglia 
cell line.  BV2 cells were cultured for 1 day with BV2 media, BV2 media and BMDC 
supernatant, and BV2 media and R10 media with and without 100 ng/ml LPS.  The 
conditioned media from these different treatment groups or BV2 media alone was then 
added to MES23.5 cells cultured with MES23.5 media, BMDC supernatant, or R10 
media as above and cell viability was determined with the celltiter-glo assay.  MES23.5 
cells cultured with different BV2 supernatants tended to exhibit decreased cell viability 
(Figure 3.21B).  BV2 cells stimulated with LPS were not significantly more toxic to 
MES23.5 cells than the unstimulated BV2 cells.  Regardless if BMDC supernatant was 
cultured with BV2 cells or MES23.5 cells, there was not significant protection of 
MES23.5 cells.  Interestingly, the group that trended to display decreased cell viability 
was the supernatant from BV2 cells cultured with BMDC supernatant and LPS 
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stimulation.  As with MPP+-treated MES23.5 cells, BMDC supernatant did not increase 
the cell viability of MES23.5 cells.   
  Because BMDC supernatant was unable to protect MES23.5 cells, next the 
ability of BMDC supernatant to decrease the release of proinflammatory mediators was 
tested.  First, we used the Griess assay to test the concentration of nitrite in the 
supernatant of LPS-stimulated or unstimulated BV2 cells cultured with BV2 media, 
BMDC supernatant, or R10 media.  There was limited nitrite in the any unstimulated BV2 
supernatant (Figure 3.22).  However, there was a significant increase in nitrite 
concentration in all LPS-stimulated BV2 cell supernatants.  This increase in nitrite 
concentration was significantly mitigated by culture of BV2 cells with BMDC supernatant 
compared to either of the media-cultured BV2 cells.  Cytokine bead array (CBA) was 
used to test the release of IL-2, IL-4, IL-6, IL-10, IL-17, TNF, and IFNγ from the same 
treatment groups of BV2 cells as above.  Only IL-6 and TNF were significantly elevated 
in LPS-stimulated BV2 cells (Figure 3.22).  As with nitrite, BMDC supernatant decreased 
the release of both IL-6 and TNF compared to either media.  These data suggest that 
BMDCs release some factor that decreases the reaction of BV2 cells to activation with 
LPS.  However, the reduced release of IL-6, TNF, and nitrite does not protect MES23.5 
cells from MPP+ or BV2 supernatant (Figure 3.21).      
GM-CSF does not increase the percentage of CD11c+ dendritic cells in the spleen 
 To determine if administration of GM-CSF increases the percentage of splenic 
myeloid DCs (CD11c+ CD11b+ cells), 50 μg/kg GM-CSF was i.p. administered each day 
for 5 days prior to sacrifice.  The spleen was removed and flow cytometry was used to 
determine the percentage and the mean fluorescent intensity of DC markers.  There was 
no significant change in the percentage of CD11c+ CD11b+ myeloid DCs in the spleen 




Figure 3.22 Release of cytokines and nitrite from BV2 cells treated with BMDC 




Figure 3.22 Release of cytokines and nitrite from BV2 cells treated with BMDC 
supernatant and LPS 
BV2 cells were cultured in BV2 media, BMDC supernatant from BMDCs cultured for 8 
days in 20 ng/ml GM-CSF and 3 days in R10 media, or R10 media with or without 100 
ng/ml LPS.  After 24 hr of culture the supernatant was removed and nitrite was 
determined by the Griess assay and the concentration of IL-6 and TNF was determined 
by CBA.  Significance was determined by one-way ANOVA followed by Tukey’s post hoc 
test.  The following markers correspond to significance from the following treatment 
groups a-BV2 media, b-BMDC supernatant, c-R10 media, d-BV2 media + LPS, e-BMDC 


















Figure 3.23 Frequency of DCs in the spleen after GM-CSF administration 
Mice were either not injected (control) or were given i.p. 50 µg/kg GM-CSF daily for 5 
days.  Spleens were removed and flow cytometry was performed to determine the 
frequency of CD11c+ CD11b+ dendritic cells in the single cells of the spleen (A).  We 
also determined the frequency of CD11c+ CD11b+ cells expressing surface MHC II+, 
CD86+, Jag-1+, OX40L+, CD39+, and CD73+.  Significance was determined by 
unpaired t test and no surface markers were determined to change significantly.  (B) We 
also determined the MFI of CD11c, CD11b, MHC II, Jag-1, CD39, and CD73 on the 
surface of CD11c+ CD11b+ cells.  Significance was determined for by unpaired t test 
significance was determined if the p <0.05.  a-significantly different from control.  n=5 for 




expressing MHC II, CD86, OX40L, Jag-1, CD39, and CD73.  There was also no 
significant change in the MFI of CD11c, CD11b, MHC II, Jag-1, and CD39 on CD11c+ 
CD11b+ cells ((Figure 3.23B).  GM-CSF did significantly decrease the surface 
expression of CD73 on CD11c+ CD11b+ cells.  Combined, these data demonstrate that 
GM-CSF does not increase the percentage and expression of these markers.  This is 
notable, given that culturing BMDCs with GM-CSF increasing the surface expression of 
Jag-1 and trends to increase surface CD73 (Figure 3.6).  While it is possible that GM-
CSF may be decreasing the expression of other markers not tested, these data suggest 
that GM-CSF alone is insufficient to alter splenic DCs to increase the percentage of 
Tregs as reported previously (Kosloski et al., 2013).  It possible that if these mice were 
intoxicated with MPTP it would increase the percentage of CD11c+ CD11b+ cells 
expressing Jag-1 or other surface markers which would promote Tregs in the spleen.        
  
DISCUSSION 
 Our first hypothesis was that GM-CSF induces and maintains a tolerogenic state 
in DC lines.  DC2.4 and DC3.2 both release more nitrite when stimulated with LPS or N-
α-Syn which is mitigated by pre-culture with GM-CSF (Figure 3.2).  However, the DC2.4 
cell line expresses high surface levels of the co-stimulatory molecule CD86 without 
stimulation which is not decreased by GM-CSF culture (Figure 3.3).  This suggests that 
the cells lines are not in a tolerogenic state and GM-CSF cannot induce a tolerogenic 
state given the conditions tested.  It is possible that a tolerogenic state could be induced 
with another inducer such as vitamin D, IL-10, or TGFβ, but GM-CSF unto itself cannot 
induce this state.  Since the DC2.4 and DC3.2 cell lines are derived from BMDCs (Shen 
et al., 1997), but are more mature than the other BMDCs used in these experiments, it is 
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unclear if these results are due to the immortalization of these cells, or because of their 
more mature state.   
 BMDCs display a trend to release lower concentrations of nitrite after continuing 
GM-CSF culture prior to LPS or N-α-Syn stimulation (Figures 3.5 and 3.8), similar to 
pretreating DC2.4 and DC3.2 cells with GM-CSF.  However, BMDCs exhibit lower 
surface expression of CD86 (Figure 3.4 and 3.6) compared to DC2.4 cells making them 
a better model of tolerogenic DCs than DC2.4 cell lines.  Interestingly, adding IL-4 during 
maturation increases the surface expression of CD86 and OX40L and decreases Jag-1 
surface expression (Figure 3.4).  As a result, IL-4 was omitted from all future 
experiments because it promotes differentiation of DCs to a more mature state 
compared to the BMDCs matured without IL-4, in line with prior research (Sallusto and 
Lanzavecchia, 1994; Lutz et al., 2000). 
     In the absence of LPS or N-α-Syn stimulation, BMDCs are in a tolerogenic 
state as determined by low costimulatory molecules (Figure 3.6), low expression and 
release of proinflammatory cytokines (Figure 3.7, 3.9), increased expression of IDO, a 
trend to increased kynurenine (Figure 3.10), and induction of Tregs in culture (Figure 
3.11).  However, when cultured in media alone prior to stimulation with N-α-Syn, surface 
expression of co-stimulatory molecules is increased (Figure 3.6), expression and release 
of proinflammatory cytokines is increased (Figure 3.7, 3.9), and IDO expression and 
kynurenine is decreased (Figure 3.10), indicating these BMDCs are in a semi-mature 
state.  GM-CSF culture prior to N-α-Syn stimulation does mitigate the surface expression 
of CD86 and MHC II (Figure 3.6) and increases Jag-1 surface expression.  There was a 
mitigation of the expression and release of some proinflammatory cytokines and 
chemokines, but most were not affected or were increased by GM-CSF culture (Figure 
3.7 and 3.9).  IDO expression and kynurenine was not effected by GM-CSF culture prior 
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to N-α-Syn stimulation (Figure 3.10).  Additionally, GM-CSF decreases the expression of 
CD40 (Figure 3.9), after N-α-Syn stimulation, in line with the decrease in the CD86 
surface expression (Figure 3.6).  However, GM-CSF does not decrease the expression 
of maturation markers such as CEBPB and CCR7 or TLR signaling genes such as 
CD14, MYD88, and NFKB1 (Figure 3.9).  Combined, these data suggest GM-CSF-
differentiation of bone marrow to BMDCs induces a tolerogenic state which is maintained 
with the culture in media and GM-CSF.  However, upon stimulation, N-α-Syn stimulation 
induces a semi-mature state.  GM-CSF cannot maintain the tolerogenic state, given that 
BMDCs increase the expression and release of proinflammatory cytokines, increased 
expression of maturation markers, and decreased IDO expression and kynurenine 
concentration.  However, GM-CSF is changing how the BMDCs respond to stimulation 
with altered expression and release of cytokines, including increased IL-10 expression 
and release as well as increased Jag-1 surface expression (Figure 3.7, 3.9).   
 Another characteristic of tolerogenic DCs is their ability to induce Tregs 
(Maldonado and von Andrian, 2010).  Culture of media-alone BMDCs with or without N-
α-Syn stimulation with CD4+ cells, leads to an increase in the percentage of Tregs 
(Figure 3.11).  However, this was significantly mitigated by continuing the culture with 
GM-CSF, even without N-α-Syn stimulation (Figure 3.11).  The resulting CD4+ CD25+ 
cells do possess Treg suppressive function indicating these are bonafide Tregs.  The 
Tregs were being induced by a mechanism other than proliferation of CD4+ cells, since 
CD3/CD28 beads do not increase the percentage of Tregs to the same degree as 
BMDCs.  This was borne out by CFSE-labelled CD4+ CD25- and CD4+ CD25+ cells 
cultured with BMDCs. There is minimal proliferation of Tregs in both populations (Figure 
3.13).  Since a minority proportion of the Tregs proliferated, the majority of Tregs from 
the co-culture were induced from the non-Treg CD4+ population.  In addition, the 
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induction of Tregs is DCs.  This demonstrates that some molecules on the surface of 
BMDCs promote Treg induction.  Based on correlation analysis, several surface markers 
that bind to receptors on CD4+ cells do positively correlate with Treg induction, including 
MHC II and Jag-1 (Figure 3.12).  It is unclear to what degree these, or other co-
stimulatory molecules, are responsible for inducing Tregs.  While the increase in Jag-1 
expression is line with other research demonstrating a role for Jag-1 inducing Tregs 
(Gopisetty et al., 2013), the negative correlation with OX40L does not correspond with 
prior work showing OX40L is involved in Treg induction (Haddad et al., 2016).  This may 
indicate that surface expression of OX40L is sufficient to promote Tregs, or other co-
stimulatory molecules, which have not been identified, may be playing a role.  It is 
interesting that the increase in IDO expression, kynurenine release and surface 
expression of CD39 and CD73 appear to increase in the BMDCs which are strong 
inducers of Tregs, yet do so through soluble mediators.  Since Tregs are still induced in 
the transwells, there may be a role for these mediators, in addition to the co-stimulatory 
molecules. 
 The ability of Tregs generated from BMDC-CD4+ co-culture to be 
neuroprotective in the MPTP model was also tested.  As of now, the mechanism by 
which Tregs are neuroprotective has not been determined.  In Figure 3.11, the ability of 
Tregs to suppress proliferation of CFSE-labelled CD4+ CD25- responder T cells is 
shown.  To see if this increase in Treg function correlates with increased 
neuroprotection, both non-adhered cells and enriched CD4+ CD25+ were transferred 
into MPTP-intoxicated mice.  In both cases, there was no significant neuroprotection 
(Figure 3.20).  The most probable explanation is that insufficient cell numbers were 
transferred to detect protection, given that previously the fewest number of Tregs 
transferred which demonstrated an effect was ~500,000 Tregs (Reynolds et al., 2007).  
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The transfer of a greater number of Tregs into each mouse could test this.  Another 
possibility is that the BMDC-induced Tregs posses less neuroprotective function and 
even more Tregs will need to be transferred to detect a significant effect.        
Our second aim was to determine if the transfer of tolerogenic DCs leads to the 
same effects as GM-CSF in the MPTP model.  Adoptive transfer of BMDCs after MPTP 
did not lead to protection of dopaminergic (TH+ Nissl+) neurons in the substantia nigra 
(Figure 3.14).  This is thought to be due to the BMDCs having insufficient time to migrate 
to the secondary lymph organs and induce Tregs that release mediators and/or migrate 
to the substantia nigra to protect neurons.  To test this, we adoptively transferred 
BMDCs prior to MPTP intoxication.  In this case, BMDCs protect both the (TH+ Nissl+) 
neurons in the substantia nigra and the TH+ termini in the striatum (Figure 3.15).  Given 
this BMDC transfer paradigm, the number of reactive microglia is decreased in the 
substantia nigra (Figure 3.16), indicative of decreased neuroinflammation.  Interestingly, 
of the genes 2-fold increased in MPTP control mice relative to PBS control mice, none 
were noticeably decreased by the adoptive transfer of BMDCs, suggesting BMDCs were 
not decreasing the expression of genes upregulated by MPTP (Figure 3.17A). There 
was an almost 2-fold increase in the expression of Il1RN, which may be part of the 
mechanism of the decreasing neuroinflammation by suppressing IL-1 receptor signaling.  
However, there was an increase in the expression of several genes for which expression 
was decreased in the MPTP control mice relative to PBS control, including CCL2, 
CCL12, RIPK2, and TLR3.  Of the genes altered between the MPTP midbrain and the 
BMDC + MPTP midbrain, 24 genes were associated with inflammatory response (Figure 
3.17B).  The adoptive transfer of BMDCs increases the expression of several 
chemokine-related genes including: CCR1, CCR3, CXCL10, CXCL6, CXCR4, CCL11, 
CCL24, CCL25, and CCL2, the gene upregulated in the pathway.  It is possible that at 
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least part of the protective mechanism of BMDCs is altering the chemokine balance 
changing the immune cell infiltration.  This is an interesting possibility since GM-CSF 
treatment also increases the expression of several chemokines, like CCL2 increased 
here (Kosloski et al., 2013).  CCL2 is an interesting chemokine since it is a ligand for 
CCR4 (Yoshie and Matsushima, 2015), and CCR4 is the major chemokine receptor on 
Tregs (Yi and Zhao, 2007; Chakraborty et al., 2012).  It is possible that the increase in 
CCL2 is increasing the migration of Tregs into the midbrain, which facilitates 
neuroprotection.  More work will be needed to test this possibility.  These data 
demonstrate that, like GM-CSF, BMDC transfer decreases neuroinflammation and 
neurodegeneration following MPTP.     
 GM-CSF increases the percentage of Tregs in mouse spleen without MPTP 
(Kosloski et al., 2013).  BMDCs were not able to increase Treg percentage or Treg 
function in vivo in the absence of MPTP (Figure 3.18).  However, GM-CSF, used here as 
a positive control, was unable to increase Tregs to the same degree as published 
previously (Kosloski et al., 2013).  Treg function was also not increased by either GM-
CSF, which was not previously reported, or by BMDC transfer.  This result suggests that 
GM-CSF may work on another cell type in vivo without inflammation to induce Tregs.  It 
is possible that Tregs express the receptor for GM-CSF (Kared et al., 2008) and 
therefore GM-CSF may directly promote the proliferation of Tregs.  Another possibility is 
that GM-CSF induces the proliferation of other immune cells such as myeloid-derived 
suppressor cells (MDSCs) which protect against and promote recovery after 
neurodegeneration (Saiwai et al., 2013) and induce Tregs (Huang et al., 2006; Serafini 
et al., 2008).  When BMDCs were transferred prior to MPTP intoxication, this increased 
the percentage of Tregs in the spleen (Figure 3.19).  This also increased the number of 
Tregs in the spleen.  This is in line with prior data, which showed GM-CSF promotes 
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Tregs in vivo during ongoing inflammation in various models of autoimmunity (Sheng et 
al., 2008; Cheatem et al., 2009; Ganesh et al., 2009).  Interestingly, MPTP intoxication, 
but not the adoptive transfer of BMDCs, increases Treg function.  This experiment was 
performed once and there was overall less inhibition compared to prior functional assays 
(Figures 3.11, 3.18).  More work would need to be done to verify these results.  While 
most research has not focused on the suppressive function of Tregs, the results here 
suggest that BMDCs and GM-CSF increase Treg number, but not function.  This is 
contrary to administering sargramostim in Parkinson’s disease does increase Treg 
function as well as number (Gendelman et al., 2017).        
 Our next experiment was to determine if BMDCs may be neuroprotective by 
mechanisms other than inducing Tregs.  It is unclear if the mechanism of 
neuroprotection is mediated though cell-to-cell contact or through the release of anti-
inflammatory factors by BMDCs.  To test that latter possibility, we cultured the MES23.5 
dopaminergic neuron cell line with supernatant from BMDCs, prior to treating cells with 
MPP+ or supernatant from BV2 microglia (Figure 3.21).  In both cases, BMDC 
supernatant did not protect the cultured MES23.5 cells from either the neurotoxin MPP+ 
or the neuroinflammatory mediators from BV2 microglia cell lines.  Interestingly, culturing 
BV2 microglia in BMDC supernatant did decrease the release of nitrite, IL-6, and TNF 
(Figure 3.22).  This would indicate that the factors released from BV2 cells that are toxic 
to MES23.5 cells are not these proinflammatory mediators.  However, BMDC 
supernatant decreased the release of these mediators that reduce neuroinflammation in 
vivo, thus not leading to neuroprotection.  These results suggest that BMDC supernatant 
may not directly protect dopaminergic neurons in vivo, but may decrease microglia 
activation, perhaps due to the release of kynurenine (Figure 3.10) or another factor 
which was not measured.     
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 Lastly, I tested if GM-CSF increases the number of myeloid DCs or the 
tolerogenic state of DCs in the spleen.  This would be consistent with myeloid DCs 
inducing Tregs and provide further evidence that DCs are the cells inducing Tregs.  
Here, we found no increase in the percentage of CD11c+ CD11b+ cells in the spleen, 
nor changes in the expression of surface molecules such as Jag-1, OX40L, MHC II, 
CD86, CD39, and CD73 (Figure 3.23).  Based on this, GM-CSF alone does not appear 
to increase the percentage or tolerogenic state of splenic myeloid DCs.  It is possible 
that other surface molecules are increased on splenic DCs that induce Tregs but were 
not tested here, such as PD-L1.  It is also possible that other DC subsets are affected by 
GM-CSF and induce Tregs.  GM-CSF may act on other immune cell types, like MDSCs, 
to induce Tregs, or GM-CSF may act on Tregs directly.   All are possibilities to be tested 
further.    
 In conclusion, GM-CSF promotes a tolerogenic state as part of the differentiation 
of bone marrow progenitors to immature DCs.  However, GM-CSF cannot maintain the 
tolerogenic state after stimulation with N-α-Syn, but GM-CSF does alter how BMDCs 
respond to the stimulus.  GM-CSF culture with BMDCs diminishes the induction of Tregs 
in culture.  Tolerogenic BMDCs are neuroprotective, decrease neuroinflammation and 
increase Tregs in the spleen after MPTP intoxication.  The neuroprotection may be 
related to inducing Tregs as wells as decreasing microglia activation, but BMDC 
supernatant is not directly neuroprotective, at least in cultured MES23.5 cells.  GM-CSF 
is not increasing percentage of myeloid DCs or the expression of surface markers in 
vivo.  This suggests that GM-CSF may act on DCs in vivo to promote Tregs during the 
MPTP-induced inflammation.  However, GM-CSF may be promoting Tregs via another 
mechanism other than through DCs.  In addition, neuroprotection may be mediated by a 
mechanism other than Treg induction.      
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CHAPTER FOUR  
CYTOKINE ENVIRONMENT IN THE VENTRAL MIDBRAIN AND 




 CD4+ T cells are required for neurodegeneration following MPTP intoxication.  
The adoptive transfer of Th1 and Th17 T CD4+ cells exacerbates MPTP intoxication, but 
it is unknown if MPTP intoxication differentiates naive CD4+ cells to these subtypes.  To 
test this, the expression and release of proinflammatory cytokines in the cervical lymph 
node and ventral midbrain was determined at peak neuroinflammation two days post 
MPTP intoxication.  Flow cytometry was also used to test the percentage of B cells, T 
cells and activated APCs in different lymph node populations after MPTP intoxication.  
Based on these data, MPTP increases the MFI of MHC II on APCs in the cervical lymph 
nodes and increases B cells in the brachial and axillary lymph nodes.  No changes in the 
CD3+ T cell percentage were detected.  In the cervical lymph nodes, expression of IFNγ 
and IL-4 was increased with increased expression of IP-10 in the ventral midbrain.  
Gene expression of many proinflammatory and anti-inflammatory genes were increased 
in the cervical lymph node and CXCL10 in the ventral midbrain.  These data found few 
changes in the expression of proinflammatory cytokines, which may be due to the timing 
or location of samples tissues.  The changes seen may suggest an environment that 





 No rodent PD models exist that fully recapitulates all the features of PD.  The 
MPTP model which is commonly used to mimic neuroinflammation and dopaminergic 
neurodegeneration in PD.  MPTP readily crosses the blood-brain barrier (BBB), taken 
into astrocytes, and is converted into the neurotoxic metabolite MPP+ by monoamine 
oxidase B (MAO-B) (Cohen et al., 1984; Heikkila et al., 1984).  MPP+ is then released 
and specifically taken up through dopamine transporters due to the structural similarity to 
dopamine (Klein et al., 1985).  Once in the dopaminergic neurons, MPP+ can be 
transported through vesicular monoamine transporter 2 (VMAT2) into intracellular 
vesicles for storage (Staal and Sonsalla, 2000), resulting in little dopaminergic neuron 
injury.  As a result, VMAT2 expression is thought to play a major role in the susceptibility 
to MPTP (Lohr et al., 2016).  MPP+ can also be transported to mitochondria and block 
complex I of the electron transport chain (Singer et al., 1988).  In doing so, metabolic 
disruption and loss of ATP synthesis in dopaminergic neurons leading to neuronal death.  
Why dopaminergic neurons in the substantia nigra pars compacta are specifically lost 
while dopaminergic neurons in neighboring brain regions are not is not clear.  The 
difference in MPTP sensitivity may be related to VMAT2 expression, dopamine 
transporter expression of downstream signaling molecules like JNK and Jun both of 
which are downregulated in MPTP-resistant mouse strains (Boyd et al., 2007).   
 As dopaminergic neurons are lost in the substantia nigra, inflammation mediated 
by activated microglia increases (Członkowska et al., 1996; Kohutnicka et al., 1998).  
After MPTP intoxication, microglia exhibit an activated M1 phenotype and release 
proinflammatory cytokines such as IL-1β as well as reactive oxygen and nitrogen 
species (Wu et al., 2002).  Activated microglia are required for neurodegeneration 
because MyD88 knockout mice are resistant to MPTP-induced degeneration (Cote et al., 
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2011).  MPP+ kills or injures a fraction of the dopaminergic neurons lost; most 
dopaminergic neurons are lost due to resulting neuroinflammation (Reynolds et al., 
2010; Cote et al., 2011).  In addition to the activation of resident microglia, infiltrating 
macrophages and neutrophils play a role (Cote et al., 2011), showing that the innate 
immune system is important for neuroinflammation following MPTP intoxication.     
In addition to the innate immune response to the MPP+, the adaptive immune 
response plays a role as well.  SCID mice, which lack lymphocytes, are relatively 
resistant to MPTP-induced neurodegeneration (Benner et al., 2008).  More specifically, 
mice that lack CD4+ T cells do not lose nigral dopaminergic neurons following MPTP 
intoxication, but mice lacking CD8+ cells are sensitive to MPTP intoxication (Brochard et 
al., 2009).  Interestingly, more CD8+ T cells infiltrate into the substantia nigra than CD4+ 
T cells in the MPTP model and in PD patients (Kurkowska-Jastrzebska et al., 1999; 
Depboylu et al., 2012) and the percentage of CD8+ cells increase and CD4+ T cells 
decreases after MPTP intoxication (Zhou et al., 2015).  Adoptive transfer of effector 
CD4+ T cells exacerbates nigal dopaminergic neuron loss after MPTP intoxication 
(Reynolds et al., 2007).  Exacerbation of MPTP-induced neurodegeneration was 
greatest by adaptive transfer of N-α-Syn-specific Th17 cells, and to a lesser extent, with 
Th1 CD4+ cells, but not Th2 cells (Reynolds et al., 2010; Liu et al., 2017).  On the other 
hand, the adoptive transfer of Tregs were neuroprotective (Reynolds et al., 2007) in the 
MPTP model.                       
 MPTP not only alters the number and distribution of innate and adaptive immune 
cells, release of proinflammatory cytokines and chemokines are increased.  In the serum 
and midbrain after MPTP, there is an increase in TNF-α, IL-6, and IL-1β levels are 
increased (Kaku et al., 1999; Barcia et al., 2005; Shen et al., 2005; Zhao et al., 2007).  
Not only do these cytokines play a role in neurodegeneration, they polarize CD4+ T cells 
179 
 
to Th1 or Th17 cells which also play a degenerative role in the MPTP model as indicated 
above.  In addition, antigens from brain, including nitrated α-synuclein, are detected in 
cervical lymph nodes, the regional draining lymph nodes from the brain (Benner et al., 
2008).  Given that the cervical lymph nodes also contain activated APCs, the possibility 
of an induced adaptive immune response toward this neoantigen exists.  To better 
characterize the early stage of the inflammatory response to MPTP, lymph node 
populations and the ventral midbrain were isolated to test immune cell numbers by flow 
cytometric analysis and cytokine expression by PCR array and Luminex arrays.  It is 
hypothesized that MPTP intoxication will increase proinflammatory gene expression in 
the lymph nodes and the midbrain.  The resulting increase in proinflammatory cytokines  
in these regions would promote differentiation of antigen-specific CD4+ T cells toward 
Th1 and Th17 subtypes and neurodegeneration and neuroinflammation.      
 While CD4+ T cells play a role in MPTP pathology that worsens by Th1 and Th17 
cells, whether and to what extent, MPTP activates CD4+ cells in the periphery is unclear.  
MPTP increases the concentration of several cytokines in the plasma, including IL-6 
(Luo et al., 2004; Shen et al., 2005), TNF-α (Barcia et al., 2005), and to a lesser extent 
IL-1β (Barcia et al., 2005; Shen et al., 2005).  However, the concentration and 
expression of cytokines in the cervical lymph nodes has not been determined.  In 
addition, the expression of IL-1β, TNF-α, CCL3, CXCL10 and CCL2 is increased 
(Kalkonde et al., 2007; Zhao et al., 2007) in the ventral midbrain and striatum.  However, 
the expression of these cytokines and chemokines is dependent on the time post MPTP 
intoxication and the brain region.  This experiment was undertaken to test the gene 
expression and cytokine release in the cervical lymph nodes and ventral midbrain.  
Because of the importance of the peripheral immune system, we well also tested the 
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percentage of B cells, T cells, and activated antigen presenting cells by flow cytometry in 
different lymph node populations.   
 
MATERIALS and METHODS 
Mice, MPTP intoxication and Isolating lymph nodes and ventral midbrain 
 Male, approximately 6-week-old C57Bl/6J mice were obtained from Jackson 
Laboratories.  All studies were conducted in accordance with National Institutes of 
Health (NIH) and the Institutional Animal Care and Use Committee (IACUC) of the 
University of Nebraska Medical Center (UNMC).  All animals had ad libitum access to 
food and water and were maintained in a 12-hour light/12-hour dark cycle.   
 Mice were randomized into one of two groups.  One was given 4 subcutaneous 
(s.c) injections at two hour intervals of 18 mg (free base)/kg MPTP (Sigma-Aldrich).  The 
other group was a control group with s.c. injection of DPBS (Gibco).  MPTP was handled 
and administered in accordance with the published guidelines from the NIH and UNMC 
IACUC (Jackson-Lewis and Przedborski, 2007).    
 After 2 days, 3 mice from MPTP- and DPBS-treated groups were sacrificed by 
CO2 asphyxiation and cervical dislocation for flow cytometric analysis.  The cervical and 
deep cervical lymph nodes (cLN), brachial and axillary lymph nodes (b/aLN) and inguinal 
lymph nodes (iLN) were removed and kept separate for each mouse and were placed in 
a 70 µM filter.  The remaining 3 mice from each treatment group were sacrificed by CO2 
asphyxiation and cervical dislocation for RNA and protein extraction.  The cLN were 
removed and placed in a 1.5ml snap-cap tube containing RNAlater (ThermoFisher).  The 
brain was removed, the frontal cortex and cerebellum was dissected and the remaining 
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ventral midbrain (VMB) was placed in a 1.5ml snap-cap tube containing RNAlater.  
These samples were kept separate and were kept on ice until tissue homogenization.      
 The PARIS kit (Ambion, Waltham, MA) was used to homogenize cLN and VMB 
tissue and isolate protein and RNA.  Tissue was removed from RNAlater, blotted on a 
Kimwipe, placed in a 1.5 ml tube containing 600 µl cold disruption buffer.  Each tissue 
from each mouse was homogenized separately.  Approximately 300 µl of homogenized 
tissue was pipetted into two 1.5ml tubes, one for protein isolation and the other for RNA 
isolation as described below. 
Flow cytometry 
 The different lymph node populations were pressed through a 70 µM filter and 
the cells were concentrated by centrifugation at 300 xg for 10 min.  The pellet was 
resuspended in 1 ml 1x Hanks Buffered saline solution (HBSS) (Gibco) for cell counting.  
A volume containing ~500,000 cells was pipetted into 5 ml flow cytometry tubes and 
cells were concentrated by centrifugation at 300 xg for 10 min.  Cells were blocked for 
20 min on ice in 10 µg/ml rat gamma globulin in FSB (0.5% bovine serum albumin 
(BSA), 0.1% sodium azide in 1x DPBS (Gibco)) to block Fc receptors.  Cells were 
stained with anti-CD11b-PECy7, anti-MHC II-AlexaFluor 700, anti-CD3-PE and anti-
CD19-FITC (eBioscience) for 20 min at 4°C.  Cells were washed in FSB and cells were 
concentrated by centrifugation at 400 xg for 5 min 2 times.  Cells were fixed in FACS Fix 
(1% formaldehyde in 1x DPBS (Gibco)) at RT for 15 min.  Cells were concentrated by 
centrifugation at 400 xg for 5 min.  Cells were resuspended in FSB for analysis using a 
LSR II (BD) in the Flow Cytometry Research Facility at UNMC.   
 Gates were drawn so that ~2% of the isotype control sample were positive for 
each of the markers.  The percentage of the total population positive for CD3 (T cells), 
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CD19 (B cells), and CD11b+MHC II+ (activated APCs) were determined.  The MFI was 
also determined for each marker.   
Protein isolation and luminex array 
 Proteins were isolated from the tissue homogenates as follows.  The 
homogenate was clarified by centrifugation at 10,621 xg in a Beckman (Brea, CA) 
1470R centrifuge for 10 min.  The supernatant was transferred to a 1.5 ml tube and was 
stored at -20°C until future analysis.   
 Total protein concentration was determined in each sample using the 
bicinchoninic acid assay(BCA) total protein assay (Pierce, Waltham, MA) performed by 
adding 200 µl of the BCA working solution (50:1 solution A:solution B) to 25 µl of an 
undiluted or 1:10 dilutions of VMB homogenate or 1:2 dilution of cLN homogenate.  The 
plate was incubated at 37°C for 30 min, allowed to equilibrate to RT for 10 min prior to 
reading at 562 nm.  Based on the normalized absorbance readings and a BSA standard 
curve, the protein concentration was determined.   
 The Milipore (Billerica, MA) Milliplex xMAP mouse cytokine and chemokine 
magnetic bead kit was used to determine the concentration of cytokines and cytokines 
from each sample as follows.  The 96-well plate was washed in wash buffer prior to 
adding 25 µl of standards, quality control samples and triplicates of each tissue (~250 µg 
cLN, ~650 µg VMB total protein).  To wells with standards and quality controls, 25 µl of 
PARIS disruption buffer was added.  The samples had 25 µl assay buffer added.  
Antibody solution containing antibodies against IFNγ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, 
IL-7, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, Lix, IL-15, IL-17, IP-10, MIP-2, MIG, 
RANTES, and TNF-α was added to all wells and the plate was incubated at 4°C with 
shaking overnight.  The beads were concentrated on a magnet and washed in wash 
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buffer 2 times.  To each well was added 25 µl of detection antibodies and incubated at 
RT for 1 hr.  To each well was added 25 µl streptavidin-PE was added to each well and 
the plate was incubated at RT for 30 min.  The beads were then concentrated on a 
magnet and washed in wash buffer twice before being for resuspended in 150 µl sheath 
fluid and data was collected using a Millipore Magpix system with Luminex Xponent 4.2 
software (Luminex corporation Austin, TX).  The software calculated the concentration of 
each of the cytokines and chemokines in each sample.  The mean cytokine and 
chemokine concentrations were determined for 3 replicates from the 3 mice for each 
tissue for the DPBS mice.  Mean concentrations from MPTP-treated mice were 
normalized to those of DPBS-treated mice. 
RNA isolation, cDNA conversion, PCR arrays and gene expression analysis 
 RNA was isolated from the cLN and VMB homogenate using the PARIS kit.  An 
equal volume of 2x PARIS lysis/binding buffer (ThermoFisher) (~300 µl) was added to 
~300 µl of homogenate and 300 µl 200 proof ethanol and the solution was mixed.  This 
volume was pipetted into a spin column and was passed through at 20,817 xg 
(Eppendorf 5417R, Hamburg, Germany) for 1 min.  The eluate was discarded and 700 µl 
PARIS wash solution 1, was passed through the filter at 20,817 xg for 1 min and the 
eluate was discarded.  For each RNA sample, 500 µl PARIS wash solution 2/3 was 
passed through the filter at 20,817 xg for 1 min and the eluate was discarded.  After 
drying the filter by centrifugation at 20,817 xg for 1 min, 40 µl of PARIS elution buffer 
heated to 95°C was added to each column and eluted from the column at 20,817 xg for 
1 min.  This was repeated with an additional 10 µl PARIS elution buffer passed through 
at 20,817 xg for 1 min.  RNA concentration and A260/A280 was determined by UV 
specteophotometry (ND-1000, NanoDrop Technologies Inc. Wilmington, DE).  Samples 
were stored at -20°C until cDNA conversion could be performed.   
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 To generate cDNA from the RNA template, the RevertAid first strand cDNA 
synthesis kit (ThermoFisher) was used as follows.  A volume of the RNA to yield 80 ng 
from each of the samples was added to each of five 0.2 ml tubes with enough water to 
bring the volume to 11 µl, and 1 µl oligo dT primers was added to each sample and 
incubated at 65°C for 5 min.  Eight microliters of master mix (containing 5x reaction 
buffer, Ribolock Rnase inhibitor, 10 mM dNTPs, and revertAID RT) was added and 
incubated at 42°C for 60 min for single strand synthesis.  The reaction was terminated 
by incubation at 70°C for 5 min and aliquots were combined and frozen at -20°C until the 
PCR arrays were run.  
 To run the array, the whole volume of 2x RT2 SYBR green master mix (Qiagen) 
(1,350 µl), 1,248 µl Rnase-free water, and ~400 ng cDNA from a single sample was 
mixed with 25 µl was added to each well of a Mouse Inflammatory Cytokines and 
Receptors array (Qiagen).  The array was performed on an Eppendorf Realplex2 
mastercycler gradient S using a PCR program with a 10 min hot start at 95°C, 40 cycles 
of 15 sec at 95°C, and 60°C for 1 min using a 26% ramp rate.  A melting curve was run 
at the end.  Ct values were determined for each well from each sample.  Fold change 
was calculated using the ΔΔCt method.  Housekeeping genes were averaged for 
normalization included for cLN samples are ACTB, GAPDH, GUSB, and HSP90AB1 and 
for VMB samples ACTB, B2M, GAPDH, GUSB, and HSP90AB1 were averaged for 
normalization.  Fold regulation was -1/fold change.   
Statistics 
 Significance of fold changes for cell percentages or MFIs in MPTP-intoxicated 
mice compared to DPBS control mice were determined by one-way ANOVA followed by 
Sidak’s post hoc test.  The fold change between the cytokine in the cLN and VMB was 
assessed by two-way ANOVA followed by Sidak’s post hoc test comparing the DPBS 
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and MPTP for each tissue for each cytokine.  All statistics and graphs were generated by 
using GraphPad Prism version 6. 
    
RESULTS 
Flow cytometry 
The purpose of this experiment was to determine the effect of MPTP on the 
distribution of T cells (CD3+), B cells (CD19+), and activated APCs (APC, CD11b+ MHC 
II+) at peak neuroinflammation, once mice were administered 18 mg/kg MPTP or DPBS 
in 4 s.c. injections, each administered every 2 hours.  After 2 days, mice were sacrificed 
and the cervical lymph nodes (cLN), brachial/axillary (b/aLN), and inguinal lymph nodes 
(iLN) were isolated and flow cytometry was performed to determine the percentages of 
cell types and then normalized to the DPBS controls.  In all 3 lymph node populations, 
there was a trend toward increased activated APCs after MPTP intoxication, but this did 
not reach statistical significance (Figure 4.1A).  As CD11b+ cells upregulate MHC II 
surface expression when they become activated (Ponomarev et al., 2005), we assessed 
MFI on the surface of MHC II on CD11b+ cells.  MHC II MFI for MPTP-intoxicated mice 
was increased compared to DPBS controls, but only reached statistical significance in 
the cLN (Figure 4.1B).  This result is congruent with previous research showing antigens 
from the brain drain into the cLN population after MPTP intoxication (Benner et al., 
2008).  We also found that percentages of CD19+ B cells were significantly greater in 
b/aLN in the MPTP-intoxicated mice (Figure 4.1C).  B cells appeared to be elevated in 
the iLN of MPTP mice as well, but did not reach significance.  Interestingly, MPTP 
intoxication did not seem to affect CD19+ cell percentages in cLN.  Lastly, no significant 








Figure 4.1 Flow cytometric profile in lymph nodes after MPTP intoxication 
Cervial (cLN), brachial and axillary (b/aLN) and inguinal lymph nodes (iLN) from DPBS 
control or MPTP-intoxicated mice were pressed through a cell strainer and the resulting 
single cells were stained with anti-CD11b, anti-MHC II, anti-CD19 and anti-CD3 
antibodies for flow cytometric analysis.  The frequency of cell type was divided by the 
average of the DPBS for each lymph node population to normalize.  Black bars are the 
DPBS controls and the red bars are from MPTP mice.  (A) Fold change in activated 
antigen presenting cells (CD11b+ MHC II+) in MPTP-intoxicated mice compared to 
control for all lymph nodes. (B) Fold change in the MHC II mean fluorescent intensity on 
CD11b+ cells was compared for MPTP-intoxicated LN compared to DPBS LN.  (C) Fold 
change in B cells (CD19+) in MPTP-intoxicated mice compared to control for all lymph 
nodes. (D) Fold change in T cells (CD3+) in MPTP-intoxicated mice compared to control 
for all lymph nodes.  Mean ±SEM for n=3 mice per group and compared by one-way 
ANOVA and Sidak’s post-hoc test whereby a-p ≤ 0.05 compared to DPBS-treated 





percentages were found in all lymph nodes (Figure 4.1D) which may be due to MPTP-
induced cell death (Chi et al., 1992; Zhou et al., 2015).  These data demonstrate that 
MPTP-intoxication induces changes to the peripheral immune compartment including 
increased activated APCs and B cells.   
Cytokine and chemokine expression in the cLN and VMB after MPTP 
 To determine the cytokine environment at the peak of neuroinflammation post 
MPTP, ventral midbrain (VMB) and cLN were homogenized and proteins extracted 2 
days after MPTP intoxication.  The extracted proteins were tested using a Millipore 
xMAP magnetic bead array for inflammatory cytokines and chemokines.  MPTP-
intoxicated mice show slight, though not significant, elevated levels of IFNγ, IL1-β, IL-4, 
IL-5, IL-7, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, Lix, IL-15, IL-17, IP-10, MIP-2, 
RANTES, and TNF-α, but only IFNγ and IL-4 reached statistical significance in cLN 
(Figure 4.2A).  In the ventral midbrain (VMB), only IP-10 was significantly elevated 
following MPTP (Figure 4.2B).  These were unexpected results since MPTP is known to 
induce proinflammatory cytokines such as IL-6 and TNF-α (Luo et al., 2004; Barcia et al., 
2005; Shen et al., 2005; Kalkonde et al., 2007; Zhao et al., 2007).   
   To test if MPTP increases the expression of proinflammatory cytokine and 
chemokine genes, RNA was extracted from VMB and cLN homogenate, RNA was 
converted to cDNA, and real time PCR was performed using an array for 
proinflammatory cytokines and chemokines and their receptors.  Genes increased or 
decreased by more than 2-fold in the cLN (Figure 4.3A) or VMB (Figure 4.3B) are listed.  
The only 2 genes with more than 10-fold increase in expression in the cLN were IL2RG 
and BMP2.  Expression of proinflammatory cytokines such as IL17A, TNF, IL1A, and 




Figure 4.2 Changes in cytokines and chemokines in the cervical lymph nodes (cLN) and 




Figure 4.2 Changes in cytokines and chemokines in the cervical lymph nodes 
(cLN) and ventral midbrain (VMB) after MPTP intoxication  
Homogenates of cLN and VMB were made and proteins extracted using the PARIS kit 
for Milliplex xMAP analysis for inflammatory cytokines and chemokines.  (A) The 
average from each cLN sample was divided by the average of the DPBS control to 
determine the fold increase for each cytokine or chemokine.  (B) The average from each 
VMB sample was divided by the average of the DPBS control to determine the fold 
increase for each cytokine or chemokine.   Means ± SEM for n=3 per treatment group 
were determined by two-way ANOVA and Sidak’s post hoc test whereby a- p ≤ 0.05 




including IL33, IL5 and IL4, and the chemokines CCL1, CCL12, CCL3, CCL24, CXCL9, 
CCL17, CCL11, and CCL5.  Interestingly, despite significant increase of IFNγ protein in 
the cLN, there is a more than 2-fold downregulation of IFNG expression.  Several 
cytokine and chemokine receptors were downregulated, including CCR4, IL5RA, IL6RA, 
CXCR5, IL10RB, IL1R1, IL10RA, CXCR3, CCR6, IL2RB, CCR3, CCR5, CCR1, CCR10, 
and CCR2.  Cytokine genes such as IL21, IL16, IL11, IL27, CSF1, CSF3, IL13, and IL15 
were also downregulated.  To visualize the connections between changed genes in cLN 
after MPTP intoxication, Ingenuity Pathway Analysis was performed.  Figure 4.4 is a 
pathway of the cytokines and chemokines altered in this experiment.  As noted above, 
there is an increase and decrease in the expression of pro- and anti-inflammatory 
cytokines.  For example, Th2 helper T cell-related cytokines IL5, IL4 were increased, but 
IL13 was decreased.  Th17 helper T cell-related IL17A was increased, while IL21 is 
decreased.   The surface marker FASLG was increased, but the co-stimulatory molecule 
CD40LG was decreased.  These data show that MPTP induces many gene expression 
changes that potentially could affect many different aspects of the interplay of innate and 
the adaptive immunity toward the induction of responses to nitrated and misfolded 
proteins such as N-α-Syn.   
The only gene with more than 2-fold changed expression in the VMB after MPTP 
intoxication was CXCL10, which is the gene for IP-10 (Figure 4.3B), also significantly 
upregulated in Figure 4.2B.  The data also point to a paucity of genes in the midbrain 
that were not affected by 2 days after MPTP intoxication, the time of peak inflammation 





Figure 4.3 Changes in gene expression following MPTP intoxication in the cLN and VMB 
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Figure 4.3 Changes in gene expression following MPTP intoxication in the cLN 
and VMB 
Homogenates from cLN and VMN had RNA extracted using the PARIS kit prior to cDNA 
conversion, and PCR using an array for pro-inflammatory cytokines, chemokines and 
receptors.  All changes reported are greater than 2-fold in the cLN (A) or in the VMB (B) 
sampled 2 days following MPTP intoxication and relative to DPBS controls.   Red cells 
are more than 2-fold upregulated expression, while green cells are more than 2-fold 
decreases in gene expression.  There are 3 samples for each group of mice treated with 










Figure 4.4 Map of dysregulated genes in the cLN following MPTP intoxication 
Ingenuity Pathway Analysis was used to map the connections of all genes that were up- 
or downregulated by at least 2-fold in the cLN assessed 2 days after MPTP intoxication.  
Cells are labelled in black with a thicker boarder.  Cytokines in the pathway that were not 
disregulated are outlined in gray.  Genes upregulated have a red outline and the darker 
fill color signifies higher upregulation.  Downregulated genes are depicted with green 





 Data from this chapter have determined if there were changes to the distribution 
of T cells, B cells, and activated APCs in different lymph node populations.  Our findings 
showed that there was no significant change in the percentage of activated APCs in the 
MPTP lymph node compared to control.  There was an increase in the MFI of MHC II on 
APCs, but only in the cervical lymph nodes.  This suggests an increase in activated 
APCs in the draining lymph nodes from the brain, which is in line with previous data 
(Benner et al., 2008).  Little work has been published on the percentage of myeloid cells 
in the periphery after MPTP intoxication, especially at this early time point.  These data 
would suggest that MPTP does not induce the proliferation or migration of APCs into 
lymph nodes, but activates the existing APCs.  This chapter also showed an increase in 
B cells post MPTP.  This is in contrast with other studies which indicated that MPTP 
does not increase the percentage of B cells (Chi et al., 1992).  However, this prior report 
was testing B cell percentage in the spleen one week after intoxication.  It is possible 
that B cell percentage returns to basal levels by this time point and/or there is no change 
in the percentage of B cells in the spleen.  Lastly, there was no change in the 
percentage of CD3+ T cells in the MPTP-intoxicated mouse lymph nodes, which is also 
in contrast to previous data (Chi et al., 1992).  Prior research demonstrated that MPTP 
decreased CD4+ CD3+ cells, but increased CD8+ CD3+ cells (Zhou et al., 2015).  In 
light of this result, it is possible this experiment may not detect an overall change in 
CD3+ cells, even though the ratio of CD4+ to CD8+ cells may be altered.  Future work 
could resolve this issue by more specifically testing the percentage of different T cell 
types.  The trend toward decreased CD3+ T cells in lymph nodes due may also be 
explained by increased mobilization of these cells into the periphery, and possibly the 
brain.     
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 Some care is needed in the interpretation of these results.  Each group contains 
only 3 mice.  While this is sufficient for performing statistical analysis, there is insufficient 
power to find statistically significant differences.  This experiment also examined only 
single time point.  While day 2 is the peak of neuroinflammation, the initiation of the 
adaptive immune response may begin prior to this time point.  As a result, future work 
should look at a time course before or after day 2 to see the rise, peak and diminution of 
the adaptive immune response.  It should also be noted we only examined in the lymph 
nodes, and not the spleen, the circulating blood, or the brain.  In conclusion, we do not 
yet possess a full picture of how many of these immune cells are present and where 
they are located at each time point during the course of MPTP intoxication.  
 We next examined the cytokine and the gene expression of cytokines in the 
draining lymph nodes and the ventral midbrain.  In the cervical lymph node, only IFNγ 
and IL-4 were significantly increased on the protein level.  This is of interest because the 
increase in IFNγ has been reported previously in the serum and spleen (Huang et al., 
2014; Zhou et al., 2015).  However, IL-4 was not increased in previous studies (Huang et 
al., 2014).  While we did not test the release of cytokines in other lymph node 
populations, it is possible that the increase in IL-4 may be responsible for the increase in 
B cells because IL-4 is produced by Th2 CD4+ T cells which support the proliferation of 
B cells.  In the VMB, only the chemokine IP-10 was significantly increased.  It is unclear 
why this experiment did not find the increase of other proinflammatory cytokines found in 
other studies.  One possibility is the low number of mice.  Another possibility is that the 
wrong brain region was tested at the wrong time.  TNF-α and IL-1β were found to be 
elevated in the striatum, but not the substantia nigra at 1 day post MPTP, but this 
increase was resolved by day 3 post MPTP (Kalkonde et al., 2007).  A prior experiment 
tested changes in the genes encoding TNF-α, IL-1β, IL-1α, IL-6, MMP-2, MMP-9 at 
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different time points post MPTP in the ventral midbrain and striatum (Hébert et al., 
2003).  This experiment reported different time courses for each gene and for each 
tissue.  This suggests it is important to evaluate over time, and in different tissues, 
because the peak expression is different for each gene in each tisuue.  Future 
experiments should examine both the ventral midbrain and the striatum at earlier and 
later time points.  If this is done, the MPTP-induced increase in the expression of the 
proinflammatory cytokines would be better characterized.        
 We also tested mRNA expression of proinflammatory cytokines and chemokines.  
In the cervical lymph node, the expression of IL4 was also increased on the mRNA level 
to coincide with the protein expression.  It is interesting that IFNG gene expression was 
decreased while the concentration of IFNγ was increased.  It is unclear why this is the 
case, but this could indicate the beginning of a phenotypic shift from the initial 
proinflammatory response to a compensatory anti-inflammatory response.  In the ventral 
midbrain, there was also only a 2-fold increase in CXCL10, and expression of the gene 
for IP-10 was increased.  Again, it is unclear why there was not more dysregulation of 
genes in the ventral midbrain, but as above, isolation of RNA in both the striatum and the 
VMB at earlier time points would be expected to detect increases in gene expression.   
 In conclusion, this chapter contains data that demonstrates changes to the 
peripheral immune system and to the RNA and protein expression of proinflammatory 
cytokines and chemokines at the peak of neuroinflammation.  Because of this single 
time point, it is possible, that there would be more changes at an earlier time point post 





CHAPTER 5  
DISCUSSION AND FUTURE DIRECTIONS 
 
DISCUSSION 
GM-CSF as a pro- and anti-inflammatory cytokine 
 Previously, GM-CSF has been thought of as a proinflammatory cytokine.  This is 
due to GM-CSF promoting differentiation, proliferation, and survival of myeloid origin 
cells such as DCs, macrophages and granulocytes.  The use of GM-CSF as an adjuvant 
improves the immune response to vaccines (Jones et al., 1996; Ryan et al., 2000; 
Cruciani et al., 2007; Parmiani et al., 2007; Spitler et al., 2009; Garcia et al., 2014) and 
in the experimental autoimmune encephalitis (EAE) model of multiple sclerosis (MS), 
GM-CSF-secreting cells are responsible for the progression of symptoms (Codarri et al., 
2011).  Genetic knockout of GM-CSF prevented EAE in one model (King et al., 2009),  
and collagen-induced arthritis (Campbell et al., 1998) further suggesting that GM-CSF is 
required for disease in some models of autoimmunity.  However, GM-CSF can also 
promote a tolerogenic state in DCs (Xu et al., 2008; Ganesh et al., 2009; Bhattacharya 
et al., 2011), where the immune response to antigens is decreased.  The divergent 
effects of GM-CSF are reported in the results of Chapter 2 where sargramostim 
treatment increased the expression of both pro- and anti-inflammatory genes in the 
CD4+ CD25- cells of PD patients.  To date, no molecular mechanism has been identified 
to determine when GM-CSF boosts the immune response and when GM-CSF 
diminishes the immune response.  However, there are several possible explanations.  
One possibility is that the concentration, duration of treatment, or the route of 
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administration of GM-CSF determines the effect.  To reconstitute the immune system 
post-chemotherapy, sargramostim is administered i.v. at a dose of 250 µg/m2 per day 
for 2 weeks (Nemunaitis et al., 1991; Rowe et al., 1995; Waller, 2007).  When 
sargramostim has been tested as an adjuvant, the dose used is variable but range from 
20 to 500 µg, usually delivered s.c. (Cruciani et al., 2007; Parmiani et al., 2007).  In 
Crohn’s disease (Korzenik et al., 2005; Valentine et al., 2009) and in PD  (Gendelman et 
al., 2017) sargramostim was administered s.c. at 6 µg/kg.  Because the dose of 
sargramostim used as an adjuvant may be lower than that used to reduce inflammation, 
there may be different effects depending on the concentration.  If this possibility is 
correct, it would suggest that a higher dose of sargramostim is needed to lead to 
decreased inflammation and induce Tregs, which would also suggest a different, 
potentially lower affinity pathway compared to the pathways which differentiate and 
proliferate myeloid cells.  Another possibility is the length of administration which tends 
to be shorter when sargramostim is used to repopulate the immune system and to act as 
an adjuvant than when sargramostim is used to reduce symptoms of Crohn’s disease or 
PD.   This would suggest that the longer sargramostim is administered, the more it 
reduces inflammation.  Perhaps this is a compensatory mechanism to ensure that the 
increase in immune cells does not lead to autoimmune response.  Lastly, post-
chemotherapy, sargramostim is administered i.v., but as an adjuvant or to reduce 
inflammation, sargramostim is administered s.c.  Perhaps the route by which 
sargramostim is administered may also effect the pharmacokinetics, 
pharmacodynamics, or cells affected.  This may also change the action and effect of 
sargramostim.  Combined, the dose, duration of treatment, or route of administration 
may be responsible for the divergent effects of sargramostim.    
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GM-CSF may also have effects not related to dosing.  For example, there may 
be a single GM-CSF-induced signaling cascade in all immune cells, but there may be 
distinct subpopulations or activation states of immune cells which favor either 
immunogenic or tolerogenic responses.  Other factors may control the relative 
abundance and distribution of these immunogenic or tolerogenic subpopulations.  GM-
CSF will then expand all myeloid cells, with the resulting immune response either being 
immunogenic or tolerogenic due to the relative ratio of the immune cell subtypes and/or 
activation states.  As technology improves, we are gaining more of an appreciation that 
genetic subpopulations exist within cells with the same surface markers.  This was 
highlighted by a recent single cell RNA-Seq study of blood myeloid cells (Villani et al., 
2017). 
 Another possibility is that GM-CSF binding its receptor leads to different 
intracellular pathways that are activated under different circumstances.  After binding its 
receptor, tyrosine kinases, especially JAK2, phosphorylate intracellular tyrosines in the 
alpha and beta chains of the GM-CSF receptor.  STATs, especially STAT5, bind to the 
phosphorylated tyrosines which can activate MAP kinases, such as ERK1/2, p38, and 
JNK, and PI3K pathways (de Groot et al., 1998).  Activation of the MAPK pathway is 
more associated with proliferation and differentiation of cells while the PI3K pathway is 
more associated with the pro-survival function of GM-CSF.  There may be a similar 
effect between immunogenic and tolerogenic functions where different signaling 
cascades induce different effects.  To date, this possibility has not been investigated.  It 
would also be interesting to determine if different tyrosine kinases, phosphorylation of 
different tyrosines, and/or different STATs binding to different tyrosines promote different 
cascades that promote the expression of different cytokines.  This could be tested by 
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activating DCs and using inhibitors and/or overexpression of different signaling pathways 
to test the resulting expression of cytokines.     
 A final possibility is that other environmental factors bias the state of DCs which 
bias the effect of GM-CSF binding its receptor.  Other factors may be biasing the 
distribution of different immune subpopulations or may be activating different pathways 
within target cells.  If transcription factors are already increased from other signaling 
cascades, GM-CSF signals may be biased for those pathways that may promote 
different immune responses.  More work is needed to differentiate these possibilities and 
the ultimate effect of GM-CSF treatment on the immune system.  This is important work 
if GM-CSF will be used for therapy to ensure that the proper immune response is 
achieved for the desired outcome.   
GM-CSF induces tolerogenic DCs that induce Tregs  
 The data presented in Chapters 2 and 3 support the model that GM-CSF 
modulates the immune response in DCs.  These GM-CSF-treated DCs in turn bias the 
activation state of CD4+ cells toward anti-inflammatory Tregs which can then be 
neuroprotective in PD and the MPTP model of PD.  The induction of Tregs is mediated 
by the surface expression of anti-inflammatory co-stimulatory molecules and not by 
soluble mediators.   
 In Chapter 2, sargramostim treatment significantly altered the expression of a 
wide variety of genes in CD4+ CD25- cells in PD patients.  Because the alpha chain of 
the GM-CSF receptor is not detected on CD3+ cells (Santoli et al., 1988; Rosas et al., 
2007), it is unclear how sargramostim (human recombinant GM-CSF) is inducing the 
dysregulation of these genes.  It has yet to be determined if CD4+ CD25- cells express 
the beta chain of the GM-CSF receptor, but if they do then it is possible that the 
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exogenous GM-CSF is at high enough concentration to bind to this receptor and directly 
alter gene expression.  Another possibility is that GM-CSF is binding to its receptor on 
myeloid cells (i.e. macrophages, monocytes and dendritic cells, neutrophils, and 
eosinophils), activating these cells to release cytokines, chemokines, and/or other 
mediators which are acting on CD4+ CD25- cells.  These possibilities are not mutually 
exclusive.  We also do not know whether the dysregulation of genes is occurring in the 
same or different CD4+ CD25- populations.  It is possible that sargramostim-treated 
patients contain different CD4+ CD25- populations in which some display increased 
proinflammatory genes, and another population with increased anti-inflammatory genes.  
Conversely, sargramostim may be increasing the expression of pro- and anti-
inflammatory cytokines in all CD4+ CD25- cells.  The first possibility would suggest that 
the global administration of sargramostim is affecting diverse cell types in different ways.  
The second possibility would suggest that while sargramostim has a uniform effect on 
CD4+ CD25-, the dysregulation is due to broad activation of CD4+ CD25- cells.      
In Chapter 3, in the absence of stimulation, BMDCs are in a tolerogenic state.  
While GM-CSF did not maintain this state after stimulation as determined by the 
increase in the surface co-stimulatory molecules, increase and proinflammatory 
cytokines, and decrease in kynurenine, GM-CSF alters how BMDCs respond to N-α-Syn 
stimulation.  Extending GM-CSF culture increased Jag-1 surface expression, the 
expression and release of IL-10, and decreased the surface expression of MHC II and 
CD86.  However, GM-CSF generally did not decrease the expression and release of 
proinflammatory cytokines and chemokines.  It is unclear how GM-CSF culture leads to 
these seemingly divergent effects of increasing anti-inflammatory and proinflammatory 
co-stimulatory molecules and cytokines.  The binding of GM-CSF to its receptor, JAK2 
activates STAT5 which can activate several downstream signaling cascades including 
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MAPK and PI3K (de Groot et al., 1998).  Tolerogenic DCs display a unique pattern of 
gene expression separate from mature, immunogenic DCs.  Expectedly, tolerogenic 
DCs exhibit decreased expression of proinflammatory cytokines and increased 
expression of anti-inflammatory cytokines (Torres-Aguilar et al., 2010; Lee et al., 2016).  
In addition, tolerogenic DCs may increase expression of IDO, an enzyme involved in 
tryptophan metabolism and associated with the induction of Tregs (Steinman et al., 
2003; Maldonado and von Andrian, 2010; Li and Shi, 2015; Raker et al., 2015).  
Tolerogenic DCs also increase the surface expression of PD-1, CD95L, ILT3 and ILT4, 
all of which are involved in the suppression of immune cell activation or induction of 
Tregs, or apoptosis (Sim et al., 2016).  Also, CLIP, the invariant MHC II chain, was 
increased on the surface of tolerogenic DCs which suggest a decrease in the 
presentation of antigens which could explain why tolerogenic DCs are weaker inducers 
of helper T cell proliferation (Torres-Aguilar et al., 2010).  Tolerogenic DCs also show 
decreased glycolysis (also detected in activated mature DCs) and increased oxidative 
phosphorylation (Sim et al., 2016).  This switch in energy production may be mediated 
by a suppression of AKT signaling in tolerogenic DCs.  Tolerogenic DCs increase 
expression of genes involved in lipid metabolism, apoptosis, cell membrane 
homeostasis, and the inflammatory response, including an increase in NFKB1 (Lee et 
al., 2016).  Despite the plethora of information about gene signatures of tolerogenic DCs, 
how GM-CSF is inducing and maintaining a tolerogenic state remains unclear.    
 In these experiments, we identified two anti-inflammatory mediators that are 
upregulated by continued culture in GM-CSF: Jag-1 and IL-10.  We tested the surface 
expression of Jag-1, and not the total gene and protein expression, so whether GM-CSF 
increases gene expression and translation of Jag-1 or merely mobilizes the Jag-1 to the 
surface is unknown in this model.  Cultured monocytes do increase jagged1 expression 
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after culture with GM-CSF (Nomaguchi et al., 2001), so the possibility remains in our 
system that total Jag-1 is increased after GM-CSF culture.  How binding of GM-CSF to 
its receptor is upregulating the surface expression of Jag-1 remains to be determined.  
TNFα treatment increases jagged1 expression (Okada et al., 2016). In this system, and 
the only source of TNFα would be from the BMDCs, but the continued culture of BMDCs 
in GM-CSF decreased the expression of Tnf (Figure 3.7) and did not change the release 
of TNFα (Figure 3.9), suggesting increases in Jag-1 surface expression are not related 
to TNFα.  Macrophage colony stimulating factor (M-CSF) regulates Jag-1 expression 
through NF-κB (Brach et al., 1991), but the expression of Nfkb1 was not altered by 
continued GM-CSF (Figure 3.7).  These results suggest that GM-CSF has another 
mechanism of increasing jagged1 through a yet undescribed pathway.   
 IL-10 is an anti-inflammatory cytokine important for the anti-inflammatory 
functions of Tregs and Th2 helper T cells.  More is known about the regulation of IL-10 
expression, though the regulatory effects on IL-10 by GM-CSF is unclear.  Several 
transcription factors have been identified that regulate IL-10 gene expression, including 
Sp1, Sp3, STAT3, ERK1/2, JUNK, p38, NF-κB, c/EBPα, and AP-1/c-Jun (Tone et al., 
2000; Ziegler-Heitbrock et al., 2003; Wang et al., 2005; Saraiva and O'Garra, 2010).  
Whether any are increased by the binding of GM-CSF to its receptor is unknown.  
Combined, the lack of knowledge about the molecular events by which GM-CSF induces 
and maintains a tolerogenic state provides potential future directions.  If a tolerogenic 
state can be induced more directly and maintained without the off-target effects of GM-
CSF, could provide a putative novel therapy for PD and autoimmunity.  Turning off the 
tolerogenic state of DCs could also serve as a novel therapy for anti-tumor immune 
responses.    
Impact of GM-CSF on other cell types 
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 GM-CSF has broad effects throughout the body.  As a result, peripheral 
administration of GM-CSF may afford beneficial effects in PD and in models apart from 
the increase in the percentage and function of Tregs.  As stated in Chapter 1, GM-CSF 
has broad effects throughout the immune system including macrophages, monocytes, 
DCs, neutrophils and eosinophils.  GM-CSF also induces the proliferation of myeloid-
derived suppressor cells (MDSCs).  These cells are either monocyte or granulocyte 
lineage and induced by proinflammatory stimuli including infections (Gabrilovich and 
Nagaraj, 2009; Parker et al., 2015).  Activated MDSCs increase the expression of 
reactive oxygen and nitrogen species (ROS/RNS), TGFβ, and PD-L1 as well as induce 
Treg differentiation all of which suppress T cell immune responses.  GM-CSF 
administration expands MDSCs in vitro and in vivo (Filipazzi et al., 2007; Dolcetti et al., 
2010; Rosborough et al., 2012).  The adoptive transfer of MDSCs reduces the 
expression of perforin and IFNγ in CD3+ cells in cancer (Filipazzi et al., 2007).  MDSCs 
are also protective in the EAE model of MS, and MDSCs from MS patients suppress 
CD4+ T cell proliferation (Ioannou et al., 2012). 
 The role of MDSCs in PD and the MPTP model of PD has not been tested.  
Possibly in PD, MDSCs could be decreased in percentage and/or function, like Tregs.  If 
this is the case, the decrease may contribute to increased neuroinflammation of PD 
patients.  During inflammation, MDSCs may act similar to tolerogenic DCs to induce 
Tregs or directly suppress T cell or myeloid effector cells.  This potential dual role for 
MDSCs merits further investigation, in PD, PD models, and other autoimmune disorders.   
 Another potential immune cell that may be affected by GM-CSF are B cells.  
These lymphocytes have unique roles for producing immunoglobulins and presenting 
antigens.  In PD, frequency of circulating B cells are deceased compared to controls 
(Bas et al., 2001; Niwa et al., 2012; Stevens et al., 2012; Horvath and Ritz, 2015).  To 
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date, the percentage of different B cell subsets or plasma cells remain undefined.  
However, since the production of antibodies reactive to α-Syn is elevated (Papachroni et 
al., 2007), antigen-specific B cells may play a significant role in the pathology of PD is 
unclear.   
 B cells express the receptor for GM-CSF, and GM-CSF promotes the survival of 
B cells (Harris et al., 2000).  While the effects of GM-CSF on B cells of PD patients have 
not yet been determined, several potential beneficial effects exist.  For example, GM-
CSF may promote the survival of B cells that produce immunoglobulins to clear 
misfolded antigens and protect in PD.  Another possibility is that GM-CSF may modulate 
the presentation of antigens by MHC II to helper T cells and modulate the response to 
be more protective in PD.  Since naïve B cells can induce Tregs in vitro (Reichardt et al., 
2007), GM-CSF may possibly have similar effects on the B cells as on myeloid cells by 
increasing the expression of anti-inflammatory mediators and/or decreasing the 
expression of co-stimulatory molecules; the combination of which would promote the 
induction of Tregs.  A final possibility is that GM-CSF increases numbers and function of 
regulatory B cells (Bregs), a B cell subset that can suppress immune cells through IL-10-
dependent and independent mechanisms (Ray and Dittel, 2017).  While a role for Bregs 
in PD has yet to be identified, these regulatory cells, like Tregs and MDSCs, could play a 
role in suppressing the inflammation and may comprise a component of the mechanism 
for protection provided by GM-CSF.     
Apart from its effects on the immune system, GM-CSF can have direct effects on 
the nervous system.  GM-CSF receptor is detected on neurons (Kruger et al., 2007) and 
neural progenitor stem cells (Kim et al., 2004; Kruger et al., 2007).  For neural progenitor 
stem cells, administration of GM-CSF decreases differentiation of these stem cells into 
astrocytes or neurons and protects them against apoptosis (Kim et al., 2004).  GM-CSF 
208 
 
treatment promotes axon regeneration in culture by inducing production of brain-derived 
neurotropic factor (BDNF) (Bouhy et al., 2006).  In models of stroke, penumbral neurons 
around the infarct increase the expression of the GM-CSF-receptor and administration of 
GM-CSF induces the expression of the pro-survival factor Bcl (Schabitz et al., 2008).  In 
fact, GM-CSF treatment decreases post-stroke infarct size.  GM-CSF also protects the 
PC12 neuron cell line from MPP+-mediated toxicity by the restoration of the Bcl-1/Bax 
ratios, which promotes survival (Kim et al., 2009).  As a result, the protection of TH-
positive neurons in the substantia nigra by intraperitoneal administration of GM-CSF 
(Kim et al., 2009; Kosloski et al., 2013) may not be completely mediated by Tregs, but 
rather by direct effects on neurons.  Given that GM-CSF crosses the blood-brain barrier 
(Schabitz et al., 2008), it may indeed elicit direct effects in the CNS.   
 In addition to neurons, the glia including astrocytes, oligodendrocytes and 
microglia also express GM-CSF receptors (Baldwin et al., 1993; Sawada et al., 1993; 
Lee et al., 1994; Guillemin et al., 1996).  The precise in vivo role that GM-CSF plays in 
the brain remains unclear, but in culture, astrocytes, oligodendrocytes and microglia 
proliferate in response to GM-CSF treatment (Baldwin et al., 1993; Lee et al., 1994; 
Guillemin et al., 1996).  GM-CSF is increased in the cerebrospinal fluid of stroke patients 
(Tarkowski et al., 1997), and cultured astrocytes produce GM-CSF after stimulation with 
viral infection, or stimulation with TNF-α or LPS (Wesselingh et al., 1990; Frei et al., 
1992); all of which suggests a role for GM-CSF in response to inflammatory stimuli in the 
brain.  Seemingly the expression of GM-CSF appears to be protective by promoting 
survival.  In fact, GM-CSF plays a role in the normal development of the brain, as 
evidenced by decreased locomotor activity and spatial memory of GM-CSF-knockout 
mice, which may be related to the decreased length of dendrites (Krieger et al., 2012).  
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In conclusion, GM-CSF has direct, positive effects on the brain, however, to what extent 
that these effects are independent of Tregs remains unclear.   
 A final, related possibility is that GM-CSF is acts on cells in the periphery and 
lead to release of more products that can enter the brain and affect PD.  While BMDC 
supernatant was unable to decrease the MPP+- or BV2-supernatatnt-mediated killing of 
MES23.5 cells (Figure 2.21), BMDC supernatant did decrease the release of pro-
inflammatory cytokines from stimulated BV2 cells (Figure 2.22).  The possibility has not 
been ruled out that supernatants from DCs could go to the brain and either decrease the 
activation state of activated microglia or protect dopaminergic neurons.    
  
FUTURE DIRECTIONS 
 While the work done in Chapter 2 was performed on a set of patient samples 
gathered for a specific study, this research could be continued with several potential 
studies.  First, this project examined gene expression in non-Treg, non-effetcor helper T 
cells (CD4+ CD25-).  This cell type was chosen because the identity of the T cells 
relevant to disease progression or protection in PD were unknown.  However, by 
excluding activated (CD4+ CD127+ CD25+) effector T cells, it is possible that we 
excluded terminally differentiated T cells and addressed the effects of sargramostim on 
T cells that could differentiate into Tregs of effector T cells.  Future work could be 
undertaken to examine the expression of proinflammatory cytokines in these cells.  In 
our current study, the expression of 84 genes were included in the array, thus 
continuation of this work using RNA-Seq or other technologies could examine the total 
transcriptome of the isolated population or in single cells.  The advent of single cell gene 
expression allows the grouping of T cells into subpopulations by gene expression, and 
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would allow for measure of unique helper T cell subsets that comprise the repertoire in 
PD patients and healthy controls, or allow tracking the distribution of these subsets over 
time.  Lastly, no work has identified a population of T cells that are reactive to post-
translationally modified α-Syn.  For instance, if APCs (be they monocytes, monocyte-
derived macrophages or DCs or B cells) were co-cultured in the presence of modified α-
Syn antigens and T cells from PD or control patients, a proliferating helper T cell 
population in response to the modified antigens could be identified.  These further 
studies could vastly improve our understanding of T cell gene expression and reactivity 
to self-antigens such as α-Syn.        
The focus of Chapter 2 is on T cells and their function in PD.  However, other 
immune cells (for example neutrophils, or CD8+ cells) may be facilitating the 
neuroinflammation and neurodegeneration in PD.  While some work in the clinical trial 
evaluated numbers and percentages of these cells in the periphery, no functional 
assessment of these cell types were performed.  Because eosinophil numbers and 
percentages in the blood were increased after sargramostim treatment (data not shown), 
whether the function of those eosinophils are affected would be of particular interest.  
This may not play a role in the development of PD or the clinical benefit in sargramostim, 
but these cells may be playing a role in the adverse effects of sargramostim treatment.  
As a result, understanding the effects of sargramostim on these cells may lead to a 
better understand of possible adverse effects and procedures to mitigate those effects  if 
sargramostim is to be included as a PD therapeutic.   
This clinical trial did not measure numbers or the percentages of MDSCs.  To 
date, no work has measured the number or function of MDSCs in PD.  However, like 
Tregs, these cells may be found in decreased number and function and contribute to the 
unharnessed inflammation in PD patients.  Given that GM-CSF can expand MDSCs, the 
211 
 
observed improvement in motor function may be related to decreased inflammation 
related, at least in part, to these cells.  These studies would highlight the function and to 
what extent MDSCs play a role in PD and whether increasing their number and function 
would improve PD symptoms 
As described in Chapter 3, we tested the hypothesis that GM-CSF induces a 
tolerogenic state in DCs, which induce Tregs and/or are neuroprotective in the MPTP 
model.  This research could be continued with several different research projects.  First, 
while I examined all the cells from BMDC cultures (both adherent and non-adherent 
CD11c+ and CD11c- cells), other published experiments with BMDCs isolated CD11c+ 
cells from only the non-adherent population.  Further experiments could further test the 
tolerogenic markers and functions of the non-adherent CD11c+ cells compared to the 
total population.  Also, flow cytometric analysis could be used to further characterize 
other DC markers and other markers for co-stimulatory molecules or functional markers 
that better describe the function of these cells.  Recently, DCs have been characterized, 
not by surface markers, but by ontology.  Within the bone marrow, 2 progenitors give 
rise to CD11c+ cells, the common DC precursor and the common monocyte progenitor 
(Helft et al., 2015).  While resulting DCs are all CD11c+ MHC II+, but the ontology 
determines whether the resulting cells are DCs and macrophages.  Future experiments 
could better determine to what extent the BMDCs used here are macrophages or DCs.   
More work is needed to determine the mechanism(s) of BMDC-mediated 
induction of Tregs.  First, we should examine the surface expression of other co-
stimulatory molecules that induce Tregs, such as PD-L1 should be examined after 
continued culture with GM-CSF.  Next, blockade of OX40L, Jag-1, PD-L1, and others 
with antibodies or antagonists should be evaluated to determine whether induction of 
Tregs during the co-culture of BMDCs with CD4+ T cells could be inhibited.  We should 
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also begin to test the expression of these molecules on BMDCs generated in culture with 
inhibitors or agonists for different components of GM-CSF signaling cascade to 
determine what is important pathways for the induction of surface markers.  Tregs from 
BMDC co-cultures should also be better characterized with other Treg markers like 
CD39, CD73, Lag-3, ICOS, PD-1, CTLA-4, Helios, GITR, as well as gene expression for 
cytokines such as IL-35, TGFβ and IL-10.  Determining increased expression in this 
population may indicate which Treg functions are needed for suppression.  This could be 
tested by knocking out or blocking some specific factors to determine whether Tregs are 
still suppressive in the proliferation suppression assay.  Lastly, Tregs derived from co-
culture should be further tested for their ability to protect dopaminergic neurons after 
MPTP intoxication.  We could use the induced Tregs to test which suppressive 
function(s) are important for neuroprotection, however, the efficiency of in vitro induction 
would need to be improved to provide sufficient numbers of Tregs for these studies.       
In vivo, more experiments are needed to determine to what extent GM-CSF 
induces tolerogenic DCs or other regulatory cells, such as MDSCs.  This could be 
achieved by determining the peripheral percentages of these cell types in peripheral 
blood after injection of GM-CSF.  In vivo blocking of co-stimulatory molecules identified 
above can determine the role of Treg-inducing myeloid cell types.  This is important to 
determine whether injection of GM-CSF working only through the tolerogenic DCs or 
other cell types.  Lastly, to test the neuroprotective capability, MDSCs can be adoptively 
transferred to MPTP intoxicated mice and surviving neurons assessed.  MDSCs can be 
isolated from the spleens of mice and transferred after MPTP, as was previously 
described with Tregs.  Evidence of decreased neuroinflammation and neuroprotection 
would indicate that other suppressor cell types protect in the model, while no changes 
may suggest a uniqueness about the suppressive function of Tregs.  Both of which are 
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novel findings and would lead to a better understanding of the immune system in the 
MPTP model and PD.   
 The research in Chapter 4 can be continued by several possible future 
experiments.  In this experiment, we tested the expression of proinflammatory cytokines 
at the peak of neuroinflammation.  However, more than likely these cytokine genes peak 
in the expression before the peak of neuroinflammation as defined by reactive microglia.  
This would make sense if proinflammatory cytokines are needed for the activation of 
microglia.  Also, we tested gene expression and cytokine release at the same time.  In 
the future, the temporal kinetics of gene and protein expression should be better 
delineated, particularly at earlier time points.  We also only tested gene expression in the 
midbrain and the cervical lymph nodes.  Future experiments could test gene expression 
and cytokine release in other tissues as well as at different time points.  While not 
typically assessed, the kinetics of gene expression and cytokine release in the striatum 
would be of particular interest as well as in other lymph node populations, the peripheral 
blood, and the spleen.  We could also further test the percentage of additional immune 
cells such as B cells, CD4+ and CD8+, and macrophages, and DCs in the cervical, 
brachial, axillary, and inguinal lymph nodes as well as in the spleen and peripheral 
blood.  This would better complete the cellular signature of immune cells that react over 
time after MPTP intoxication.  In addition, future experiments could test the percentage 
and function of other regulatory immune cells post-MPTP. While Tregs would be the 
obvious target population, MDSCs, B regulatory cells, and CD8+ regulatory T cells would 
be interesting populations to assess over time.  The results of these studies would 
provide us a complete understanding in the MPTP model of immune repertoire of cells 
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